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CHAPTER I 
 
INTRODUCTION 
 
Macrophages have been proposed as a potential therapeutic target because 
of their central role in the progression of cancer and cardiovascular disease. This is 
mediated through their potent effector functions on the rest of the immune system. 
In particular, macrophages demonstrate the ability to secrete a wide range of 
intercellular signals, including pro-inflammatory cytokines and chemokines, as well 
as growth factors and angiogenic signals (Brown & Goldstein, 1983; Devaraj & Jialal, 
2011; A. Mantovani, Sozzani, Locati, Allavena, & Sica, 2002; Miselis, Wu, Van Rooijen, 
& Kane, 2008; Ribatti, Levi-Schaffer, & Kovanen, 2008). The diversity of the 
macrophage secretome is linked to the polarization state of these cells. Through 
environmental triggers, macrophages can be directed into performing a spectrum of 
functions, with the pro-inflammatory “M1” state and the anti-inflammatory, pro-
healing “M2” state at opposite ends (Mosser & Edwards, 2008). Recent evidence 
demonstrates the prevalence of M2-polarized and M1-polarized macrophages in 
tumors and in atherosclerotic plaques, respectively (Hirose et al., 2011; A. Sica et al., 
2008). The re-polarization of macrophages may present a promising strategy for the 
treatment of these diseases, but while some methods have emerged, a vast majority 
of them are not clinically translatable—involving methods that have produced a 
slew of critical side effects in humans (e.g. systemic cytokine therapy).  
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Through nanomaterials, macrophage-specific targeting may be achieved in a 
clinically-translatable fashion. The emergence of ‘smart’ biomaterials and 
nanoparticles has led to a new paradigm in the design of drug delivery platforms—
producing injectable materials that circulate as inactive prodrugs until their 
activation at sites of disease, as well as homing drugs that target pathologically-
specific biomarkers. Because macrophages are among the most phagocytic cells in 
the body, and further, have been observed as permanent residents in various 
organs—including the liver and bone marrow, the injection of nanomaterials into 
animal models has usually resulted in the accumulation of the materials in such 
organs. Therefore, site-specific targeting of nanomaterials to macrophages at 
diseased sites stands as a significant challenge to the success of this therapeutic 
strategy. 
 We have developed MMP-activatable nanoparticles that respond to local 
MMP activity by unveiling cell-specific ligands. This enables the localization of 
nanoparticles to sites that present two features—MMP activity and a cell type of 
interest (Sewell & Giorgio, 2009; Smith, Sewell, & Giorgio, 2008). We will apply 
these nanoparticles for the delivery of siRNA to macrophages, with the goals of 
modifying their phenotype and polarization. Finally, the clinical relevance of this 
strategy will be assessed in mouse models of metastatic human cancer. 
 
Objectives 
The central hypothesis of my dissertation is that the polarization of macrophages 
into pro-inflammatory and anti-inflammatory subtypes facilitates their important 
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functions in promoting human diseases—including cancer and cardiovascular 
disease. Through the delivery of siRNA, it would be possible to modify macrophage 
polarization (ie, inducing M1 polarization in M2 macrophages and vice versa), 
resulting in therapeutic benefits. Therefore, the objectives of this work are to (1) 
develop novel biomaterials to enable macrophage-targeted drug delivery, as well as 
(2) to investigate the use of siRNA to modulate macrophage polarization. 
 
Specific Aims 
Specific Aim 1. Macrophage-specific nanoparticles will be assembled, containing 
multifunctional polymers that have the capability of condensing siRNA, as well as 
targeting motifs to macrophage endocytic receptors (scavenger receptors and 
mannose receptor are candidates). Optimization of nanoparticle targeting and 
endosomolytic behavior will be performed here. 
 
Specific Aim 2. M1 or M2 macrophages will be induced in vitro, providing a system 
for identification of siRNA sequences that can swing the polarization into the 
opposite direction. Measurements of cytokine release (cytokine bead arrays), gene 
expression of M1/M2-related biomarkers (real time PCR), and reactive oxygen 
species will be used in order to assess M1 or M2 polarization. 
 
Specific Aim 3. The marriage of the first two aims should produce a macrophage-
specific siRNA-delivering construct suitable for in vivo administration. To enhance 
the clinical relevance of this work, these immunomodulatory nanoparticles will be 
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delivered to mice with metastatic cancer. Nanoparticle homing will be assessed, as 
well as the effects of treatment on mouse survival and tumor burden. Tumor-
associated macrophages will also be analyzed for changes in gene expression by real 
time PCR. 
 
Background and Significance 
 For my dissertation, I proposed to synthesize ‘smart’ nanomaterials that 
home in on macrophages located within their areas of highest activity (MMP release 
/ ROS release). The proposed nanoparticles will then be endocytosed, escape the 
endosomes in response to lower pH (characteristic of late endosomes), and deliver 
siRNA into the cytosol. Knockdown of target genes is expected to elicit desired 
changes in macrophage polarization. Ultimately, this strategy is intended to ‘jump-
start’ quiescent macrophage functions in order to produce potential therapeutic 
benefits in human disease. In this section, I will discuss macrophage biology in 
relation to cancer and cardiovascular disease, and review previous work by others 
that guides the design of macrophage-targeted biomaterials. 
 
Macrophage Polarization: Pro- versus Anti-inflammatory 
The immune system has evolved to be specialized in the clearance of foreign 
debris from the body. An intricate network of intercellular signaling, involving a 
coordinated effort of multiple cell types over various time scales—regulates the 
powerful ability of the immune system to discriminate self from non-self. The 
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effector arms of the immune system center on the CD4+ T-helper (Th) cells, which 
receive stimuli from leukocytes among others, and respond by activating the  
 
appropriate immune system responses. Often, these downstream responses are 
classified into Th1 responses—involving eradication of viruses and intracellular 
pathogens (cell-mediated immunity)—or Th2 responses, which result in the 
 
FIGURE 1. Monocyte differentiation into macrophages and macrophage polarization. 
Circulating monocytes can differentiate into macrophages via the cytokines M-CSF or 
CXCL4, resulting in very different macrophage phenotypes. The latter has been dubbed the 
M4 macrophage, and to date have not been completely characterized (Gleissner, Shaked, 
Little, & Ley, 2010). Macrophages that have been differentiated via M-CSF are capable of 
being primed by local LPS or IFNγ to produce M1 pro-inflammatory macrophages or via IL-
4 or IL-13 to produce alternatively activated M2 macrophages. The presence of IL-10 
deactivates the macrophages (*), resulting in a very different expression profile from M1 
and M2 macrophages, but these macrophages are still commonly classified as M2 
macrophages. Nevertheless, M1 and M2 macrophages represent two poles in a spectrum of 
macrophage polarization, and these versatile cell types maintain the ability to re-polarize to 
different phenotypes throughout their lifetime. 
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construction of antibody libraries specific for blood-borne and extracellular 
pathogens (humoral immunity). The Th1/Th2 paradigm continues to drive 
immunological research today (Scott, 1993). Analogous to this spectrum of Th-
mediated inflammatory activity, macrophages have been typically classified into M1 
or M2 cells, depending on their ‘classical activation’ via IFNγ/LPS or ‘alternative 
activation’ via IL-4/IL-13 (Gordon, 2003; A. Mantovani, et al., 2002). Unlike Th1 and 
Th2 cells, M1 and M2 macrophages have not, to date, been observed in pure form in 
vivo. This suggests that macrophage phenotype and activity tends to fall within a 
spectrum with the M1 and M2 phenotypes on opposite poles, and supports recent 
thought that macrophages maintain a great degree of functional plasticity in their 
life cycle (Figure 1) (Mosser & Edwards, 2008). To reflect the current understanding 
of macrophage polarization and activity, M1-like and M2-like macrophages will be 
hereafter denoted as pro-inflammatory or anti-inflammatory macrophages. 
As implied by this classification system and confirmed extensively in vitro 
and in vivo, macrophages are very involved in the clearance of pathogens and 
foreign debris (Kindt, Goldsby, Osborne, & Kuby, 2007). To complicate matters, 
macrophages have also been shown to facilitate the wound healing process by 
releasing an array of growth factors and pro-angiogenic factors, including EGF, 
PDGF, VEGF, TGF-β, among others (Brancato & Albina, 2011; A. Sica, et al., 2008). 
This diverse array of functions is reflected in the activities performed by 
macrophages at the site of a wound. Unlike most inflammatory cells, which exhibit 
activities within very short time frames, macrophages are among the first 
inflammatory cells to arrive the site of injury, and may remain there weeks after the 
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injury, facilitating the fibrotic response. While the pro-healing macrophage 
phenotype has previously been classified with the anti-inflammatory macrophages, 
this subject continues to be under debate (Brancato & Albina, 2011). 
 
TABLE 1. Selected Biomarkers of Polarization-Dependent Macrophage Activity, 
Gene Expression, and Cytokine Release 
 M1 M2 References 
IL-1 + - (A. Sica, et al., 2008) 
IL-6 + - (Alberto Mantovani, Sica, & Locati, 2005) 
IL-10 - + (Alberto Mantovani, et al., 2005; Porta et al., 2009) 
IL-12 + - (Porta, et al., 2009) 
IL-23 + - (Alberto Mantovani, et al., 2005) 
CCL2 (MCP-1) - + (Porta, et al., 2009) 
CCL3 (MIP-1α) + - (Gordon, 2003; A. Sica, et al., 2008) 
CCL17 (TARC) - + (Gordon, 2003; Porta, et al., 2009) 
CCL22 - + (Porta, et al., 2009) 
CXCL9 + - (Martinez, Gordon, Locati, & Mantovani, 2006) 
CXCL10 + - (Martinez, et al., 2006) 
CXCL11 + - (Martinez, et al., 2006) 
MMP-1 / MMP-9 - + (Gordon, 2003) 
Scavenger 
receptor 
(CD204) 
- + (A. Sica, et al., 2008) 
Mannose 
Receptor 
(CD206) 
- + (A. Sica, et al., 2008) 
TNF-α + - (Porta, et al., 2009) 
Arginase I - + (Porta, et al., 2009) 
iNOS (NOS2) / 
ROS Products 
+ - (A. Sica, et al., 2008) 
+ indicates upregulated activity or gene expression relative to polarization towards the 
opposite phenotype.  
– indicates lower or lack of activity/gene expression relative to polarization towards the 
opposite phenotype. 
 
 
Recent work in Klaus Ley’s group has also shown that monocytes 
differentiated in platelet factor-4 (CXCL4) become macrophages with very distinct 
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gene expression profiles from pro- and anti-inflammatory macrophages (Gleissner, 
et al., 2010). The CXCL4-differentiated macrophages expressed the same canonical 
macrophage markers as the M-CSF-differentiated macrophages (CD45, CD11b, 
CD14). However, the expression of a variety of cytokines and chemokines were 
vastly different from typical profiles expected with M1 and M2 macrophages. This 
newly identified macrophage subtype has been dubbed the “M4” macrophage, but 
this finding has yet to be accepted into the dogma of macrophage biology. 
 
Macrophages as a Therapeutic Target in Cancer 
Because the metastatic phase of cancer is so lethal compared to the primary 
tumor, focus on treatment of metastasis is paramount to the goal of eradicating 
deaths due to cancer.  Treatment of distributed disease through the induction of an 
anti-tumor immune response has the potential to provide acute therapeutic effects.  
In addition, immune memory of the anti-tumor response may provide long-term 
therapy against emergent micrometastases that possess a phenotype similar to the 
original primary tumor. To achieve this goal, others continue to investigate cell 
therapies centered on tumor-associated dendritic cells, T-cells, and NK-cells. While 
they have received some interest, tumor-associated macrophages (TAMs) have not 
been investigated as heavily. 
TAMs have been proposed as a potential drug target in cancer because they 
have been shown to support tumor growth and invasiveness through the secretion 
of growth and angiogenic factors, as well as MMPs and cathepsins that degrade the 
local extracellular matrix (A. Mantovani, et al., 2002; Miselis, et al., 2008) . Pro-
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inflammatory macrophages play key roles in activating the immune response 
against early-stage tumors, in part by mediating immune recognition of aberrant 
protein expression profiles.  However, the macrophage infilitrate at later-stage 
breast tumors mostly consists of anti-inflammatory macrophages, which suppress 
the anti-tumor immune response and facilitate tumor survival and growth (de 
Visser, Eichten, & Coussens, 2006; Dirkx, Oude Egbrink, Wagstaff, & Griffioen, 2006; 
Murdoch, Muthana, Coffelt, & Lewis, 2008; Pollard, 2008). This pro→anti-
inflammatory transition has been implicated as a key mechanism in facilitating the 
metastatic progression of tumors (de Visser, et al., 2006). Recently, reversal of this 
transition has been achieved in vitro and in vivo in mouse models, and has triggered 
activation of the immune system-mediated anti-tumor cascade (Stout et al., 2005; 
Watkins, Egilmez, Suttles, & Stout, 2007). The activation of an anti-tumor immune 
response correlated with a reduction in tumor mass (Guiducci, Vicari, Sangaletti, 
Trinchieri, & Colombo, 2005). Clinical trials investigating the potential impact of 
such treatment in humans are ongoing in Taiwan and results have not yet been 
reported to date (ClinicalTrials.gov ID# NCT00690261). 
Nevertheless, it is clear that systemic immunotherapy leads to significant off-
target side effects, and intratumoral injection of cytokines—as done in the 
laboratory—is not always practical in the clinic. Novel, translational technologies 
are necessary to harness the power of immunotherapy in cancer. Nanomaterials 
have been known to passively accumulate in solid tumors due to the presence of 
leaky vasculature and poor lymphatic drainage. Further, macrophages are among 
the most phagocytic cells in the body. Recently, others have begun to leverage these 
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features to synthesize nanoparticles that localize to TAMs (Larsen et al., 2009). 
However, the use of this technology to modulate the polarization state of TAMs is as 
yet uninvestigated. 
 
Macrophages as a Therapeutic Target in Atherosclerosis 
Cardiovascular disease continues to be the leading cause of death in the 
United States, accounting for 1 of every 2.9 deaths (Lloyd-Jones et al., 2010). 
Development of atherosclerotic plaque is responsible for many of these events, and 
is characterized by a cascade of events including the accumulation of lipids in 
arterial walls, oxidation of the lipids, and recruitment of inflammatory cells into 
these lipid-rich regions (Insull, 2009). Under the influence of chronic lipid 
deposition and oxidation, inflammatory activity, and resulting abnormal blood flow 
and mechanical loading conditions in the region, these plaques may suddenly 
rupture, producing emboli that may potentially lead to a lethal acute event such as a 
stroke or a myocardial infarction. 
Because of the intimate involvement of macrophages throughout plaque 
progression, atherosclerosis is commonly thought of as an inflammatory disease, 
and this classification continues to guide burgeoning work in this area (Libby, 2002). 
This is highlighted in descriptions of events that may contribute to plaque 
destabilization, which include: (1) active inflammatory activity, (2) thin fibrous caps 
and large lipid cores, (3) endothelial erosion and thrombosis, (4) fissured or 
ruptured caps, and (5) luminal stenosis (>90%) (Naghavi & Falk, 2010; Saam et al., 
2007).  Contrary to this theory, it continues to be difficult to clinically identify 
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‘vulnerable plaques’ that are most likely to rupture—as many ruptured plaques 
occur in otherwise asymptomatic regions, and therefore, the concept of a vulnerable 
plaque remains somewhat controversial.  
Nevertheless, it is clear that macrophages play multiple roles in destabilizing 
atherosclerotic plaques, some of which are particularly important to note here. 
Their production of matrix metalloproteinase (MMP)-8 and -9 in response to 
pathological stimuli leads to degradation and destabilization of the local 
extracellular matrix, increasing the likelihood of plaque rupture (de Nooijer et al., 
2006; Gough, Gomez, Wille, & Raines, 2006; Herman et al., 2001; Johnson, Sung, 
Lessner, Fini, & Galis, 2004; Sluijter et al., 2006). Moreover, macrophages are 
recruited to lesions and express various scavenger receptors that facilitate 
endocytosis of lipids and other interstitial debris. This activity eventually results in 
transformation of macrophages into foam cells, and contributes to the gradual 
expansion of the necrotic core (Pluddemann, Neyen, & Gordon, 2007). 
This array of events in the plaque is explained by the co-existence of pro- and 
anti-inflammatory macrophages within plaque regions (Alberto Mantovani, 
Garlanda, & Locati, 2009). Due to the prevalence of Th1 cells in plaque development, 
pro-inflammatory macrophages are found in the earlier stages of plaque 
progression, resulting in elevated local levels of ROS, inflammatory mediators, and 
MMPs. Local ROS production leads to the emergence of oxidized lipoproteins such 
as oxLDL, which is one of the leading biomarkers of plaque progression (Tsimikas, 
Willerson, & Ridker, 2006). However, oxLDL also activates transcription factors 
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related to anti-inflammatory mediators. A number of products of anti-inflammatory 
macrophages have been shown to counter plaque de-stabilization and dampen 
inflammation. Because of this, the anti-inflammatory macrophage is the more 
desired phenotype in atherosclerosis. Indeed, commercially available PPAR agonists 
have been shown to contribute to the induction of anti-inflammatory macrophage 
polarization and stabilize atherosclerotic plaques, although side effects from 
systemic administration continue to hinder the success of this therapeutic strategy 
(Tabas, 2010). 
 
Molecular Homing of Drugs & Nanoparticles to Macrophage-Specific Receptors 
  As one of the most phagocytic cells in the human body, macrophages are 
among the first cells of the innate immune system to arrive at a site of injury, but 
have also been observed as permanent residents in certain organs, such as in the 
liver and bone marrow (Bouwens, Baekeland, de Zanger, & Wisse, 1986; Felix et al., 
1990; Martin, 1997). Pro-inflammatory macrophages are central to the clearance of 
pathogens and microbes, while anti-inflammatory macrophages aid in the removal 
of host cell and matrix debris that are present at an injury site. Macrophages 
recognize and interact with this multitude of potential targets through a variety of 
pattern recognition receptors, including toll-like receptors, mannose receptor 
(CD206) and scavenger receptor A (CD204) (Brown & Goldstein, 1983; Kindt, et al., 
2007; Linehan, Martinez-Pomares, & Gordon, 2000). The polygamous nature of 
these pattern-recognition receptors is not restricted to endogenous ligands and 
targets—for example, CD204 has been shown to contribute to the uptake of 
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nanoparticles surface-functionalized with carboxylic acids, antibodies, as well as 
poly(ethylene glycol) (PEG) (Chnari, Nikitczuk, Wang, Uhrich, & Moghe, 2006; 
Lipinski et al., 2006). Therefore, it is not very difficult to target synthetic 
nanoparticles to macrophages through non-specific means. However, the rational 
design of macrophage receptor-targeted nanoparticles for in vivo use requires an 
application-driven minimization of such nonspecific interactions between 
macrophage pattern recognition receptors and the nanoparticles. 
Nonspecific interactions between macrophage receptors and nanoparticles 
may be dictated by particle size, shape, surface charge, and hydrophobicity, and 
facilitated by surface chemistry-specific complement activation on the nanoparticle 
(Doshi & Mitragotri, 2010; Thomas et al., 2011). Doshi and Mitragotri treated 
macrophages at 4°C with a library of polystyrene microparticles exhibiting a variety 
of sizes and shapes to mimic bacterial dimensions, and observed optimal 
attachment for rod-shaped particles with the longest dimension at 2-3μm (Doshi & 
Mitragotri, 2010). Raynal et al. showed in 2004 that macrophages exhibit size-
dependent uptake of nanoparticles functionalized with dextran (Raynal et al., 2004). 
While the findings of these two studies furthered understanding of macrophage-
particle interactions, significant questions remain unanswered. The smallest 
particles investigated in Doshi’s study were in the range of 500 nm, and have yet to 
be extended to the sub-100 nm dimensional range of interest in many in vivo 
applications. Raynal et al.’s study was conducted before the identification of a 
dextran receptor (SIGNR1/CD209b) on murine macrophages. 
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TABLE 2. Known biomarkers of the monocyte/macrophage lineage and known 
expression in other cell lines. 
Biomarker Description Monocytes Macrophages Other Cells 
CD11b αM integrin/iC3B receptor + + NK, 
granulocytes 
CD64 Fc fragment of IgG receptor 
(FcγR1A) 
+ + DCs 
CD115 Colony stimulating factor 1 
receptor / CSF1R 
+ + Osteoclasts, 
breast, 
microglia 
CDw136 Macrophage-stimulating 
protein receptor / MST1R 
– + Epithelial cells 
CD163 Hemoglobin scavenger 
receptor, M130 
+ + Hematopoietic 
progenitors 
CD204 Scavenger receptor 1 – + – 
CD206 Mannose receptor C type 1 – + DCs 
Information up-to-date as of June 16, 2011, based on NCBI-GENE database: 
http://www.ncbi.nlm.nih.gov/gene . 
 
While a very small, baseline level of nonspecific uptake may be acceptable, 
the optimization of specific targeting strategies remains an area of intense activity 
today. A number of monocyte/macrophage-specific cell surface biomarkers have 
been identified for this purpose, but in most cases, have later also been discovered 
on other cell types (Table 2). For example, while mannose receptor/CD206 is 
primarily expressed in macrophages, they have also been reported on dendritic cells, 
and therefore, macrophage targeting approaches to this receptor may also lead to 
off-target effects. Studies in the 1990’s discovered that the mannose receptor 
binds—as the name implies—mannose, as well as a few other sugars such as fucose, 
glucose, and N-acetylglucosamine, and more avidly binds oligosaccharides 
composed of these sugars as opposed to monosaccharides (Stahl & Ezekowitz, 
1998). Espuelas et al. confirmed these findings by tethering mannose 
monosaccharides, disaccharides, or tetrasaccharides onto liposomes, and observed 
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that liposomal uptake into dendritic cells was enhanced by multivalent presentation 
of mannose ligands on the liposomal surface (Espuelas, Thumann, Heurtault, 
Schuber, & Frisch, 2008).  
The macrophage scavenger receptor 1 (CD204) is one of the very few known 
endocytosis receptors to have not been discovered in other cell lines besides those 
of the monocyte/macrophage lineage. Originally discovered by Brown and Goldstein 
in the 1980s, CD204 enhances macrophage uptake of acetylated low-density 
lipoproteins and was later observed to also facilitate the endocytosis of oxidized 
LDLs, branched fucose polymers (e.g., fucoidan), dextran, polyanions, and even 
PEGylated particles (Brown & Goldstein, 1983; Chnari, et al., 2006; Raynal, et al., 
2004). Optimization of specific targeting strategies to this receptor remains difficult 
due to its nature as a pattern recognition receptor. High-affinity ligands for CD204 
are well-characterized and include fucoidan and polyinosinic acid, which have 
classically been used to compete away binding of modified LDLs to the receptor 
(Brown & Goldstein, 1983). 
Intracellular delivery of drugs and nucleic acids, as proposed in this work, is likely to require 
molecular targeting approaches to endocytotic receptors. Therefore, CD204 and CD206 are 
leading molecular targets for the nanoparticles to be described here. 
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Candidate Target Genes for Therapeutic siRNA-Mediated Knockdown to 
Modulate Macrophage Polarization 
 
 
FIGURE 2. The Signaling Pathways of the NF-κB Transcription Factor Family. The NF-
κB family includes the Rel proteins, NF-κB1, and NF-κB2. The canonical pathway is 
activated through LPS, TNFα, IL-1, or CD40L and results in the activation of the IκB kinase 
(IKK) complex. IκB proteins retain dimers of RelA and NF-κB1-p50 in the cytoplasm, and 
phosphorylation of IκB enables the dimer to translocate to the nucleus, resulting in 
activation of downstream genes. In the alternative pathway, LTβ or BAFF activate the IKKα 
subunit of IKK independently of the other IKK subunits, as well as another kinase—NIK. 
These two kinases act on the RelB-NF-κB2 dimer, resulting in the degradation of the NF-
κB2-p100 subunit, translocation of RelB-p52 (p52 is the remaining subunit of NF-κB2) to 
the nucleus, and activation of downstream genes. Adapted from (Cao & Karin, 2003b). 
 
Current understanding of the molecular mechanisms governing macrophage 
polarization remains hazy. However, preliminary work has identified a few pieces to 
the puzzle, as a number of transcription factors have been correlated with the 
expression of hallmark pro- and anti-inflammatory polarization markers. 
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Previous work suggests that the NF-kappaB (NF-κB) transcription factor in 
macrophages contributes to their impact during tumorigenesis (Figure 2) (de Visser, 
et al., 2006; Dirkx, et al., 2006; Murdoch, et al., 2008; Pollard, 2008; Stout, et al., 
2005; Watkins, et al., 2007).  A number of these studies have demonstrated aberrant 
expression of NF-κB in breast cancer cell lines and primary tumors (Cogswell, 
Guttridge, Funkhouser, & Baldwin, 2000; Dejardin et al., 1995; Nakshatri, Bhat-
Nakshatri, Martin, Goulet, & Sledge, 1997; Sovak et al., 1997).  While NF-κB 
activation in TAMs may elicit anti-tumor effects by polarizing these cells towards an 
M1 phenotype, elevated NF-κB signaling has been observed in breast cancer cells 
and has been shown to promote cell growth through the activation of cyclins (Cao & 
Karin, 2003b; Guiducci, et al., 2005; Porta, et al., 2009). Therefore, macrophage-
specific modulation of NF-κB activity has potential as a novel therapeutic approach 
for breast cancer, including triple-negative and refractory phenotypes.  NF-κB family 
members exist as dimers sequestered in the cytoplasm of most mammalian cells by 
inhibitory molecules. In the canonical NF-κB pathway, inhibitors such as IκBα are 
destroyed upon cell stimulation, allowing NF-κB to enter the nucleus and associate 
with cognate DNA binding sites, influencing gene transcription (Vallabhapurapu & 
Karin, 2009; Verma, Stevenson, Schwarz, Van Antwerp, & Miyamoto, 1995). 
Activation of NF-κB by the canonical pathway is known to be a key modulator of 
multiple intracellular activities and is responsible for a wide variety of consequent 
cellular behaviors.  In the alternative NF-κB signaling pathway, interaction between 
p100 and RelB maintains the complex in the cytoplasm until processing of the p100 
to the mature p52 form results in translocation of the complex to the nucleus 
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(Senftleben et al., 2001; Solan, Miyoshi, Carmona, Bren, & Paya, 2002). The 
alternative pathway can be activated by upstream signals that are different from 
those that activate the canonical pathway (Xiao, Rabson, Young, Qing, & Qu, 2006). 
The upstream activators specific to the alternative pathway include; receptor 
activator of NF-κB ligand (RANKL) (Cao et al., 2001) and tumor necrosis factor 
(TNF)-like weak inducer of apoptosis (TWEAK) (Saitoh et al., 2003). Cellular 
responses to NF-κB activation by the alternative pathway are relatively unexplored, 
especially for applications in cancer immunology, but are likely to have distinct 
functions to those of the canonical pathway (Bonizzi & Karin, 2004). Both the 
canonical and the alternative pathways have been implicated in oncogenesis (Cao & 
Karin, 2003a; Eliopoulos et al., 2003; Perkins, 2003; Romieu-Mourez et al., 2001). 
Since the NF-κB signaling pathway is regulated through the balance of 
several inhibitor proteins, enzymes, and DNA-binding domains, there are a number 
of ‘druggable’ targets within this pathway that can be leveraged in an attempt to 
induce pro-inflammatory (knockdown of IκB/other inhibitors) or anti-inflammatory 
polarization (knockdown of IκB kinases or DNA-binding domains). 
Alternatives to this NF-κB-centric siRNA targeting scheme include the STAT 
family of transcription factors and the suppressor of cytokine signaling (SOCS) 
family. Williams et al. installed a constitutively active STAT3 transcription factor 
into macrophages and replicated the IL-10 induced suppressed macrophage 
phenotype in the transfected cells (Williams et al., 2007). In converse, the siRNA-
mediated silencing of STAT3 in macrophages, dendritic cells, and B-cells results in 
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the re-activation of an anti-tumor immune response (Kortylewski et al., 2009). 
Others showed that knockdown of the SOCS3 protein attenuates M1 macrophage 
activity and activates expression of CD206, arginase, and STAT3-related genes, 
indicating activation of the M2 macrophage phenotype (Liu et al., 2008). In the later 
parts of this work, these pathways will be considered alongside the NF-κB pathway 
for siRNA-mediated knockdown, with the goals of re-polarizing M1 or M2 
macrophages to the opposite phenotype. 
 
Design of Macrophage-Targeted Biomaterials 
 My dissertation is organized in to several manuscripts, a few of which are 
already published, based on the following steps as we pursued the design and 
validation of macrophage-targeted biomaterials: (1) Optimization of nanoparticle 
characteristics that would reduce non-specific recognition of the particles by 
macrophages that may exist outside of the desired site of intervention, (2) 
Optimization of nanoparticle characteristics that would increase site-specific 
recognition of pathologic macrophages, (3) Design of a localized delivery platform 
that may serve as an implantable patch for delivery of nanoparticles to a site of 
pathologic inflammation, and (4) Identification of potential molecular and gene 
pathway targets for biomaterials-mediated, therapeutic intervention in vivo.  
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CHAPTER II 
 
SIZE- AND CHARGE-DEPENDENT NON-SPECIFIC UPTAKE OF PEGYLATED 
NANOPARTICLES BY MACROPHAGES 
 
The assessment of macrophage response to nanoparticles is a central 
component in the evaluation of new nanoparticle designs for future in vivo 
application. This work investigates which feature, nanoparticle size or charge, is 
more predictive of non-specific uptake of nanoparticles by macrophages. This was 
investigated by synthesizing a library of polymer-coated iron oxide micelles, 
spanning a range from 30-100 nm in diameter and -23 mV to +9 mV, and measuring 
internalization into macrophages in vitro. Nanoparticle size and charge both 
contributed towards non-specific uptake, but within the ranges investigated, size 
appears to be a more dominant predictor of uptake. Based on these results, a 
protease-responsive nanoparticle was synthesized, displaying a matrix 
metalloproteinase-9 (MMP-9)-cleavable polymeric corona.  These nanoparticles are 
able to respond to MMP-9 activity through the shedding of 10-20 nm of 
hydrodynamic diameter.  This MMP-9-triggered decrease in nanoparticle size also 
led to up to a six-fold decrease in nanoparticle internalization by macrophages and 
is observable by T2-weighted magnetic resonance imaging. These findings guide the 
design of imaging or therapeutic nanoparticles for in vivo targeting of macrophage 
activity in pathologic states (Yu et al., 2012). For the purposes of the dissertation, 
the results presented in this chapter aided in the design and selection of optimal 
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nanoparticle characteristics to reduce non-specific recognition of nanoparticles by 
macrophages. 
 
Introduction 
As one of the most phagocytic cells in the human body, macrophages are 
among the first cells of the innate immune system to arrive at a site of injury, but 
also have been observed as permanent residents in certain organs, such as in the 
liver and bone marrow (Bouwens, et al., 1986; Felix, et al., 1990; Martin, 1997). They 
function to clear pathogens and microbes, as well as host cell and matrix debris that 
are present at sites of tissue injury. Macrophages recognize and interact with this 
multitude of potential targets through a variety of mechanisms, including 
phagocytosis and receptor-mediated endocytosis. The latter is mediated primarily 
through pattern recognition receptors, which include toll-like receptors, the 
mannose receptor (CD206), and scavenger receptor A (CD204) (Brown & Goldstein, 
1983; Kindt, et al., 2007; Linehan, et al., 2000). The polygamous nature of these 
pattern-recognition receptors is not restricted to natural ligands and targets. For 
example, CD204 has a wide range of molecular partners, leading to receptor-
mediated endocytosis, distinct from the non-specific uptake due to pinocytosis 
(Pluddemann, et al., 2007). For the purposes of this dissertation, we have defined 
this polygamous behavior as ‘non-specific’ uptake or internalization. This is 
emphasized by evidence that CD204 has been shown to contribute to the non-
specific uptake of nanoparticles surface-functionalized with carboxylic acids, 
antibodies, as well as synthetic polymers.(Chnari, et al., 2006; Lipinski, et al., 2006) 
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Therefore, the rational design of nanoparticles for in vivo use requires an 
application-driven minimization or optimization of such non-specific interactions 
between macrophages and synthetic nanoparticles. However, this area remains 
largely uninvestigated. 
Therefore, in this work, we sought to investigate non-specific uptake of 
synthetic nanoparticles by macrophages, extending the work of these earlier groups 
into sub-100 nm PEGylated nanoparticles. To our knowledge, this is the first 
investigation of the effects of nanoparticle size, surface chemistry, and charge on 
non-specific uptake by macrophages. The rationale for using a PEG-functionalized 
nanoparticle system to accomplish these objectives is that macrophages are unlikely 
to have specific receptors for PEG. Further, PEG can be easily modified to display 
various chemical functionalities, enabling the modulation of nanoparticle charge 
without significantly varying the bulk properties of the PEG coating. This is also a 
relevant model system for study because PEGylation of nanoparticles is commonly 
performed in order to render synthetic nanoparticles water-soluble and applicable 
for in vivo use. This is, in part, because PEG has been shown to discourage protein 
adsorption and opsonization on nanomaterial surfaces (Ratner, 1996).  
Therefore, we used block copolymers of poly(ethylene glycol)-bl-
poly(propylene sulfide) (PEG-PPS), which are amphiphilic copolymers that are 
capable of forming micelles and stabilizing hydrophobic drugs and nanoparticles at 
their liquid, PPS core (Velluto, Demurtas, & Hubbell, 2008; S. S. Yu, R. L. Scherer, et 
al., 2011). The incorporation of ultrasmall superparamagnetic iron oxides (USPIOs) 
into the micellar core of PEG-PPS block copolymers serves two functional 
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purposes—enabling easy quantification of particle uptake through colorimetric 
assays, while also being a widely investigated contrast agent for T2-weighted 
magnetic resonance imaging (MRI). Through the use of a variety of materials 
processing techniques to form the micelles, including thin film hydration and direct 
hydration, the same starting PEG-PPS copolymers and iron oxide cores can lead to 
monodisperse micelles (PEG-PPS-USPIOs) exhibiting hydrodynamic diameters at 
30, 40, or 100 nm. Additionally, PEG-PPS-USPIOs can be fashioned with different 
surface chemistries at the PEG terminus, enabling an examination of charge-
dependent non-specific uptake of nanoparticles by the macrophages. 
 To demonstrate the utility of these studies, we evaluated a protease-activity 
MRI probe design against these results. To make activity probes, PEG chains 
containing a protease-cleavable peptide substrate were synthesized and conjugated 
to PPS, in order to fashion surfactants for the micellization of USPIOs. The resulting 
nanoparticles that are ‘activatable’ by protease activity through a ≥10 nm decrease 
in hydrodynamic diameter. Macrophages are therefore expected to internalize 
protease-treated nanoparticles differently than untreated nanoparticles. We 
hypothesize these differences can be visualized via MRI with the aid of the contrast 
agent USPIOs encapsulated within the micelles. Taken together, the work presented 
here shows methods to design ideal nanoparticle dimensions and properties in 
order to better optimize nanoparticle behavior in vivo. 
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Materials and Methods 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
purchased unless otherwise noted below. MMP-9, MMP-9 inhibitor, Fmoc-protected 
L-amino acids, and resins for solid-phase peptide synthesis were purchased from 
EMD Biosciences (Gibbstown, NJ). PEG reagents were purchased from Laysan 
Biosciences (Arab, AL). All dialysis supplies were ordered from Pierce Scientific 
(Rockford, IL) and used with modifications to the factory-provided protocol as 
indicated in the appropriate sections below. Copper TEM grids with Formvar film 
and uranyl acetate were purchased from Electron Microscopy Sciences (Hatfield, 
PA). RPMI-1640 medium, penicillin-streptomycin, and fetal bovine serum (FBS) 
were purchased from Invitrogen (Carlsbad, CA).  
 
PEG-PPS Block Copolymers and Functionalization 
Synthesis of ~7kDa carboxy-PEG-PPS (cPEG-PPS) was carried out as previously 
described (S. S. Yu, R. L. Scherer, et al., 2011). For fluorescent polymers, FITC-PEG-
NH2 was used in place of cPEG-NH2 in the coupling reaction to PPS. The MMP-9-
cleavable peptide GGPRQITAGC (M9C; Gly-Gly-Pro-Arg-Gln-Ile-Thr-Ala-Gly-
Cys)(Deguchi et al., 2006) was synthesized on a Rink-amide MBHA resin support, 
via standard Fmoc-based solid phase peptide synthesis on an automated system 
(Protein Technologies PS3, Tucson, AZ) (Chan & White, 2000). The peptide (1.5eq, 
45mmol) was then reacted overnight with 1eq of 5kDa methoxy-PEG-maleimide 
(mPEG-MAL; 30 mmol; 150 mg), in an aqueous buffer containing 0.1M Na3PO4 and 
0.15 M NaCl at pH 7.2. Unbound peptide was removed by dialysis across a 2 kDa 
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molecular weight cutoff membrane overnight at room temperature. The completed 
mPEG-[M9C] conjugate was lyophilized, then coupled to cPEG-PPS via standard 
carbodiimide chemistry to yield mPEG-[M9C]-PEG-PPS block copolymers.  
For FT-IR spectroscopy, polymer samples were prepared by mixing with IR-
grade KBr and pelleting on a KBr press (Specac, Slough, United Kingdom). FT-IR was 
performed on a Bruker Tensor 27 system (Billerica, MA).  
1H NMR spectra were obtained at 400 MHz using a 9.4 T Oxford magnet 
operated by a Bruker AV-400 console. The main NMR probe for the instrument is a 5 
mm Z-gradient broadband inverse (BBI) probe with automatic tuning and matching 
capability (ATM).  
Gel permeation chromatography (GPC) was performed on three resolving 
columns running in series (Tosoh Biosciences 1x TSKGel Alpha4000, 2x TSKGel 
Alpha3000; King of Prussia, PA) with DMF + 0.1 M LiBr mobile phase. Columns were 
incubated at 60°C, and chromatograms were obtained with a Shimadzu SPD-10A UV 
detector and RID-10A refractive index detector (Shimadzu Scientific Instruments, 
Columbia, MD), and a Wyatt miniDAWN Treos multi-angle light scattering detector 
(MALS; Wyatt Technology, Santa Barbara, CA). Data collection and analysis was 
achieved through the Wyatt ASTRA software (version 5.3.4). 
 
Encapsulation of Ultrasmall Superparamagnetic Iron Oxides (USPIOs) in PEG-
PPS Copolymers 
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Synthesis of hydrophobic, monodisperse USPIO core particles and their 
encapsulation in PEG-PPS copolymers was carried out as previously described (S. S. 
Yu, R. L. Scherer, et al., 2011). In brief, USPIO cores of predictable diameters were 
first synthesized through thermal decomposition, by controlling the molar ratios of 
iron precursor to oleic acid introduced in the reaction feed (Figure 3). A 1:2 mass 
ratio of dried hydrophobic USPIO cores to PEG-PPS polymers were then dissolved in 
toluene, vortexed to mix, sonicated for 5 s to break apart clumps, and then dried by 
rotary evaporation for 20 min. The dried polymer/USPIO mixture was then 
rehydrated in 3 mL of nanopure water and vortexed vigorously to suspend all 
particulates. Large clumps and byproducts were removed by magnetic pelleting, and 
the colloidal phase was collected and further centrifuged at 2500 × g for 5 min to 
precipitate excess polymers. The supernatant is gently aspirated by pipette into 
fresh scintillation vials and stored at 4°C. 
 
 
FIGURE 3. Tuning USPIO diameters by varying surfactant to precursor feed ratios. 
Feed ratio of oleic acid surfactant to iron pentacarbonyl precursors and resulting USPIO 
diameters. 6 mmol of Fe(CO)5 was introduced into reactors containing 40 mL octyl ether 
and varying amounts of oleic acid at 100°C. USPIO cores were allowed to grow and then 
oxidize as described above, and then imaged by HRTEM. Core diameters were measured via 
ImageJ software. 
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To fabricate fluorescent micelles, a 1:40:20.5 mass ratio of FITC-PEG-PPS : 
PEG-PPS : iron oxide cores was mixed and micellized as described above. Therefore, 
the overall mass ratio of polymers to iron oxides is preserved at 1:2 for all 
micellization procedures. To make “proximity-activated” USPIOs (PA-USPIOs)—
which are able to respond to local MMP-9 activity, OA-USPIOs were encapsulated in 
MMP-9-cleavable mPEG-[M9C]-PEG-PPS polymers using the same protocol. 
 
Pluronic-PPS Nanoparticles and Loading with USPIOs 
Pluronic-stabilized PPS NPs were synthesized by inverse emulsion 
polymerization as described previously (Rehor, Hubbell, & Tirelli, 2005; Thomas, et 
al., 2011). Pluronic F-127 (a block copolymer of polyethylene glycol and 
polypropylene glycol terminated by α and ω hydroxyl groups) was used alone or in 
combination with carboxyl-terminated Pluronic derivatized as previously described 
(van der Vlies, O'Neil, Hasegawa, Hammond, & Hubbell, 2010). The hydrophobic 
core was stabilized by di-sulfide crosslinking of the linear PPS chains (Rehor, et al., 
2005). However, since crosslinking cannot reach completion, remaining free 
sulfhydryl groups on the NP surface were irreversibly capped by reaction with the 
alkylating reagent iodoacetamide. NP solutions were sterile-filtered, and then 
loaded with 3 nm USPIO cores through a direct hydration process. 100μL of the 
hydrophobic OA-USPIOs (20 mg/mL in THF) was added to 1mL of the Pluronic-PPS 
NPs (15 mg/mL in water) with swirling, and was followed by removal of THF by 
rotary evaporation, and removal of non-encapsulated OA-USPIOs by filtration 
through 0.45 μm Teflon filters (Whatman Inc., Piscataway, NJ). 
28 
Nanoparticle Characterization 
Size and ζ-potential of NPs were investigated by dynamic light scattering 
(DLS) in a Malvern Zetasizer Nano-ZS with the reusable dip-cell kit (Malvern 
Instruments Ltd., Worcestershire, U.K.). For measurements of ζ-potential in serum 
media, nanoparticles were mixed with THP-1 growth medium and allowed to 
incubate at 37°C for 24 h prior to DLS measurements. No further purification of the 
nanoparticles was performed. This is because the purification process ends up 
diluting the particles (along with the adsorbed proteins), and may lead to further 
protein exchange interactions with media used downstream of isolation procedures, 
as per the Vroman effect (Ratner, 1996). Therefore, in order to best mimic in vivo 
conditions, the nanoparticles were measured in the presence of serum. 
Measurements of hydrodynamic diameter demonstrated the presence of a peak at < 
5 nm that corresponded to proteins, while nanoparticles could still be easily 
discerned within the 20-100 nm diameter range. 
Transmission electron microscopy (TEM) was conducted on a Philips CM20 
system operating at 200 kV. Carbon film-backed copper grids were inverted onto 
droplets containing nanoparticle suspensions of interest and blotted dry. Images 
were collected using a CCD camera with AMT Image Capture Engine software 
(Advanced Microscopy Techniques, Danvers, MA), and sizing of the particles was 
automated using a particle analyzer on ImageJ software. Images were thresholded, 
and then the built-in Analyze Particles function was used to measure the major and 
minor axes of the fit ellipses around each particle. After artificially discarding 
clumps of particles encompassed within single fit ellipses (usually identified by 
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major and minor axes that were >10% different from one another), or ellipses 
drawn around globs in the carbon grid (usually identified by any dimension < 1 nm), 
the diameter of individual particles was taken to be the average of the major and 
minor axis.  
For aqueous samples, nanoparticles on TEM grids were also counterstained 
with 3% uranyl acetate in water for 2 min, gently blotted dry, and dried in a vacuum 
desiccator for 2 h prior to imaging. 
 
Cell Culture and Nanoparticle Co-incubation Experiments 
Non-adherent THP-1 human leukemic monocytes (American Type Culture 
Collection, Manassas, VA) were grown in RPMI-1640 medium supplemented with 
10% FBS, 1% penicillin-streptomycin, 1X MEM vitamins (Mediatech, Manassas, VA), 
120 μM β-mercaptoethanol, and 10mM HEPES at 37°C in a 5% CO2 incubator. For all 
cell experiments, monocytes were seeded into standard tissue culture-treated plates 
at a density of 300,000 cells/cm2, and differentiated for 3 days in growth medium 
(above) supplemented with 200 nM of phorbol myristate acetate (PMA). The 
differentiation process leads to induction of cell adherence onto tissue culture 
polystyrene surfaces.  
For nanoparticle co-incubation experiments, cells were washed 1x with PBS 
to remove unbound cells, prior to addition of growth medium. The medium was 
supplemented with nanoparticles and fucoidan. Nanoparticle dosing was based on 
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total iron concentration as measured through the colorimetric phenanthroline assay 
as previously described (Christian, 1994). Final iron concentrations in the wells 
were calculated to be between 30-200μM. For fucoidan competition experiments, 
media was supplemented with fucoidan to a final concentration of 0-500 μM. 
 
 
FIGURE 4. Lowry protein assay standard curves. Bovine serum albumin (BSA) was 
dissolved in PBS and treated with either 0.1 N NaOH or 6N HCl prior to performance of the 
Lowry protein assay. While the assay is typically run under alkaline conditions (blue), 
strong acidic conditions do not significantly affect the sensitivity or reliability of this assay. 
 
 At selected time points, cells were washed 3X with PBS to remove unbound 
nanoparticles, and then lysed in 3N HCl and 0.25% Triton X-100 for at least 2 h. The 
strongly acidic environment also promotes solubilization of the endocytosed USPIOs 
via oxidation of the amphiphilic PEG-PPS shell on the nanoparticles into fully 
hydrophilic polymers (Rehor, et al., 2005), as well as leaching and mineralization of 
the iron in the USPIO core. The cell lysate was analyzed for protein content using a 
commercial Lowry protein assay kit (Bio-Rad Laboratories, Hercules, CA), while iron 
content was measured using the colorimetric phenanthroline assay as previously 
described (Christian, 1994). While the acidic conditions for the Lowry protein assay 
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deviate significantly from the protocol described by the supplier (alkaline 
conditions), this does not significantly affect the sensitivity or results of the assay 
(Figure 4). 
 
TABLE 3. Quantification of nanoparticle uptake into THP-1 cells 
Nanoparticle 
Type 
Required 
Measurements 
Units Equation Rationale 
PEG-PPS-
USPIOs 
[Fe] and 
[Protein] in cell 
lysates 
μg Fe / 
mg 
protein 
    
         
 
Result is a quantity 
normalized to cell 
number, but reflects 
dose-dependence and 
cell number-dependence 
of quantified 
internalization. 
Pluronic-PPS-
USPIOs 
[Fe] and 
[Protein] in cell 
lysates, and [Fe]0 
(concentration 
of iron 
administered at 
time 0)  
% / mg 
protein 
(
    
     
)     
         
 
Different surface 
chemistries led to 
differing loading 
efficiencies of Pluronic-
PPS nanoparticles with 
USPIOs. Quantification 
method enables 
experiments to be run at 
constant nanoparticle 
concentrations, without 
worry of effects of 
different loading 
efficiencies on measured 
iron internalization. 
 
 Calculation of nanoparticle internalization was dependent upon nanoparticle 
type, as shown in Table 3. The rationale behind the two different measurement 
types is inherent to the loading efficiencies possible. Because PEG-PPS-USPIO 
samples are purified, all cell-nanoparticle interactions in experiments involving 
them involve an iron ‘tag’. However, since Pluronic-PPS-USPIOs are a subpopulation 
of the nanoparticles used in this system, not all cell-nanoparticle interactions here 
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involve the iron ‘tag’. Due to differing USPIO loading efficiencies across the different 
Pluronic-PPS surface chemistries available to us, an additional normalization 
method was required in order that resulting figures fully represented charge-
dependent uptake of nanoparticles. The normalization of internalization data to the 
initially administered dose of iron was therefore used to report internalization of 
Pluronic-PPS-USPIOs (Table 3). 
 For cell viability experiments, cells were incubated for 24 h with PEG-PPS-
USPIOs, at a final iron dose of 30, 60, or 120 μM. After rinsing cells 3x with PBS to 
remove unbound nanoparticles, they were stained with a commercial calcein-
AM/ethidium homodimer live-dead assay kit (Invitrogen, Carlsbad, CA), and 
quantified according to the manufacturer’s instructions. 
 
Protease-Activatable Nanoparticles 
“Proximity-activated” USPIOs (PA-USPIOs)—which are able to respond to 
local MMP-9 activity, were formed as described for other PEG-PPS-USPIOs above. 
For protease experiments, 50 μL PA-USPIOs (Iron dose = 600 μM) were incubated 
with 10 μL MMP-9 (final concentration = 2 μg/mL) in an aqueous buffer containing 
0.1 M HEPES, 0.15 M NaCl, and 5 mM CaCl2 (pH 7.2) for 24 h at 37°C. For control 
experiments, PA-USPIOs were incubated with buffer only. Following cleavage, 
nanoparticles were added directly to cell cultures. The final concentration of iron 
and MMP-9 in the cell cultures is 120 μM and 400 ng/mL, respectively. In some 
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control experiments, MMP-9 inhibitor was also added to the cell cultures, to a final 
concentration of 300 ng/mL. 
 
Magnetic Resonance Imaging (MRI) 
MRI was performed on a Varian 4.7 T horizontal bore imaging system. T2 
signal decay was measured using a Carr-Purcell-Meiboom-Gill (CPMG) spin-echo 
pulse sequence with N = 8 echoes with 6.5 millisecond echo spacing.  The signal 
from each voxel at the 8 imaging time points was fit to a mono-exponential signal 
decay model to determine T2 for each voxel: 
          
 
 
       [1] 
A region of interest (ROI) was manually drawn using MATLAB (MathWorks, 
Inc, Natick, MA) for the first imaging time point and translated to the images from 
later echoes. The mean T2 and standard deviation for each well was then calculated 
from all voxels within this ROI. Other imaging parameters included TR = 2 seconds, 
field of view = 22 mm x 22 mm, data matrix = 128 x 128, slice thickness = 1 mm, 
number of acquisitions = 24 (total scan time ~ 1 h 45 m). 
 To prepare cells for MRI, the supernatant containing unbound nanoparticles 
in medium was aspirated and replaced with PBS, prior to scraping of the cells into 
the buffer (Corning Life Sciences, Lowell, MA). Cells were centrifuged into a pellet at 
300 x g for 5 min, and rinsed with PBS twice more. Cells were then fixed with 10% 
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buffered formalin, gently mixed, and allowed to incubate for 30 min at room 
temperature before they were pelleted and imaged. 
 
Results and Discussion 
 The primary objective of this study was to investigate size- and charge-
dependent non-specific uptake of nanoparticles by macrophages. With the targeted 
size range being in the sub-100 nm hydrodynamic diameter range, the objectives 
required the synthesis of a library of highly monodisperse, water-soluble 
nanoparticles in order to reduce size overlap between different nanoparticle 
formulations and elucidate trends between size and uptake. Therefore, USPIO cores 
were synthesized by thermal decomposition in organic solvents, which led to oleic 
acid-stabilized USPIOs (OA-USPIOs) of 3.0 ± 0.4 nm (Figure 5A, n ~ 200) and 12.0 ± 
1.0 nm (Figure 5B, n > 400). Control over USPIO core diameters was accomplished 
by adjusting the molar ratios of oleic acid surfactant to iron pentacarbonyl 
precursor in the reaction feed, and to date, we have synthesized OA-USPIOs of up to 
24 nm in diameter using this method (Figure 3). These results extend previous work 
by Woo et al. (Woo et al., 2004), who showed the ability to synthesize particles from 
5 – 19 nm in diameter using this same exact method. Additionally, we were also able 
to scale up this original synthesis and now are able to produce the uniform OA-
USPIOs in 1-gram amounts. 
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FIGURE 5. Characterization of USPIOs and PEG-PPS-USPIO micelles. HRTEM images of 
(A) 3 nm and (B) 12 nm hydrophobic, oleic acid-stabilized USPIO cores (γ-Fe2O3), which 
were synthesized via thermal decomposition. To render particles water-soluble, they were 
coated with PEG-PPS block copolymers via thin-film hydration to yield, respectively, (C) 30 
nm and (D) 40 nm PEG-PPS-USPIO micelles. (E) 100 nm PEG-PPS-USPIO micelles can also 
be synthesized via direct hydration using the same feed materials used to create micelles in 
(D); this TEM image has been counterstained with 3% uranyl acetate. (F) Size-number 
distributions of these PEG-PPS-USPIO micelles were obtained by dynamic light scattering. 
(G) As shown in this representative photograph, 40 nm PEG-PPS-USPIOs remain stable in 
water and do not flocculate even after storage at room temperature over four months. Scale 
bars = (A,C) 20 nm; (B.D) 100 nm; (E) 500 nm. 
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To render the OA-USPIOs water-soluble, either a thin-film hydration or a 
direct hydration method was employed, effectively encapsulating OA-USPIOs within 
micelles composed of amphiphilic PEG-PPS block copolymers (1.65 kDa PPS block, 
4.2 kDa PEG block; Figure 5C-E). Prior to cell experiments, the micelles were sterile-
filtered; size-number distributions of the completed USPIO-loaded micelles are 
shown in Figure 5F. However, due to the larger size of the 100 nm micelles, these 
materials tended to be caught in the Teflon filters and were thus used as synthesized. 
The 30 nm and 40 nm micelles were particularly stable in water and flocculated 
minimally even after storage for several months at room temperature (Figure 5G). 
These two formulations were also extremely difficult to pellet by centrifugation or 
through the influence of an externally-applied 1 T neodymium magnet. The 
completed micelles exhibited ζ-potentials that were weakly anionic (Table 4), owing 
partly to the terminal mono-methyl ether group on the PEG block that is displayed 
on the nanoparticle surface. 
 
TABLE 4. Size and ζ-potential of as-synthesized PEG-PPS-USPIO micelles 
Sample Name USPIO Core 
Diameter (nm) 
Micelle Diameter 
Range (nm) a 
ζ-Potential (mV) 
30nm PEG-PPS-USPIOs 3 30.0 ± 2.6 -2.8 ± 5.9 
40nm PEG-PPS-USPIOs 12 36.6 ± 11.9 -1.7 ± 4.6 
100nm PEG-PPS-USPIOs 12  -7.8 ± 5.1 
a Determined after filtration through a 0.45μm PTFE filter. 100 nm PEG-PPS-USPIOs were 
not as stable to filtration and were not subjected to this additional treatment step prior to 
use in cell experiments. 
 
Nanoparticles were next administered to THP-1 human leukemic 
macrophages in order to establish a quantitative basis for the remainder of the 
experiments, while also examining the kinetics of particle uptake. THP-1 cells were 
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chosen for this study because uptake and processing of lipid nanoparticles by THP-1 
and primary human monocyte-derived macrophages is not significantly different 
between the two cell types (Griffin, Ullery, Cox, & Jerome, 2005; Jerome, Cox, Griffin, 
& Ullery, 2008). We expected, therefore, that macrophage interactions with 
synthetic nanoparticles can be similarly modeled through this readily available, in 
vitro system. 
As an example, varying doses of the 100 nm PEG-PPS-USPIOs were 
administered to THP-1 macrophages. Because first-order rate equations are often 
used as governing equations in efforts to model receptor-mediated endocytosis of 
nanoparticles by macrophages (Ece Gamsiz, Shah, Devalapally, Amiji, & Carrier, 
2008), the resulting 24 h uptake profiles (Figure 6A) were fit to first-order rate 
kinetic equations (Figure 6A-B). The successful curve-fit suggested that USPIO 
concentration is the primary determinant of uptake rate. The best-fit equations take 
the form: 
[2]                
     
where [C]max represents the maximum possible concentration of iron in the cells and 
[C] is a measure of the accumulated iron content in the cells. As the fit equations 
show (Figure 6A), the calculated [C]max values are proportional to the initially 
administered doses of PEG-PPS-USPIOs (standard errors < 13%), while the 
calculated rate constants k do not vary significantly across the doses (standard 
errors 25-40%). Relative to the initial doses of USPIOs, macrophages receiving 30, 
60, and 120 μM of iron endocytosed 8.4 ± 3.7%, 7.7 ± 3.2%, and 6.2 ± 0.9% of the 
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FIGURE 6. Dose- and size-dependent internalization of PEG-PPS-USPIOs by THP-1 
macrophages. THP-1 cells were treated for up to 24 h with standard growth serum 
medium supplemented with varying doses of PEG-PPS-USPIOs in PBS. As a negative control, 
PBS was used in place of the PEG-PPS-USPIO colloidal suspension. Iron internalization and 
initial doses were quantified using a colorimetric phenanthroline assay, and internalized 
iron content was normalized to cell number indirectly via a protein assay. (A) 
Internalization of nanoparticles over the time period of interest is described by first-order 
rate kinetics, indicating that initial dose of nanoparticles is the primary determinant of 
internalization rate and total internalization amount. Relative to the initial doses of USPIOs, 
macrophages receiving 30, 60, and 120 μM of iron endocytosed 8.4 ± 3.7 %, 7.7 ± 3.2 %, and 
6.2 ± 0.9 % of the maximum possible USPIOs, respectively. Error bars indicate standard 
deviations from 6 independent experiments. (B) Derivatives of the best-fit kinetic equations 
plotted in (A) demonstrate further the dependence of uptake rate on initial dose of PEG-
PPS-USPIOs. (C) Of the three sizes investigated, 100 nm nanoparticles were most effectively 
internalized by the macrophages. Smaller nanoparticles were internalized less effectively, 
and 30 nm nanoparticles experienced almost negligible uptake levels over the 24 h 
experimental period. Normalization of the 24 h uptake amounts to the initially administered 
doses shows that macrophages internalized 6.2 ± 0.9 %, 1.4 ± 2.3 %, and 1.1 ± 0.3 % of the 
100 nm, 40 nm, and 30 nm PEG-PPS-USPIOs, respectively. Error bars represent standard 
deviation from 3-6 independent experiments. (D) Fluorescent imaging of the delivery of 40 
nm and 100 nm fluorescent PEG-PPS-USPIO micelles. The uptake of 100 nm nanoparticles 
was easily visualized at 20X magnification with a 0.7 s exposure time, but even with a lower 
magnification and roughly a threefold higher exposure time, the microscope was 
insufficiently sensitive to visualize the internalization of the 40 nm nanoparticles. (E) 40 nm 
PA-USPIOs (at 200 μM Fe) or 100 nm PEG-PPS-USPIOs (at 120 μM Fe) were co-
administered to THP-1 macrophages with varying amounts of fucoidan for 24 h, and 
allowed to incubate overnight prior to cell lysis and measurement of internalized iron. 
Increasing concentrations of fucoidan correlated with decreased uptake of the 
nanoparticles, suggesting that the mechanism of PEG-PPS-USPIO uptake is via receptor-
mediated endocytosis, and facilitated by the scavenger receptor CD204. Error bars 
represent standard deviation of three independent experiments. 
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maximum possible USPIOs, respectively. In order to ensure that the measurements 
excluded USPIO binding events not resulting in uptake, some experiments were also 
conducted at 4°C to block endocytosis, resulting in insignificant iron levels 
quantified in the lysates (Figure 7). In addition, a live-dead cytotoxicity assay was 
also conducted in order to confirm that treatment of macrophages with the PEG-
PPS-USPIOs resulted in minimal cell death (Figure 8). 
 
 
FIGURE 7. 24 h uptake of nanoparticles by THP-1 macrophages. Cells were treated with 
40 nm PEG-PPS-USPIOs for 24 h, and then measured for iron content via the phenanthroline 
assay. Iron content was normalized to cell number indirectly via a protein assay. To confirm 
that the phenanthroline assay measures internalized nanoparticles and not just 
nanoparticles that have bound to macrophage receptors, some cells were incubated with 
nanoparticles at 4°C. Results showed about 10-fold lower iron content in these samples 
relative to samples treated at 37°C, indicating that the protocol successfully lyses cells and 
enables measurements of internalized iron. Error bars indicate standard deviation of 3 
independent experiments (*p < 0.01). 
 
 Similar nanoparticle uptake kinetics were also observed for particles of 
smaller hydrodynamic diameters (Figure 6C). The results also show that by mass, 
smaller nanoparticles are internalized less effectively than their larger counterparts. 
The 40 nm nanoparticles shown in this graph were based on a higher iron dose for  
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easier visualization; however, the same nanoparticles, administered at the same 120 
μM Fe dose as the other two samples, were internalized at 0.36 ± 0.55 μg/mg 
protein (curve not shown). Normalization of the 24 h uptake data to the initially 
administered doses shows that THP-1 macrophages were able to internalize 1.1 ± 
0.3 %, 1.4 ± 2.3 %, and 6.2 ± 0.9 % of the 30 nm, 40 nm, and 100 nm PEG-PPS-
USPIOs, respectively. When nanoparticle internalization is normalized to cell 
number, a 70% decrease in PEG-PPS-USPIO diameter corresponded with almost a 
10-fold decrease in iron uptake per cell. This was supported by fluorescence 
microscopy experiments, where macrophages were treated with FITC-tagged 
nanoparticles (Figure 6D), demonstrating the accumulation of 100 nm micelles 
 
FIGURE 8. Cell viability measurements on nanoparticle-treated THP-1 cells. All 
measurements have been normalized to untreated cells (media + PBS). Cells were treated 
with increasing doses of 100 nm PEG-PPS-USPIOs for 24 h, prior to removal of unbound 
nanoparticles and assessment of cell viability via quantification of calcein-AM/ethidium 
homodimer staining. Dosage on the x-axis represents actual iron concentration within the 
samples. No statistically significant differences in viability were observed between any of 
the treatment groups (n = 3). 
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within the macrophages. Despite longer exposure times at a lower magnification, 
the microscope was insufficiently sensitive to visualize the internalization of the 40 
nm micelles by the macrophages. Taken together, these data suggest a positive 
correlation between nanoparticle size and their non-specific recognition and 
internalization by macrophages. 
Given the lack of any specific targeting moieties on the micelle surface, this 
evidence suggested that within the nanoparticle size range investigated, 
macrophages were able to optimally recognize and internalize PEGylated 
nanoparticles of > 100 nm diameter. Further, smaller nanoparticles seemed to 
experience significantly less non-specific uptake by the macrophages. One of the 
mechanisms of uptake is likely through receptor-mediated endocytosis via CD204—
as PEG-PPS-USPIO internalization can be effectively blocked by co-administration of 
nanoparticles with fucoidan, which is a well-known CD204 ligand (Figure 6E) 
(Brown & Goldstein, 1983). 
We next investigated the effects of nanoparticle charge on non-specific 
uptake. Because the sub-40 nm nanoparticles provided a satisfactorily minimal 
baseline uptake over 24 h, we opted to focus on nanoparticles of this size for this 
section of the study. End-carboxylated, -aminated, or -thiolated Pluronic were used 
as surfactants in inverse emulsion polymerization as described previously (Thomas, 
et al., 2011). The resulting Pluronic-PPS nanoparticles were loaded with USPIOs via 
direct hydration (Figure 9A-C), and delivered to THP-1 macrophages under the 
same conditions described for the other cell experiments above. Since Pluronic 
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polymers are PEG-containing block co-polymers, the properties of Pluronic-PPS are 
not very different from those of PEG-PPS used in the other studies shown here, and, 
in effect, still produce PEG-PPS-coated USPIOs. Pluronic-PPS enables facile synthesis 
schemes necessary to produce the various end-functionalized polymers used in this 
work that would be difficult to generate from PEG-PPS coatings (Rehor, et al., 2005). 
In order to account for differences in USPIO loading efficiencies across the 
library of Pluronic-PPS nanoparticle formulations, uptake was not only reported as 
[Fe]/[Protein] as above, but further normalized to initial doses of iron and reported 
as % injected dose/protein (%ID/mg protein; Figure 9D). We hypothesized that this 
system would enable us to parse out the roles of surface charge from size on 
nanoparticle internalization, leading us to identify the sensitivity of size and charge 
on nanoparticle non-specific uptake by macrophages. 
The Pluronic-PPS-USPIOs initially exhibited surface charges from -23 mV up 
to +9 mV, but following incubation in 10% serum media for 4 h, all nanoparticle 
formulations experienced significant changes in zeta potential (Figure 9D). 
Therefore, while the zeta potential of the nanoparticles was tunable to some extent 
by varying the surface chemistry of the nanoparticles, electrostatic interactions with 
serum proteins and components, as well as protein adsorption and opsonization 
processes contributed to significant changes in nanoparticle properties. The 
addition of serum into the incubation medium for these studies is intended to reflect 
an interaction environment that includes important components of the in vivo 
environment.  Since there is no opportunity for nanoparticle purification following 
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intravenous injection, we elected to allow nanoparticle interaction with serum 
proteins during zeta potential measurements, and later on, incubation with THP-1 
cells. One outcome of this approach, and equally true in vivo, is the modulation of 
initial nanoparticle zeta potential by serum protein adsorption. These processes 
have been studied in detail for the Pluronic-PPS nanoparticle system, as reported by 
Thomas et al (Thomas, et al., 2011). In particular, varying the surface chemistry of 
this nanoparticle system influenced the ability of the nanoparticles to become 
functionalized with the C3 complement proteins (Thomas, et al., 2011). More 
generally, this phenomena is well known in the synthetic gene delivery field, in 
which cationic nanoscale carriers of pDNA or siRNA rapidly interact with albumin 
and other serum proteins in vivo, and is consistent with the findings reported here 
(Phillips & Heydari, 1996). This is significant because many consider that a 
minimum zeta potential of ±30mV is necessary in order to form stable nanoparticle 
suspensions (Han, Li, Yin, Liu, & Xu, 2008). Because electrostatic interactions and 
adsorption processes between serum proteins and the nanoparticle surface are 
inevitable following in vivo administration, higher zeta potential magnitudes may 
actually promote these processes, and in turn, opsonization processes ultimately 
leading to nanoparticle clearance from the bloodstream. 
The observed decrease in the magnitude of the nanoparticle zeta potentials 
did not correspond with increased agglomeration, as no flocculation or 
sedimentation was observed in any of the samples following treatment with serum. 
This observation was true of all nanoparticle formulations regardless of surface 
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chemistry, possibly owing to the colloidal stability of Pluronic-PPS nanoparticles as 
shown previously (Rehor, et al., 2005). 
 
 
FIGURE 9. Effects of nanoparticle surface charge and chemistry on macrophage 
uptake. Representative TEM images of hydrophobic, unloaded 3 nm OA-USPIOs (A) and 
water-soluble Pluronic-PPS nanoparticles after loading with the OA-USPIOs (B). (C) The 
loading process does not significantly affect the hydrodynamic diameters or the zeta 
potentials inherent to the Pluronic-PPS nanoparticles. (D) ζ-potential of all nanoparticle 
formulations (color-coded by surface chemistry) was originally measured in PBS following 
synthesis, and again following incubation in 10% serum media. While modulation of surface 
chemistry allows for a wide range of ζ-potentials, this range is compressed due to 
interactions between nanoparticles and media components. Uptake of nanoparticles 
correlated with their surface charge as measured in media (inset; red dotted boxes indicate 
source of data for x-axis), according to a parabolic distribution. To account for differences in 
USPIO loading efficiency across the different Pluronic-PPS nanoparticle formulations, 
nanoparticle uptake was normalized to the initial dose administered as well as cell content 
indirectly, via a protein assay. Error bars indicate standard deviation for 3 independent 
experiments. (E) Cell internalization data is plotted versus nanoparticle ζ-potentials 
measured in 10% serum media (solid squares). In order to determine which nanoparticle 
feature may be more determinant of non-specific interactions with macrophages, the effects 
of nanoparticle diameter have also been plotted for comparison (open squares). 
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The two formulations that were most efficiently internalized were the 
nanoparticles displaying the terminal OH (12 ± 5% ID/mg protein) and the 
10%COOH/90% OH/SH (11 ± 5 %/mg). Uptake correlated with nanoparticle charge 
as measured in serum, yielding a parabolic trend with maximum uptake observed 
for cationic and strongly anionic nanoparticles (Figure 9D, R2 = 0.94, inset). 
However, because interactions with serum compressed the range of nanoparticle 
zeta potentials, we were unable to experimentally explore uptake of the 
nanoparticles beyond the -10 mV – 0 mV range. Despite the narrow window of zeta 
potentials covered by the data, the trends suggest that non-specific uptake of 
nanoparticles may be promoted by nanoparticle cationicity or high anionicity. This 
is consistent with previous observations (Raynal, et al., 2004). 
 Uptake of nanoparticles in serum was minimized in the range of zeta 
potentials from -9.0 mV to -3.5 mV. A three-fold increase in uptake was measured 
for identically sized nanoparticles having zeta potentials in serum from -3.5 mV to -
0.8 mV, representing a 77% decrease in anionicity. In comparison, a four-fold 
change in uptake was observed for a 60% decrease in PEG-PPS-USPIO diameter 
(100 nm to 40 nm).  Over these ranges and conditions, macrophage uptake of these 
nanoparticles is 42% more sensitive to size than to zeta potential (Figure 9E). 
To expand on this conclusion, we synthesized PEG-PPS-USPIOs containing an 
MMP-9-degradable peptide ([M9C]) within the PEG chain (Figure 10A-B). This 
design results in particles that respond to active MMP-9 in the environment by 
releasing a layer of PEG, effectively leading to a decrease in nanoparticle diameter.  
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FIGURE 10. Behavior of MMP-9-responsive PA-USPIOs. (A) Synthesis of MMP-9-
cleavable PEG-PPS chains (mPEG-[M9C]-PEG-PPS; PA) and (B) encapsulation of USPIOs to 
form PA-USPIOs. MMP-9 is able to recognize and cleave the [M9C] peptide sequence, 
resulting in release of a layer of PEG from the nanoparticle surface, accompanied by a 
decrease in nanoparticle hydrodynamic diameter. (C) DLS characterization of 
hydrodynamic diameters of as-synthesized 60 nm PA-USPIOs (C; green) and 30 nm PA-
USPIOs (D; blue) demonstrates a loss in hydrodynamic diameter following treatment with 
MMP-9. (E) Buffer-treated or MMP-9-pretreated nanoparticles were delivered to THP-1 
macrophages for 24 h. As a control, PBS was used in place of the nanoparticles. For both PA-
USPIO formulations tested, the decrease in nanoparticle size following MMP-9 treatment 
results in less effective nanoparticle internalization by the macrophages. Error bars 
represent standard deviations from 3-6 independent experiments.*p < 0.05 by Student’s t-
test. (F) T2-weighted MRI of THP-1 cells treated with MMP-9-cleaved PA-USPIOs appeared 
brighter than cells incubated with untreated PA-USPIOs, indicating that less cleaved 
nanoparticles were internalized by the macrophages versus the untreated PA-USPIOs. 
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Probes for MMP-9 activity are of wide interest because of the upregulation of MMP-
9 in the progression of atherosclerosis (Gough, et al., 2006; Schellenberger et al., 
2008; Sluijter, et al., 2006). Based on the studies described earlier, we hypothesized 
that this experimental contrast agent would experience less uptake by macrophages 
following treatment with MMP-9, relative to the as-synthesized, intact form.  
These MMP-9-responsive contrast agents were synthesized by encapsulating 
10 nm and 3 nm OA-USPIOs using ~10 kDa mPEG-[M9C]-PEG-PPS (subsequently 
referred to as ‘PA’ for protease-activatable), to produce 60 nm and 30 nm PA-
USPIOs (Figure 10 C-D). Both PA-USPIO formulations responded to MMP-9 
treatment with a 10-20 nm decrease in nanoparticle hydrodynamic diameters as 
measured by DLS, while ζ-potentials were not significantly affected (30 nm PA-
USPIOs: -3.9 ± 6.4 mV pre-cleavage, -2.8 ± 5.9 mV post-cleavage; 60 nm PA-USPIOs: 
0.0 ± 7.1 mV pre-cleavage, -4.7 ± 5.5 mV post-cleavage). For cell experiments, PA-
USPIOs were incubated with MMP-9 for 24 h prior to their administration to THP-1 
cells at equivalent iron doses. In both cases, MMP-9-treated PA-USPIOs were 
internalized significantly less effectively than their non-cleaved counterparts 
(Figure 10E). Most notably, the 30 nm PA-USPIOs experienced a six-fold decrease in 
nanoparticle uptake following MMP-9 cleavage (0.12 ± 0.04 μg Fe/mg protein pre-
cleavage vs. 0.02 ± 0.02 μg/mg post-cleavage). Also of note is the slightly higher 
uptake of the MMP-9-treated 60 nm PA-USPIOs (final diameter = 40.0 ± 6.2 nm) 
relative to the untreated 30 nm PA-USPIOs (30.0 ± 2.6 nm).  
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FIGURE 11. Negligible effects of MMP9 on uptake of MMP9-insensitive nanoparticles. 
Co-administration of 40 nm PEG-PPS-USPIOs (do not contain MMP-9-cleavable peptide) 
with MMP-9 does not significantly affect internalization of nanoparticles. THP-1 cells were 
treated with media only (untreated), nanoparticles only, or nanoparticles co-administered 
with 200 ng/mL MMP9 and/or 300 ng/mL MMP9 inhibitor. Because these nanoparticles do 
not contain MMP9-cleavable elements, their diameter is unaffected by treatment (data not 
shown). MMP9 treatment does not change the properties of the THP-1 cell membrane in a 
way that affects their interactions with nanoparticles. Error bars indicate standard 
deviation for three independent experiments. 
 
Because these changes in nanoparticle internalization may be due to MMP-9-
mediated modifications on the cell membranes, a series of control experiments were 
also performed, using non-cleavable, 40 nm PEG-PPS-USPIOs (Figure 11). In these 
experiments, co-administration of non-cleavable nanoparticles with MMP-9 did not 
lead to significant differences in nanoparticle internalization. Further, co-
administration with a MMP-9 inhibitor also did not affect internalization. Taken 
together, the results suggest that the variations in PA-USPIO internalization by the 
THP-1 cells were attributable to the size of the nanoparticles, as the nanoparticle 
zeta potentials did not vary significantly before versus after treatment with MMP-9. 
Further, cellular capacity for nanoparticle internalization was unaffected by 
exposure to protease. 
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To determine if these MMP-9-dependent differences in nanoparticle 
internalization result in statistically significant changes in sample T2 relaxation, and 
therefore, clinically relevant detection of MMP-9 activity in cell samples, 60 nm PA-
USPIO-treated cells were pelleted and imaged on a 4.7T magnetic resonance 
imaging scanner (Figure 10F). Through the use of a Carr-Purcell-Meiboom-Gill 
(CPMG) spin-echo pulse sequence, MMP-9-treated PA-USPIOs appeared to exhibit 
higher mean gray intensities versus cells incubated with untreated PA-USPIOs.  
 While the PA-USPIOs exhibited T2 = 4.82 ± 0.02 ms, the PA-USPIOs on the 
macrophages exhibited T2 = 23.2 ± 3.5 ms. These rather strong changes in T2 are 
somewhat surprising assuming that ~1% of the administered dose was taken up by 
the macrophages as measured in the earlier sections of this work. This implies that 
for each imaging slice, the concentration of iron responsible for T2 signal modulation 
within that slice is about 100-fold less in the nanoparticle-treated cell samples 
versus the positive control. To quantify this phenomenon, the calculated values 
above (from first-principles measurements) can be plugged into the R2 relaxivity 
equation: 
[3]    
 
       
 
in order to produce a measure of how effective the USPIOs are in modulating the 
local negative contrast. Given that measured T2 in the cell samples is only ~5 times 
higher than the measurements in the positive control, the iron concentration in the 
cell samples would need to be about a fifth of the concentration in the positive 
control in order to maintain the same R2 value. As we have seen, this is hardly the 
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case, and based on our data, we can conclude that the R2 values in the cell sample 
would have to be on the order of 20-fold larger than the R2 of the free-floating PA-
USPIOs. These results indicate that following internalization by the macrophages, 
the PA-USPIOs are being manipulated in such a way that increases their ability to 
exert T2 contrast. 
 This phenomenon can be explained by previous observations that aggregated 
or clustered superparamagnetic nanoparticles result in higher R2 versus fully 
dispersed, singlet nanoparticles (Perez, O'Loughin, Simeone, Weissleder, & 
Josephson, 2002; S. S. Yu, R. L. Scherer, et al., 2011). Others have demonstrated via 
TEM that following endocytosis of iron oxide nanoparticles, macrophages can 
process the particles into lysosomes, where dense clusters of particles can usually 
be observed (Muller et al., 2007). Taken together, these other observations help 
explain how even a small amount of nanoparticle uptake results in a marked change 
in T2 contrast in the system. 
 
Summary 
 PEGylated nanoparticles are internalized by macrophages in a size-
dependent fashion for diameters between 30-100 nm. Charge-uptake relationships 
were investigated by varying the surface properties of nanoparticles. While the data 
supports the possibility that cationic and strongly anionic nanoparticles may be 
internalized most effectively, within the ranges investigated, nanoparticle size, not 
charge, is a stronger determinant of non-specific uptake by macrophages. Based on 
this information, an MMP-9-sensitive nanoparticle was developed that decreases in 
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size following treatment with MMP-9. Macrophages respond to MMP-9-treated 
nanoparticles in a predictable fashion, and cleaved nanoparticles were consistently 
phagocytosed less efficiently than their untreated counterparts, demonstrating the 
effects of dynamic nanoparticle size modulation on macrophage uptake. These 
MMP-9-induced differences in uptake are also detectable via MRI. Despite the low 
levels of overall uptake over the 24 h incubation periods (≤ 1% initially 
administered dose), a significant increase in macrophage R2 was observed.  
Presumably, and consistent with quantitative analysis, the clustering of 
nanoparticles into endosomes following endocytosis results in an increase in 
nanoparticle R2, providing amplification of negative MR image contrast. The results 
presented here inform the design of nanoparticles to target or evade macrophages 
in future in vivo applications. 
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CHAPTER III 
 
MACROPHAGE-SPECIFIC RNA INTERFERENCE VIA ‘CLICK’, MANNOSYLATED 
POLYMERIC MICELLES 
 
Macrophages represent an important therapeutic target, because their 
activity has been implicated in the progression of debilitating diseases such as 
cancer and atherosclerosis. However, macrophage-specific drug delivery within 
pathologic sites is a significant challenge, as non-specific drug delivery may lead to 
off-target side effects and undesired interference with molecular mechanisms in 
healthy tissues. In this work, we designed and characterized pH-responsive 
polymeric micelles that were mannosylated using ‘click’ chemistry. Mannose was 
chosen in order to achieve CD206 (mannose receptor)-targeted drug delivery, 
though this ‘clickable’ platform could be generally used to attach other targeting 
ligands to this efficient siRNA carrier.  CD206 is almost exclusively expressed on 
macrophages and dendritic cells, and upregulated in tumor-associated macrophages, 
a potentially useful target for cancer therapy. The glycosylated nanoparticles 
improved siRNA delivery into primary macrophages relative to a non-mannosylated 
version of the same carrier. Further, the mannose-targeted siRNA carriers achieved 
85±10% knockdown of a model gene within 24h of delivery, relative to non-
transfected macrophages. Finally, these nanoparticles were also avidly recognized 
and internalized by human macrophages, and facilitated the delivery of 13-fold 
more siRNA into these cells relative to model breast cancer cell lines. We anticipate 
these glycoconjugates to become an enabling technology to target macrophage 
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activity in various diseases, especially those where CD206 is up-regulated in 
macrophages present within the pathologic site. 
 
Introduction 
Macrophages perform a spectrum of functions, some of which have cytotoxic 
effects (i.e., when fighting infection) and others which promote cell growth, matrix 
remodeling, and wound healing (Kindt, et al., 2007). However, the dysregulation of 
these multifaceted activities can initiate pathogenesis and promote disease 
progression. For example, in various cancers, significant levels of macrophage 
infiltration have been observed, and this has been correlated with poor prognoses. 
This is hypothesized to occur because tumor-associated macrophages (TAMs) 
overexpress growth factors, VEGF, and matrix metalloproteinases, promoting tumor 
growth and invasiveness (Dirkx, et al., 2006). Therefore, macrophages are believed 
to represent an important therapeutic target in order to address a major underlying 
cause of cancer progression. Based on this hypothesis, technologies that enable cell-
specific phenotypic modulation of aberrant macrophage activity would potentially 
be of high impact on human health. 
 A promising strategy to address aberrant macrophage behavior is through 
the use of RNA interference (RNAi) therapy. One approach to therapeutically 
harnessing RNAi involves the delivery of duplex RNA sequences called small 
interfering RNA (siRNA).  siRNA is processed by the target cell’s inherent machinery, 
with the ultimate effect of gene silencing through cleavage and degradation of 
mRNA complementary to the antisense strand of the delivered siRNA duplex (Fire et 
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al., 1998). By silencing master genes that regulate aberrant macrophage activity, 
RNAi therapy has the potential to directly block macrophage functions that lead to 
disease progression. However, due to their highly degradative phagocytic, 
endosomal, and lysosomal compartments, delivery and cytoplasmic release of siRNA 
in macrophages is particularly challenging, especially in primary cells (Stacey, Ross, 
& Hume, 1993). Conventional transfection methods have led to limited success, 
because they involve chemically-mediated transfection, based on strongly cationic 
materials which are cytotoxic and have been largely restricted to the laboratory 
bench (Lv, Zhang, Wang, Cui, & Yan, 2006). 
While strategies exist for targeting macrophages at pathologic sites, some of 
these strategies require prior knowledge of the locations of these sites, in order to 
design injection routes for local delivery directly into the site of the macrophages 
(Kortylewski, et al., 2009; Watkins, et al., 2007). Such strategies include, for example, 
intratumoral or peritumoral injections of biologics, which may be useful when 
treating a primary tumor site but are poorly translatable to the treatment of 
dispersed, metastatic cancers. Alternative strategies require expensive technologies 
with uncertain practical clinical applicability, such as macrophage extraction, ex vivo 
modification, and adoptive transfer (Hagemann et al., 2008); antibody-nanoparticle 
conjugates (Briley-Saebo et al., 2011; Lipinski, et al., 2006); or custom phospholipids 
(Cormode, Skajaa, et al., 2008). Very few of these proposed approaches can be 
practically scaled for pharmaceutical purposes. Some of these methods deliver 
drugs to all cells non-specifically, and systemic interference with macrophage 
behavior may lead to autoimmune manifestations. Therefore, the clinical translation 
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of macrophage-targeted drug delivery is hampered by barriers spanning multiple 
disciplines, including targeting method, synthesis, and cost. 
 
 
FIGURE 12. Smart Polymeric Nanoparticles for Macrophage-Specific Cytosolic 
Delivery of siRNA. (A) Schematic representation of the triblock copolymers developed in 
the manuscript, and resulting, multi-functional nanoscale siRNA delivery vehicles. The 
blocks include (red) a pH-responsive block that is capable of disrupting endosomes at low 
pH, (blue) a cationic block for condensation of nucleic acids, and (green) an azide-displaying 
block for conjugation of targeting motifs (purple) via ‘click’ chemistry. (B) Synthetic scheme 
for RAFT polymerization of triblock copolymers composed of blocks of AzEMA, DMAEMA, 
and the DMAEMA-co-BMA-co-PAA terpolymer. (C-D) Uranyl acetate-counterstained 
transmission electron micrographs of (C) micelles of diblock copolymers (2), which had an 
average diameter of 13.0 ± 6.1 nm (n = 367). (D) ManNPs had an average diameter of 9.7 ± 
6.2 nm (n = 415). Scale bars = 50 nm. 
 
 
Therefore, we designed and evaluated a polymeric glycoconjugate that can be 
assembled into nanocarriers for macrophage-specific siRNA delivery (Figure 12A). 
These agents represent a targeted version of construct reported by Convertine et al. 
(Convertine, Benoit, Duvall, Hoffman, & Stayton, 2009), which is capable of 
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mediating the escape of its cargo from the endosomal pathway, due to their ability 
to disrupt phospholipid membranes at pH < 6.5. The original version of this efficient 
siRNA carrier lacked any molecular targeting functionality and has the ability to 
enter a range of cell types via non-specific mechanisms.  
The molecular structure includes a hydrophobic, pH-responsive component, 
a cationic, siRNA-condensing component, and a terminal segment with reactive sites 
for ‘click’ bioconjugation. These multifunctional polymers were synthesized via 
reverse addition-fragmentation chain transfer (RAFT) polymerization, which has 
the advantage of enabling the orthogonal polymerization of acrylate monomers 
displaying a wide range of chemical functionalities (Boyer et al., 2009). Additionally, 
it is a controlled radical polymerization method that leads to highly monodisperse 
products in an industrially-scaleable fashion, making it appropriate for 
pharmaceutical applications. Therefore, it is ideal for the proposed block 
copolymers, which feature carboxylic acids, azides, and tertiary amines among their 
functional groups (Figure 12). In aqueous media at pH 7.4, the polymers self-
assemble into micelles and can be surface-functionalized with a wide range of 
possible molecular structures through the azide-alkyne ‘click’ reaction. ‘Click’ 
reactions have been widely employed to perform covalent conjugations for 
biological applications, due to their orthogonality, specificity, speed, and efficiency 
(Kolb & Sharpless, 2003).  
Mannose was chosen as the targeting motif, since mannose receptor (CD206) 
is primarily expressed by macrophages and some dendritic cells (Taylor, Gordon, & 
Martinez-Pomares, 2005). In these cells, CD206 mediates the recognition and 
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endocytosis of mannosylated, fucosylated, or N-acetylglucosaminated substrates, 
which occurs via clathrin-coated vesicles (East & Isacke, 2002). Further, CD206 is 
upregulated in TAMs, and the potential to directly target these macrophages via 
mannose has not been explored (Vasievich & Huang, 2011). Mannose is also readily 
available at significantly lower costs than most alternative targeting motifs, 
improving the practicality of the approach. In this study, the capabilities of the 
mannose-targeted nanocarrier for cytosolic siRNA delivery and gene knockdown 
were evaluated in primary, murine bone marrow-derived macrophages (BMDMs). 
Specificity of the carriers was examined based on the ability of the glycoconjugate to 
deliver siRNA into immortalized human macrophages in competition with cancer 
cell lines. Results indicate that the described carrier offers significant opportunities 
for drug and siRNA targeting to TAMs.  
 
Materials and Methods 
All reagents and materials were purchased from Sigma-Aldrich (St. Louis, MO) 
and used as described unless described otherwise. Monomers for radical 
polymerization, including BMA, DMAEMA, PAA, and AzEMA, were all purified by 
vacuum distillation and stored at 4°C in clean, inhibitor-free containers. 
Riboshredder RNAse blend was purchased from Epicentre (Madison, WI). 
Immortalized cell lines were acquired from American Type Culture Collection 
(Manassas, VA). Cell culture supplies, including media, fetal bovine serum, 
antibiotics, and non-essential amino acids were obtained from Life Technologies 
(Carlsbad, CA). The siRNA sequences purchased for transfections were: FAM-labeled 
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anti-GAPDH siRNA (FAM-siRNA) and Cy3-labeled siRNA. The anti-PPIB siRNA used 
in knockdown experiments was purchased from Integrated DNA Technologies 
(Coralville, IA). Horse serum was purchased from Atlanta Biologicals (Norcross, GA). 
 
Synthesis of 2-azidoethanol 
 
FIGURE 13. Synthetic scheme for 2-Azidoethyl methacrylate (AzEMA).  
 
In a 500 mL round-bottom flask, 15.6 g of sodium azide (0.24 mol) was 
dissolved in 100 mL of nanopure water, followed by the addition of 5.67 mL of 2-
bromoethanol (10 g, 0.08 mol; Figure 13). After capping the system with a septum, 
the reaction was heated to 80°C and allowed to stir overnight, during which the 
reaction changes darkens from yellow to orange. After allowing the reaction to cool 
to room temperature, the product was extracted 4x with 75 mL diethyl ether. 
Following two extractions, the aqueous phase changed colors from orange to clear. 
The pooled organic fractions were concentrated by rotary evaporation to yield a 
clear, colorless oil (95% yield; 6.66 g : 27.6137g – 20.9532g). 1H NMR (400 MHz, 
(CD3)2SO): δ (ppm) 3.20 – 3.27 (t, 2H, CH2N3), 3.44 (s, 1H, OH), 3.54 – 3.60 (q, 2H, 
CH2O). FT-IR (KBr pellet): 3380 cm-1 (broad, O-H), 2100 cm-1 (N3), 1295 cm-1 (C-N), 
1050 cm-1 (C-O). 
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Synthesis of 2-Azidoethyl methacrylate (AzEMA) 
In a round-bottom flask, 10 g of 2-azidoethanol (0.11 mol) was mixed with 
30.6 mL of Et3N (22.3 g, 0.22 mol) in 50 mL of CH2Cl2 in a dry ice-acetone bath (-
78°C; Figure 13). The reaction vessel was capped with a septum and degassed by 
alternating evacuation of the vessel and equilibration with nitrogen gas, 6x.  Next, 
8.6 mL of methacryloyl chloride (9.2 g, 0.088 mol) was injected into the system 
dropwise, and the reaction proceeded overnight (Caution: azide compounds may 
become shock-sensitive above 75-80°C, and this step is highly exothermic). The dry 
ice-acetone bath was allowed to warm to room temperature during this reaction. 
The crude product was extracted 3x with 1N hydrochloric acid to remove excess 
Et3N, extracted 2x with 1N aqueous NaOH, and precipitated in nanopure water. 
After drying the organic fraction over MgSO4, the product was concentrated under 
rotary evaporation to yield a dark red-orange liquid, which was further distilled 
under high vacuum to produce pure 2-azidoethyl methacrylate. 1H NMR (400 MHz, 
CDCl3): δ (ppm) 1.97 (s, 3H, CH3), 3.5 (t, 2H, CH2N3), 4.33 (t, 2H, CH2O), 5.62 (s, 1H), 
6.18 (s, 1H).  
 
Synthesis of alkyne-functionalized mannose 
The reaction diagram and characterization have been shown in Figure 14. In 
a round-bottom flask, 11 g of D-mannose (60 mmol) were dissolved into 30 mL 
dimethylsulfoxide (DMSO). To activate the sugar into a nucleophile, 10 mL Et3N 
(triethylamine; 72 mmol) was added to the reaction, prior to the addition of 5 g 
propargyl chloride (67 mmol). After flushing the reaction with argon, the reaction 
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proceeded for 24 h at 40°C. Excess reagents were removed by 5X extraction into 
diethyl ether. The remaining ether-insoluble phase was dissolved into nanopure 
water and further extracted 5X with dichloromethane to remove other byproducts 
and DMSO. The product was flash-frozen in liquid N2 and lyophilized. 1H- and 13C-
NMR and HPLC characterization data are presented in Figure 14. 
 
 
FIGURE 14. Synthesis and characterization of alkyne-functionalized mannose. (A) 
Reaction diagram for the synthesis of alkyne-functionalized mannose. The ideal product is 
shown on the right, but the scheme was not designed to be specific for the substitution of a 
particular hydroxyl group with a propargyl group. (B) Characterization of the precursor and 
product by HPLC. Evaporative light scattering chromatograms have been shown. The 
appearance of a large, later-eluting peak at ~0.1 min is due to the addition of a propargyl 
group onto the monosaccharide, which makes the molecule less polar than its precursor. 
The presence of excess precursor is not a concern, since the next reaction involving this 
mixture results in the ‘clicking’ of the modified sugar onto macromolecular assemblies 
(ManNPs), and purification by dialysis simply removes the excess precursor. (C) NMR 
spectroscopy of the precursor and product, with D2O as the solvent.  Because the propargyl 
chloride reagent is immiscible with water, the purification protocol used ensures the lack of 
this reagent in the final product. Blue arrowheads indicate peaks unique to the product, and 
are consistent with the attachment of alkyne groups onto the monosaccharide. 
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RAFT Polymerizations 
Synthesis of the RAFT chain transfer agent (CTA) 4-cyano-4-
(ethylsulfanylthiocarbonyl) sulfanylpentanoic acid (ECT) and 2-propylacrylic acid 
monomer have been described in detail in our previous work (Convertine, et al., 
2009; C. E. Nelson et al., 2012). Polymerization of the 47%BMA-25%PAA-
28%DMAEMA terpolymer was conducted at 70°C under N2 for 18 h with DMF as the 
solvent (90 wt% in feed), an initial monomer-to-CTA molar ratio of 100, and a CTA 
to initiator molar ratio of 10. After rapidly cooling the reaction in an ice bath, the 
organic mixture was mixed 1:1 (by volume) with aqueous HCl at pH 2, which 
initially results in a turbid mixture but quickly turns clear-yellowish as the 
monomers and polymers equilibrate with the acidic environment. Next, the polymer 
was precipitated 7x in hexanes and 2x in diethyl ether to remove residual 
monomers. Finally, the polymers, which were at this point still soluble in the acidic 
aqueous medium, were dialyzed across 10kDa molecular weight cutoff membrane 
(Pierce, Rockford, IL) against nanopure water (pH ~ 5, so no change in polymer 
solubility was observed) overnight. Lyophilization yielded pure terpolymer, which 
was a yellowish powder (Table 5). 
 
TABLE 5. Characterization of Polymers Synthesized via RAFT Polymerization 
Polymer dn/dc 
(mL/g) a 
Target 
Mn (Da) 
Mn 
(Da) b 
Mw (Da) 
b 
PDI Dh (nm) ζ-Potential 
(mV) 
Terpolymer 0.081 14000 11400 13900 1.22   
Diblock 0.049 21000 16800 20700 1.23 34.2 ± 2.2 10.8 ± 11.2 
Triblock 
(Before ‘click’) 
--- 22000 22300 28900 1.29 28.0 ± 1.5 19.6 ± 11.7 
aMeasured in off-line batch mode in a Shimadzu RID-10A differential refractive index (dRI) 
detector, with DMF + 0.1M LiBr as the solvent. 
bMeasured via gel-permeation chromatography with MALS and dRI in-line with columns.  
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 The same monomer:macroCTA:I molar ratios, and 90 wt% DMF conditions 
were used to polymerize the DMAEMA block onto the terpolymer macroCTA. To 
purify the diblock, the completed reaction was precipitated in ether at -20°C for 1h, 
and then pelleted by centrifugation at 800 x g for 5 min. After discarding the 
supernatant, the pellet was resuspended in deionized water, forming a slightly 
turbid suspension. Dialysis against deionized water for 48 h, across 10kDa-MWCO 
membrane, and lyophilization yielded pure diblock, which was a yellow-white 
powder. 
 
 
FIGURE 15. Characterization of Copolymers Synthesized via RAFT Polymerization. 
NMR spectra of the purified copolymers were collected following each round of synthesis 
and dialysis. Polymers were dissolved in CDCl3 prior to spectral acquisition. The key 
difference between the terpolymer and the diblock is a quantifiable increase in DMAEMA 
composition (for diblock, relative to terpolymer). The triblock exhibits an additional peak at 
~3.7 ppm, which is characteristic of the alkyl protons next to the free N3 group presented on 
the AzEMA block. 
 
 The polymerization of the AzEMA block onto the diblock was done to form 
triblock copolymers according to the same protocol. This mixture was then 
extensively dialyzed across 10kDa MWCO membranes overnight, against nanopure 
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water, to yield the completed triblocks. Triblocks were dissolved in deionized water 
at 1 mg/mL and stored at -20°C until ready for use in ‘click’ reactions. 
 1H-NMR spectra for all polymers are shown in Figure 15. 
 
‘Click’ Chemistry 
 
FIGURE 16. NMR Spectroscopy of Micelles of Block Copolymers in D2O. The surface 
moieties displayed by the various micelles are plotted at different steps of synthesis. All 
polymers were extensively dialyzed across 10 kDa-MWCO membranes and lyophilized, 
prior to reconstitution in D2O for NMR measurements. The diblock co-polymer forms 
micelles that display DMAEMA, as evidenced by the broad peaks in its characteristic regions 
(red). This layer is effectively shielded following the polymerization of AzEMA, which yields 
strong azide peaks and a small hump in the polymer backbone region (characteristic of the 
alkyl backbone that composes all poly-acrylates). The mannosylation of the triblock by 
‘click’ chemistry results in the appearance of new peaks in the 3.0-3.5 ppm region, which is 
slightly lower than where mannose peaks have been shown to appear (Figure 14), but is 
consistent with the immobilization of these polar molecules onto a hydrophobic polymeric 
backbone. 
 
In a scintillation vial, 1 mL of triblock co-polymer (1 mg/mL in nanopure H2O) 
was mixed with 6 mg alkyne-functionalized mannose (27.5 mmol). After the 
addition of CuSO4 and sodium ascorbate to final concentrations of 1 mM and 5 mM, 
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respectively, the reaction was allowed to proceed at 37°C on an orbital shaker in the 
dark for 48 h. Excess copper was removed by treating the crude product with Chelex 
100 Resin (Bio-Rad Laboratories, Hercules, CA) according to manufacturer’s 
instructions. The product was filtered through a 0.45 μm Teflon filter to remove the 
resin, and then dialyzed through a 2 kDa-MWCO membrane against deionized water 
to remove excess reactants. 1H-NMR characterization of the micelles before and 
after ‘click’ chemistry is shown in Figure 16. 
 
NMR and Chromatography 
Proton and carbon nuclear magnetic resonance (1H and 13C NMR) spectra 
were obtained at 400 MHz using a 9.4 Tesla Oxford magnet operated by a Bruker 
AV-400 console.  
Gel permeation chromatography (GPC) was performed with 
dimethylformamide (DMF) + 0.1 M LiBr as the mobile phase, by running samples 
through three resolving columns in series (1 × TSKGel Alpha4000, 2 × TSKGel 
Alpha3000; Tosoh Bioscience, King of Prussia, PA). Columns were maintained at 
60°C, and chromatograms were collected via a Shimadzu RID-10A refractive index 
detector (Shimadzu Scientific Instruments, Columbia, MD) and a Wyatt miniDAWN 
Treos multi-angle light scattering detector (MALS; Wyatt Technology, Santa Barbara, 
CA). Data collection and analysis was achieved through the Wyatt ASTRA software 
(v 5.3.4). Determination of absolute molecular weights was done by preparing 
known concentrations of purified polymer samples, and measuring their dn/dc in 
offline batch mode. 
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Analytical high performance liquid chromatography−mass spectrometry 
(HPLC-MS) was performed on an Agilent 1200 series system (Palo Alto, CA) as 
described elsewhere (S. S. Yu, R. L. Koblin, et al., 2011).  
 
Nanoparticle Characterization 
To prepare polymeric nanoparticles for transmission electron microscope 
(TEM) imaging, carbon film-backed copper grids (Electron Microscopy Sciences, 
Hatfield, PA) were inverted onto droplets containing aqueous nanoparticle 
suspensions (1 mg/mL) and blotted dry. Next, all samples were inverted onto a 
droplet of 3% uranyl acetate and allowed to counterstain for 2 min. After blotting 
the sample dry, samples were further desiccated in vacuo for 2 h prior to imaging on 
a Philips CM20 system operating at 200 kV. Images were collected using a CCD 
camera with AMT Image Capture Engine software (v 600.335h; Advanced 
Microscopy Techniques, Danvers, MA).  
Hydrodynamic diameter and ζ-potential of NPs were investigated by 
dynamic light scattering (DLS) in a Malvern Zetasizer Nano-ZS (Malvern 
Instruments Ltd., Worcestershire, U.K.). 
 
siRNA Protection Experiments 
50 pmol Cy3-labeled siRNA was complexed with mannosylated nanoparticles 
at N:P ratios of: 1:2, 1:1, 2:1, and 4:1. Ratios were calculated by using the 
concentration of NH+ (based on the degree of polymerization of the DMAEMA 
homopolymer block of the polymers, and the concentration of the polymers in μM) 
66 
and PO4- (based off the number of siRNA base pairs and the concentration of siRNA 
in μM). Because the pKa of the DMAEMA occurs at around pH 7.2, we assumed that 
the DMAEMA block was 50% charged for the calculation of N:P ratios. The 
complexes were loaded onto a 2% agarose gel containing 1.5 μM ethidium bromide. 
The RNAse protection experiment was performed on siRNA complexes with 
either diblock copolymers (0.5:1 N:P ratio) or mannosylated nanoparticles (0.5:1 or 
4:1 N:P ratios), as described elsewhere (Kirkland-York et al., 2010), 
 
Animals and Cell Lines 
Animal work was approved by the Vanderbilt University Institutional Animal 
Care and Use Committee. All mice were on an FVB background strain. Bone marrow-
derived macrophages were isolated from tibiae and femurs immediately after 
sacrificing the mice and cultured as described elsewhere (Connelly, Jacobs, Palacios-
Callender, Moncada, & Hobbs, 2003). Cells were seeded at 300,000 cells/cm2 for all 
experiments. 
L929 murine areolar fibroblasts were cultured in DMEM (purchased 
containing 4.5 g/L glucose, 110 mg/L sodium pyruvate, and 3.7 g/L NaHCO3), 
supplemented with 10% FBS, 1 U/mL penicillin, 1 μg/mL streptomycin, and 1% 
MEM non-essential amino acids. To create the macrophage colony-stimulating 
factor (M-CSF) source for differentiating bone marrow into BMDMs, 1.16 x 107 L929 
cells were seeded into T-225 flasks, in 77 mL of media. After 10 d of culture without 
any media changes, the supernatant was filtered through a 0.2 μm nylon membrane, 
and stored at -80°C until further use (Weischenfeldt & Porse, 2008). 
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 THP-1 human leukemic monocytes were cultured in RPMI-1640 media 
containing 10% FBS, 1 U/mL penicillin, 1 μg/mL streptomycin, 1 X MEM vitamins 
(Mediatech, Manassas, VA), 120 μM β-mercaptoethanol, and 10 mM HEPES. For 
experiments, these non-adherent cells were plated at 300,000 cells/cm2 in growth 
media containing 1 μg/mL lipopolysaccharide for 3 d, which activates the 
monocytes into macrophages and induces adherence of the cells to the substrate. 
For one experiment (shown in Figure 4), cells were seeded at 25,000 cells/cm2, in 
order to keep cell number constant across the three independent variables that 
were tested (cell type). 
MDA-MB-231 and MDA-MB-468 cells were cultured in DMEM (purchased 
containing 4.5 g/L glucose, 110 mg/L sodium pyruvate, and 2 mM L-glutamine), 
supplemented with 10% fetal bovine serum, 1 U/mL penicillin, 1 µg/mL 
streptomycin, and 1% MEM non-essential amino acids. For experiments, the cells 
were trypsinized and then re-seeded into 24-well plates at a density of 25,000 
cells/cm2. 
All cells were maintained in a 5% CO2 incubator at 37°C. 
 
Transfections 
Complexes were prepared by as described above. For some transfections, 
Lipofectamine RNAiMAX® (Life Technologies, Carlsbad, CA) was used to complex 
siRNA, and was used according to manufacturer’s instructions (Except for 
knockdown experiment, which was conducted for 24 h in order to compare all 
vehicles in head-to-head fashion). Cells were prepared for transfection by rinsing 
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wells twice with PBS to remove growth medium. This was replaced with serum-free 
medium, which is composed of DMEM with 4.5 g/L glucose, 1 U/mL penicillin, 1 
μg/mL streptomycin, and 2 mM L-glutamine. Complexes were then added to the 
wells such that the final concentration of siRNA in the wells was 50 nM (ten-fold 
dilution from stock). At set time points, wells were rinsed thrice with PBS to remove 
unbound complexes. Cells were then processed according to the desired experiment 
as described below. 
Transfected cells were analyzed for cell viability using a Live-Dead kit (Life 
Technologies) according to the manufacturer’s instructions. Quantification of live 
and dead cells was done by flow cytometry.  
 
Quantitative real-time PCR 
Total RNA was isolated from cell samples using the RNeasy Kit and 
QIAShredder columns (Qiagen). After the removal of genomic contamination 
through DNAse treatment (DNA-free kit, Life Technologies), cDNA libraries were 
constructed using a reverse transcriptase kit (Life Technologies). 
For qRT-PCR, Primers were purchased from Integrated DNA Technologies 
(Coralville, IA). PPIB sense: 5’- TTCCATCGTGTCATCAAG-3’ and antisense: 5’- 
GAAGAACTGTGAGCCATT-3’. β-actin sense: 5’ – CACACCTTCTACAATGAG – 3’ and 
antisense: 5’ – GGTCTCAAACATGATCTG – 3’. CD206 sense: 5’- 
CAAGGAAGGTTGGCATTTGT - 3’ and antisense: 5’– CCTTTCAGTCCTTTGCAAGC - 3’. 
Samples were treated with a SYBR Green PCR Master Mix in MicroAmp Fast optical 
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96-well plates (both from Life Technologies), according to the manufacturer’s 
instructions. 
Data was analyzed for CT values using the Applied Biosystems 7500 Fast 
Software (version 1.4.0). All plots of SYBR Green fluorescence versus cycle were set 
to the same baseline (usually within cycles 3-10; all of the sigmoidal amplification 
curves did not appear until after cycle ~15), thresholded evenly (same within 
samples analyzed for the same gene), and the intersection of the amplification curve 
and the threshold was reported as the CT value. Relative expression (RE) of a gene of 
interest (goi) was calculated against a control gene (cont; GAPDH or β-actin), 
according to the formula:         
               .. Fold-change in goi expression 
was calculated by dividing REgoi of experimental samples over REgoi of control 
samples (usually untreated cells). 
 
Flow Cytometry 
Flow cytometry was performed on a BD FACSCalibur system (Franklin Lakes, 
NJ), operated via a BD Cellquest Pro (version 5.2) software. The FL1 channel was 
used for the quantification of FAM emission of each cell. Data analysis and reporting 
were performed on FlowJo (version 7.6.4). 
 
Confocal Microscopy 
Transfections were performed as described above for 1,2, or 4 h. To prepare 
cells for confocal microscopy, they were washed with PBS, fixed for 15 min with 
10% buffered formalin, rinsed 3x with PBS, and then stained with DAPI (Invitrogen, 
70 
Carlsbad, CA) for 10 min. After rinsing cells 3x with PBS, slides were mounted with 
the Invitrogen ProLong Antifade kit. Imaging was performed on a Zeiss LSM 710 
system (Oberkochen, Germany). 
Images were processed via ImageJ software (version 1.43u; National 
Institute of Health, Bethesda, MD). 8-bit LSM images were converted to RGB images 
in order to make them compatible with the built-in “Merge Channels” function on 
the software, which creates the merged fluorescence overlay images used for some 
of the figures. Due to the low DAPI signal in some raw image files, the 
brightness/contrast of the DAPI channels for all images reported here were 
enhanced to varying levels. 
 
Hemolysis Assays 
Whole, unfractionated human blood samples were obtained from consenting 
anonymous, healthy adults under Vanderbilt University Institutional Review Board 
(IRB) approval (Protocol #111251). Whole blood (in K2EDTA-coated Vacutainer 
tubes) was centrifuged at 1500 rpm for 5 min (400 x g), and plasma was replaced 
with an equivalent volume of 150 mM NaCl. After inverting the tubes a few times to 
resuspend the pellet, and centrifuging the tubes at 1500 rpm for 5 min, the buffer 
was replaced with PBS at pH 7.4. The cell suspension was split into four tubes, 
corresponding to each pH to be assayed, and centrifuged at 1500 rpm for 5 min 
again. The supernatants were discarded, and replaced with PBS pre-adjusted to pH 
5.6, 6.2, 6.8, or 7.4. 1 mL of each stock suspension was further diluted 1:50 into PBS 
at the corresponding pH, prior to further use. 
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 In black, round-bottom 96-well plates, 10 μL of each test polymer, at three 
concentrations (20, 100, 800 μg/mL), were loaded. After the addition of 190 μL of 
purified red blood cells, the final concentrations of these polymer samples were 
adjusted to 1, 5, and 40 μg/mL, respectively. As controls, plain PBS (negative control) 
or 20% Triton X-100 (positive control) were added to some wells. These mixtures 
were allowed to incubate at 37°C in a 5% CO2 incubator for 1 h, following which 
they were centrifuged at 1500 rpm for 5 min. 100 μL of the supernatant in each well 
was transferred to clear, flat-bottom 96-well assay plates. This protocol enables the 
quantification of the release of hemoglobin as erythrocytes are lysed. Absorbance 
was plate-read at 450 nm using a Tecan Infinite F500 system (Männedorf, 
Switzerland), operated by Tecan i-Control software (version 1.7.1.12). The 
absorbance of the negative control sample was set to 0% hemolysis, and the 
absorbance of the positive control sample was set to 100% hemolysis. After setting 
up a linear regression based on these two data points, the resulting formula was 
applied on all other wells to calculate % hemolysis. 
 
Statistical Significance 
For all experiments, statistical significance was assessed using the unpaired 
Student’s t-test or one-way ANOVA as indicated in the text.  
 
Results 
Modular Design, Synthesis, and Characterization of Mannosylated siRNA 
Delivery Vehicles 
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The synthesis of the mannosylated delivery vehicles could be summarized 
into three parts: (1) the polymeric components were synthesized in three sequential 
iterations of RAFT polymerization and purification (Figure 12), (2) alkyne-
functionalized mannose was separately synthesized (Figure 14), and (3) the 
polymers from (1) are formed into micelles and reacted with the alkyne-
functionalized mannose from (2).  These steps result in immobilization of mannose 
onto the micelle corona through reaction with the distal azide groups via ‘click’ 
chemistry (Figure 12A).  
The polymers that make up the mannosylated siRNA carriers were 
synthesized via RAFT polymerization. These modules include a pH-responsive block 
(Figure 12A, red), a cationic block for condensing nucleic acids (blue) and an azide-
presenting block (green) for the attachment of alkyne-functionalized ligands. First, a 
~14 kDa random terpolymer block composed of 47% butyl methacrylate (BMA), 
25% 2-propylacrylic acid (PAA), and 28% 2-dimethylaminoethyl methacrylate 
(DMAEMA) was synthesized (Figure 12B; Table 5). The percentages represent 
molar composition of each monomer in the copolymer structure, as determined by 
proton nuclear magnetic resonance spectroscopy (1H-NMR).  
To form a hydrophilic, corona-forming segment, a cationic DMAEMA block 
(8.9 kDa by 1H-NMR) was block-polymerized from the terpolymer, yielding a diblock 
copolymer (22.8 kDa; Figure 12, red and blue; Table 5). This diblock copolymer 
forms micellar nanoparticles (Figure 12C), consistent with previous work by others 
(Benoit, Srinivasan, Shubin, & Stayton, 2011; Convertine, et al., 2009; Duvall, 
Convertine, Benoit, Hoffman, & Stayton, 2010; Palanca-Wessels et al., 2011).  
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FIGURE 17. RAFT Polymerization Kinetics of AzEMA. (A) Semilogarithmic kinetic plot of 
monomer conversion. (B) Mn vs. monomer conversion. (C) Gel permeation chromatograms 
of light scattering response (signal normalized to tallest peak in chromatogram, therefore 
scale is not the same across samples) vs. elution volume, as a function of monomer 
conversion (see legend). Reaction conditions: [AzEMA]:[DCT]:[AIBN] 1000:10:1, 85 vol % 
DMF, T = 70°C. 
 
Finally, an azide-presenting block composed of 2-azidoethyl methacrylate 
(AzEMA) was extended from the DMAEMA terminus of these polymers (Figure 15). 
The synthetic route for AzEMA (Figure 13) was significantly modified from 
published schemes for the synthesis of 3-azidopropyl methacrylate, a similar 
monomer, in order to remove the need for chromatographic purification of the 
desired product (Crownover, Duvall, Convertine, Hoffman, & Stayton, 2011; 
Sumerlin, Tsarevsky, Louche, Lee, & Matyjaszewski, 2005). The polymerization 
kinetics of AzEMA have also been shown here (Figure 17). 
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Morphologically, the triblock copolymers are expected to form assemblies as 
depicted in Figure 12, where the azide-presenting block effectively shields the 
pDMAEMA block in the final micellar structures. However, the addition of the final, 
AzEMA block to the base diblock leads to a 6 nm decrease in the hydrodynamic 
diameter of the resulting micelles, and a corresponding +10 mV increase in ζ-
potential (Table 5). NMR spectra of the micelles were also obtained in D2O. The base 
diblock micelles featured peaks in chemical shift regions characteristic of DMAEMA, 
while the micelles composed of the triblock produced none of these peaks (Figure 
16). Furthermore, the latter micelles featured a strong peak at 3.6 ppm, a region that 
is consistent with the expected chemical shift of alkyl protons adjacent to an azide 
group. Therefore, the triblock copolymers form micelles that present azide groups 
at their corona, enabling the facile immobilization of alkyne-functionalized ligands 
onto the micelles. 
The synthesis of alkyne-functionalized mannose (Figure 14) was adapted 
from a synthetic scheme for derivatized sugars presented by Plotz and Rifai (Plotz & 
Rifai, 1982). The resulting NMR spectra of the product indicated the successful 
alkyne-functionalization of the monosaccharide. HPLC showed that the product is 
70-80% pure following synthesis. No further purification was done because during 
micelle functionalization, any non-functionalized mannose that was present would 
be unable to ‘click’ onto the polymers and was easily removed via dialysis from the 
final, mannosylated nanoparticles (ManNPs). 
Following the ‘click’ reaction to functionalize the polymers with mannose, the 
polymers retained the ability to form micellar nanoparticles, similar to those formed 
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by the diblock copolymers lacking the azide block and mannose (Figure 12C-D). The 
ManNPs also exhibited a distinct NMR signature compared to that of the micelles 
made of triblock copolymer before the ‘click’ mannosylation reaction (Figure 16). 
This is particularly evident in the 3.0-3.5 ppm region, where the appearance of a 
broad peak, corresponding to mannose, is consistent with the success of the ‘click’ 
reaction.  
 
ManNPs Form Complexes with siRNA and Protect Cargo from Degradation 
The completed ManNPs are able to complex siRNA in an N:P ratio-dependent 
fashion as evidenced by a gel retardation assay (Figure 18A). The slow-moving band 
corresponding to siRNA/ManNP complexes increased in brightness with increasing 
N:P ratios, while the fast-moving band corresponding to free siRNA decreased in 
brightness. The ManNPs are also able to protect their cargo from degradation by 
RNAses, and this ability is elevated at higher N:P ratios (Figure 18B). In this study, 
the degradation of siRNA results in a hyperchromic effect, which is characterized by 
increased sample absorbance at 260 nm (Kirkland-York, et al., 2010). The 65% 
increase in Abs260 of free siRNA within 10 min of RNAse treatment is a 
demonstration of this effect and is used as a positive control. At a 1:2 N:P ratio, 
diblock copolymers were more effective than the ManNPs in protecting siRNA from 
degradation. At an 4:1 N:P ratio, the ManNPs were most effective at protecting their 
cargo from RNAse degradation, which was in agreement with the siRNA 
complexation seen in the gel retardation assay. 
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FIGURE 18. ManNP siRNA Complexation, Nuclease Protection, and Enhanced siRNA 
Delivery into Macrophages. (A) Gel retardation assay of siRNA-loaded ManNPs at various 
N:P ratios. Control samples included the DNA ladder (L; numbers indicate # base pairs 
corresponding to band) and free, Cy3-labeled siRNA (s). (B) Protection of siRNA from 
degradation by RNAses. Micelle/siRNA complexes were incubated with RNAse cocktails. 
RNAse-mediated degradation of siRNA was characterized by a hyperchromic effect at 260 
nm, which is less pronounced for samples containing the polymeric nanoparticles. (C) 
Cytotoxicity assay of immortalized THP-1 macrophages, treated with ManNPs complexed 
with siRNA at various N:P ratios. Error bars represent standard deviation from 3 
independent experiments (*,¶ p < 0.01). (D) ManNPs enhanced siRNA delivery to 
macrophages up to 26-fold over two model breast cancer cell lines, and 3-fold in 
macrophages relative to untargeted diblock carriers, as measured via flow cytometry. (*p < 
0.01 vs. all other treatment groups at 4 h timepoint; n = 3). (E) Flow cytometry confirms 
improved delivery of FAM-siRNA into BMDMs via ManNPs (blue) relative to untargeted 
nanoparticles (orange) or free siRNA without vehicle (black) within 4 h of administration. 
Co-administration of 100 mg/mL free mannose with the ManNPs reduces delivery of siRNA 
into BMDMs (red).  
 
ManNPs Are Cytocompatible at N:P < 8:1 
Immortalized human THP-1 macrophages were incubated with siRNA-loaded 
ManNPs at various N:P ratios, with siRNA concentration kept at 50 nM for all 
conditions. Cell viability was assessed via calcein AM/ethidium homodimer 
incorporation at 4 or 24 h after ManNP delivery, and experimental groups were 
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quantified via flow cytometry relative to untreated cells (100%) or methanol-killed 
cells (set to 0%; Figure 18C). For all N:P ratios investigated, negligible cytotoxicity 
was observed at 4 h of treatment. However, at 24 h, only 76 ± 1% of the cells treated 
at the 8:1 N:P ratio remained viable, indicating that prolonged treatment of BMDMs 
with ManNPs/siRNA at this charge ratio results in significant cytotoxicity (¶ p < 0.01, 
vs. 4 h treatment; *p < 0.01 relative to 24 h untreated cells). The 4:1 N:P ratio was 
selected for further experiments because it did not result in significant cytotoxicity 
at 24 h. 
 
ManNPs are Avidly Internalized by Human Macrophages, but not Cancer Cells 
To examine the potential of using the ManNPs to selectively target TAMs, 
ManNPs loaded with FAM-siRNA were incubated with immortalized human 
macrophages (THP-1) or human breast cancer cell lines (MDA-MB-231 & MDA-MB-
468) for up to 4 h.  Cellular internalization of the siRNA was assessed via flow 
cytometry (Figure 18D). As controls, untreated cells were measured, as well as cells 
treated with complexes made with the non-targeted diblock copolymers. For both 
breast cancer cell lines, internalization of FAM- siRNA/ManNPs was relatively 
minimal, and both cell types experienced less than a two-fold increase in FAM mean 
fluorescence intensity (MFI) over the 4 h study period. With the macrophages, the 
same study period led to a 26-fold increase in the FAM MFI of the cells, showing that 
these cells preferentially internalize the constructs relative to the model cancer cell 
lines (Figure 18D; *p < 0.01 vs. all other treatment groups at 4 h). Further, ManNPs 
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facilitated a 3-fold increase in siRNA delivery to the macrophages, relative to the 
non-targeted diblock micelles. 
 
ManNPs Enhance CD206-Dependent Intracellular siRNA Delivery and Target 
Gene Knockdown in Primary Murine Macrophages 
 
siRNA delivery and gene knockdown were next examined in primary murine 
bone marrow-derived macrophages (BMDMs). Within 4 h of siRNA administration, 
ManNPs improved delivery of FAM-siRNA into macrophages by more than 40-fold 
relative to free siRNA or fourfold relative to the untargeted, diblock copolymers 
(Figure 18E; p < 0.01). Notably, the uptake of ManNPs can be partially blocked via 
co-administration with D-mannose, indicating that internalization of the ManNPs is 
mediated by the mannose receptor. 
 In support of these observations, imaging of the uptake of fluorescently-
labeled siRNA into BMDMs was accomplished by confocal microscopy (Figures 19-
20). Consistent with the flow cytometry results, mannose targeting significantly 
increased siRNA delivery into macrophages, and co-administration of D-mannose 
with the ManNPs reduced FAM-siRNA signal in the BMDMs. Significant levels of 
FAM-siRNA can be visualized in the BMDMs within 1-2 h of administration. The 
punctate staining (Figure 20) is consistent with the sequestration of the siRNA into 
intracellular vesicles. Within 4 h, the FAM staining becomes more diffuse, suggesting 
that the FAM-siRNA has escaped the endosomal compartment and accessed the 
cytosol. 
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FIGURE 19. Improved Delivery to Primary Macrophages using ManNPs with 
Specificity for Mannose Receptor (CD206). Following 4h of transfection with FAM-siRNA 
(green; free or complexed into nanoparticles), BMDMs were fixed, nuclei stained with DAPI 
(blue), and imaged via confocal microscopy. (Scale bars = 50 μm). Mannosylation of the 
polymeric vehicles enhanced their internalization by BMDMs. This could be competed away 
by co-administration of the ManNPs with 100 mg/mL of free D-mannose. Brightness & 
contrast were enhanced in the DAPI channel to account for small differences in staining 
between samples. FAM channels were left unaltered. 
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FIGURE 20. Kinetics of ManNP-Mediated siRNA Delivery into Primary Macrophages. 
BMDMs were transfected with FAM-siRNA (green; complexed into ManNPs) for 1-4 h prior 
to being fixed, stained with DAPI (blue), and imaged via confocal microscopy. (Scale bars = 
50 μm). As a comparison, BMDMs treated with non-fluorescent, scrambled siRNA 
(complexed into ManNPs) have been shown. Brightness & contrast were enhanced in the 
DAPI channel to account for small differences in staining between samples. FAM channels 
were unaltered. Punctate green signal is observed within 1-2 h of administration, 
suggesting internalization of siRNA into vesicles. At 4h, the green fluorescence is more 
diffuse, consistent with endosomal escape of the siRNA into the cytosol. 
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The enhanced delivery of siRNA via the ManNPs also corresponded with 
significantly improved knockdown of target gene expression in BMDMs relative to 
non-transfected cells and cells treated with free siRNA (PPIB; Figure 21A; *p < 0.05). 
The commercially-available Lipofectamine RNAiMAX® transfection reagent was 
even more effective at facilitating the knockdown of PPIB expression, but was also 
cytotoxic at the 24 h time point used in this study. In spite of lower levels of siRNA 
delivery into the BMDMs relative to ManNPs (Figure 19), the diblock nanoparticles 
also facilitated a significant level of PPIB knockdown (p = 0.06 relative to ManNPs, 
via one-way ANOVA). This is likely due to the higher hemolytic activity of the 
diblock nanoparticles at endosomal pH ranges, relative to the ManNPs (Figure 21B). 
 
 
FIGURE 21. ManNPs Enhance Knockdown of PPIB Expression in BMDMs. (A) siRNA-
mediated knockdown of PPIB expression by transfection vehicle. PPIB expression levels 
were quantified relative to the housekeeping gene GAPDH. qRT-PCR confirmed ManNPs 
carrying anti-PPIB siRNA mediated 87 ± 10% decrease in target gene expression following 
24 h of treatment, relative to non-transfected (NT) cells. Error bars represent standard 
deviation of 3 independent experiments (*p < 0.05 by one-way ANOVA, **Not statistically 
significant). (B) Erythrocyte hemolysis assay showcases pH-responsive behavior of diblock 
nanoparticles and ManNPs. The block copolymers exhibit pH-dependent disruption of 
phospholipid membranes, and better facilitate erythrocyte lysis at pH < 6.8 . Error bars 
represent standard deviation of 4 independent experiments. 
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Discussion 
Recently, polymers for siRNA delivery applications were described by 
Convertine et al., but these polymers lack cell specificity, due to their cationic corona 
(Convertine, et al., 2009). Other variants of these carriers have been recently 
developed that target folate receptor and CD22 (Benoit, et al., 2011; Palanca-
Wessels, et al., 2011). In spite of the improved cell specificity of these constructs, 
their production required the use of more tedious, multi-step synthetic schemes 
(Benoit, et al., 2011; Henry, Convertine, Benoit, Hoffman, & Stayton, 2009) or 
expensive targeting motifs such as  antibodies (Palanca-Wessels, et al., 2011). 
Furthermore, unlike the approach described herein, these approaches did not 
generate a generalized platform that can be utilized for “clicking” on alternative 
targeting agents. Because macrophage-specific siRNA delivery is the central goal of 
the current work, CD206 was evaluated as the target receptor, motivated by its 
expression primarily on macrophages and some dendritic cells (Taylor, et al., 2005). 
Therefore, the first objective of this work was to develop a simple and rapid 
method for the immobilization of mannose onto micelle-forming polymeric siRNA 
carriers. Due to the presence of a number of reactive functional groups in the 
structure of the polymers, an orthogonal synthetic scheme was necessary to enable 
the synthesis of the desired block co-polymers, followed by site-selective 
functionalization with mannose in a final step. To accomplish this goal, we opted for 
a strategy involving the rapid and highly-efficient Huisgen 1,3-dipolar cycloaddition 
reaction, otherwise known as azide-alkyne ‘click’ chemistry (Figure 12).  
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Compared with other variants of the mannosylated carriers, our synthetic scheme 
yields the modular, molecularly-targeted siRNA delivery vehicles from less costly 
starting materials, and requires fewer reaction steps.  
The terpolymer block confers pH-responsiveness to the final polymers 
because at pH 7.4, approximately 50% of the carboxylic groups on PAA and 
approximately 50% of the amine groups on DMAEMA are protonated, resulting in 
approximate charge neutrality of this block. Electrostatic and hydrophobic 
interactions enable this block to form a micelle core at pH 7.4, when it is covalently 
attached to a hydrophilic polymeric block. With decreasing pH, the PAA and 
DMAEMA become increasingly protonated, leading to a net cationic charge on this 
block that triggers micelle disassembly (Convertine, et al., 2009). The exposed 
terpolymer is hypothesized to disrupt endosomal and lysosomal membranes and 
ferry siRNA into the cytoplasm. 
Diblock copolymers composed of a cationic DMAEMA component bound to 
this terpolymer were next synthesized (Figure 12B-C). Such polymers have been 
shown to facilitate the cytosolic delivery of siRNA and peptides into immortalized 
cell lines in vitro (Benoit, et al., 2011; Convertine, et al., 2009; Duvall, et al., 2010; 
Palanca-Wessels, et al., 2011). These ‘base’, diblock nanoparticles can enter many 
cell types because of their cationic surface charge, arising from the DMAEMA corona, 
which promotes interactions with the anionic cell membrane, triggering 
internalization (Kumari, Yadav, & Yadav, 2010). 
The ManNPs retain the functional properties of the cationic DMAEMA 
component, endowing the micelles with the ability to complex siRNA and protect it 
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from nucleases that may be present in the in vivo environment (Figure 18). These 
properties are somewhat attenuated from those of the diblock copolymers, and is 
likely due to the morphology of the ManNPs, as the mannosylated corona may 
partially alter the properties of the underlying DMAEMA layer, including access of 
siRNA to binding through its cationic charge (Figure 16). Therefore, the ManNPs are 
likely to be slightly less amenable to complexation with siRNA than is the base 
diblock copolymer, which displays an outermost corona of DMAEMA. Nevertheless, 
the resulting ManNPs form multifunctional nanoparticles that display mannose on 
the surface, while veiling underlying structures designed to carry nucleic acids and 
other biologics into the cytosol of targeted cells. 
The ManNPs show cell selectivity, and the data suggest that in a tumor 
environment where cancer cells coexist with a significantly smaller population of 
macrophages, the ManNPs will enter macrophages markedly faster than the cancer 
cells (Figure 18D). While this increased internalization rate was also observed for 
the non-targeted diblock copolymers, the effect was more enhanced for the 
mannosylated constructs. Despite significant levels of cytotoxicity at N:P ratios of > 
4:1, these results were not surprising, as cationic transfection agents have been 
shown to exhibit charge-dependent cytotoxicity (Lv, et al., 2006). To counter this, all 
polyplexes for subsequent experiments were prepared at N:P ratios for which 
negligible cytotoxicity was observed at 24 h treatment time (Figure 18C). It is 
anticipated that the presented strategy for preferential macrophage targeting can be 
leveraged in diseases where infiltrating macrophages at pathologic sites exhibit 
upregulated CD206 expression, including cancer (Luo et al., 2006). Therefore, 
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ManNPs provide a promising platform for macrophage-specific delivery of RNAi 
therapeutics in pathologic sites.  
The ManNPs also facilitated improved siRNA delivery into primary murine 
macrophages and generated robust knockdown of a model gene (Figures 18-21). 
The untargeted, diblock polymers also achieved potent gene knockdown despite 
delivering significantly lower amounts of siRNA into the macrophages. However, 
like the ManNPs, the diblock polymers are capable of efficiently escaping from the 
endosomal compartment in a pH-dependent manner, as modeled via the hemolysis 
assay (Figure 2G) (Evans et al., 2012). Therefore, even if the diblock copolymers are 
not as efficiently internalized into BMDMs as are the ManNPs, the diblock 
copolymers still deliver sufficient siRNA to cause significant levels of gene 
knockdown. This effect can depend on the potency of the siRNA sequence itself, as 
different siRNA sequences against the same target gene can exhibit widely different 
abilities to recognize the targeted mRNA sequence for knockdown (Rettig & Behlke, 
2012). 
Nevertheless, these results are significant because primary macrophages 
possess highly degradative phagocytic, endosomal and lysosomal compartments, 
providing a formidable barrier to the cytosolic delivery of siRNA (Stacey, et al., 
1993). Moreover, these data suggest that the ManNPs and their cargo are interacting 
with an endocytotic receptor, leading to internalization of the complexes. The cargo 
is then able to escape the endosomal pathway, through a mechanism that is likely 
mediated by the pH-responsive, endosomolytic behavior of the terpolymer block 
within the ManNPs (Convertine, et al., 2009). Moreover, the data implies that the 
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targeted receptor is likely CD206, as it is known to effectively bind mannosylated 
substrates, resulting in internalization of the bound substrates via receptor-
mediated endocytosis or phagocytosis (Stahl & Ezekowitz, 1998). 
 
Summary 
The data presented here showcase a novel strategy to selectively target 
TAMs. The capacity of this system for endosomal disruption enables biologics to be 
delivered into the cytosol, promoting their access to intracellular drug targets and 
processes. In a broader sense, this work is the first demonstration of a ‘clickable’ 
siRNA delivery platform that will enable the attachment of other targeting ligands to 
the azide-functionalized corona of pH-responsive, endosomolytic micelles. These 
strategies will potentially open up new areas in cancer immunotherapy, enabling 
selective intervention with the activities of TAMs while leaving surrounding cells 
relatively undisturbed.  
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CHAPTER IV 
 
LEVERAGING PATHOLOGIC MACROPHAGE OXIDATIVE ACTIVITY FOR 
LOCALIZED DRUG DELIVERY VIA OLIGO(PROLINE) CROSS-LINKED  
POLYMERIC SCAFFOLDS 
 
Chronic inflammation-mediated oxidative stress is a common mechanism of 
implant rejection and failure. Therefore, polymer scaffolds that can degrade slowly 
in response to this environment may provide a viable platform for implant site-
specific, sustained release of immunomodulatory agents over a long time period. In 
this work, proline oligomers of varying lengths (Pn) were synthesized and exposed 
to oxidative environments, and their accelerated degradation under oxidative 
conditions was verified via high performance liquid chromatography and gel 
permeation chromatography. Next, diblock copolymers of poly(ethylene glycol) 
(PEG) and poly(ε-caprolactone) (PCL) were carboxylated to form 100 kDa 
terpolymers of 4%PEG-86%PCL-10%cPCL (cPCL = poly(carboxyl-ε-caprolactone); 
i% indicates molar ratio). The polymers were then crosslinked with bi-aminated 
PEG-Pn-PEG chains—where Pn indicates the length of the proline oligomer flanked 
by PEG chains. Salt-leaching of the polymeric matrices created scaffolds of 
macroporous and microporous architecture as observed by scanning electron 
microscopy. The degradation of scaffolds was accelerated under oxidative 
conditions, as evidenced by mass loss and differential scanning calorimetry 
measurements. Immortalized murine bone marrow-derived macrophages were 
then seeded on the scaffolds, and activated by adding γ-interferon and 
88 
lipopolysaccharide to cells throughout the 9-day study period. This treatment 
promoted the release of H2O2 by the macrophages, and the degradation of proline-
containing scaffolds compared to the control scaffolds. The accelerated degradation 
was evidenced by increased scaffold porosity, as visualized through scanning 
electron microscoopy and X-ray microtomography imaging. The current study 
provides insight into the development of scaffolds that respond to oxidative 
environments through gradual degradation, for the controlled release of 
therapeutics targeted to diseases that feature chronic inflammation and oxidative 
stress (S. S. Yu, R. L. Koblin, et al., 2011). 
 
Introduction 
 Abnormal changes in environmental parameters, such as temperature, pH, 
protease activity, or redox balance, have been documented in a wide array of 
pathophysiological conditions (Cammas et al., 1997; Galis, Sukhova, Lark, & Libby, 
1994; Gupta, Vermani, & Garg, 2002; Halliwell, Clement, & Long, 2000; Scherer, 
McIntyre, & Matrisian, 2008). Therefore, the development of ‘smart’, synthetic 
biomaterials that are capable of responding specifically to changes in these 
environments holds promise in facilitating the programmed delivery of therapeutics 
and imaging contrast agents in a site and/or timing-specific way (Fattori & Piva, 
2003; Schmedlen, Elbjeirami, Gobin, & West, 2003; Tanaka et al., 2009; Zhang, 
Srivastava, & Misra, 2007). 
 In particular, elevated levels of reactive oxygen species (ROS), such as H2O2 
and O2-, are typically observed in the pro-inflammatory response to pathogens and 
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to implanted biomaterials. In the latter case, the chronic production of ROS has been 
a mechanism behind implant rejection and failure, necessitating follow-up implant 
replacement surgeries years after the original procedure. This phenomenon has 
been observed for a wide array of applications, including orthopedic, vascular, and 
neurological implant materials (Azuma & Tilney, 1994; Massia, Holecko, & 
Ehteshami, 2004; Moilanen et al., 1997). Consequently, ROS-responsive materials 
would be desirable as implant coatings for such applications, in order to facilitate 
controlled local release of inflammatory modulators and suppressors without off-
target side-effects elsewhere in the body. 
 The first example of a ROS-responsive biomaterial was demonstrated by 
Napoli et al. using a poly(propylene sulfide)-(PPS) based system, which is initially 
hydrophobic but becomes oxidized into more hydrophilic sulfones by peroxides 
(Napoli, Valentini, Tirelli, Muller, & Hubbell, 2004). In this work, the authors self-
assembled vesicles composed of PPS cores with hydrophilic poly(ethylene glycol) 
(PEG) coronas. Within a few hours of H2O2 addition, the vesicles exhibited a 
hydrophobic-to-hydrophilic transition—a behavior that can be leveraged for 
controlled release applications. These materials have now begun to see applications 
in immunobioengineering, leading to new vaccine nanoparticles that have been 
validated in vivo in mouse models (Reddy, Rehor, Schmoekel, Hubbell, & Swartz, 
2006; Reddy et al., 2007; Thomas, et al., 2011). At the same time, it may also be 
desirable to produce materials that respond to oxidative environments with slower 
changes in material properties.  
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The accumulation of oxidatively modified proteins has been demonstrated as 
a hallmark of the aging process and also in certain diseases (Berlett & Stadtman, 
1997; E. R. Stadtman & Berlett, 1997). Within such proteins, the amino acids 
histidine, proline, arginine, and lysine have been found to be particularly susceptible 
to oxidative processes (Amici, Levine, Tsai, & Stadtman, 1989). Further, the reaction 
of proline residues with environmental oxidants can lead to cleavage of the parent 
polypeptide chains at these sites (E. R. Stadtman & Levine, 2003). 
 Inspired by this work, we synthesized polymeric scaffolds crosslinked with 
proline oligomers and assessed their degradation following exposure to oxidative 
environments. As a backbone, we selected a terpolymer system composed of PEG, 
poly(ε-caprolactone) (PCL), and poly(carboxyl-ε-caprolactone) (cPCL). The selection 
of this terpolymer system was driven by the functional properties of each 
component, as the PEG provides hydrophilicity and reduces protein adsorption 
(Sung et al., 2010), the PCL provides elastic mechanical strength and hydrophobicity 
for cell adhesion (Sung et al., 2005), and the cPCL provides carboxylic groups that 
can be chemically crosslinked with biaminated species under mild conditions. 
Copolymers of x mol % PEG, y mol % PCL, and z mol % cPCL are identified as 
x%PEG-b-y%PCL-co-z%cPCL where PEG-PCL is a block copolymer but cPCL addition 
is random within the PCL subunit.  The polymers are abbreviated x%PEG-y%PCL-
z%cPCL.  This new class of copolymers is designed provide tunable properties for 
biomedical applications as polymer properties are influenced by the molar ratios of 
the individual subunits and, by varying their aforementioned contributions, the 
resulting physical, chemical and mechanical properties can be controlled (Crowder, 
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Gupta, Hofmeister, Zachman, & Sung, 2011). In particular, the studies below used a 
4%PEG-86%PCL-10%cPCL system, where the numbers include molar percentages 
of the individual units. PCL was chosen as the majority component because it has 
been shown to be minimally degraded in environments containing H2O2 over more 
than 20 weeks, requiring much stronger metal-catalyzed oxidative environments to 
produce any significant degradation within this time frame (Ali, Doherty, & 
Williams, 1994). 
 The proline oligomers Ac-KPnK, in which n indicates the number of proline 
residues, were synthesized by standard Fmoc chemistry on a Rink amide resin to 
fashion two free amines for the coupling of Fmoc-PEG12-COOH (MW = 500 Da). The 
oxidative degradation of the peptides with and without PEGylation was first 
assessed through gel permeation chromatography (GPC) and high performance 
liquid chromatography-mass spectrometry (HPLC-MS). Next, scaffolds of 4%PEG-
86%PCL-10%cPCL were covalently crosslinked with PEG-Pn-PEG crosslinkers, and 
degraded in acellular and cellular in vitro models mimicking physiologic oxidative 
conditions. Oxidation-dependent changes in scaffold material properties and 
morphology were assessed via scanning electron microscopy (SEM), differential 
scanning calorimetry (DSC), and X-ray micro-computed tomography (μCT) imaging.  
 
Materials and Methods 
Materials 
All reagents, including murine γ-interferon (IFNγ) and bacterial 
lipopolysaccharide (LPS), were purchased from Sigma-Aldrich (St. Louis, MO) and 
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used as purchased unless otherwise noted below. ε-caprolactone was purchased 
from Alfa Aesar (Ward Hill, MA). Fmoc-protected L-amino acids and resins for solid-
phase peptide synthesis were purchased from EMD Biosciences (Gibbstown, NJ). 
RPMI-1640 medium, penicillin-streptomycin, and fetal bovine serum (FBS) were 
purchased from Invitrogen (Carlsbad, CA). 3-morpholinosydnonimine (SIN-1) was 
purchased from Invitrogen as packages of individual 1 mg aliquots. Dialysis filters 
were purchased from Thermo Fisher (Rockford, IL). All organic solvents, including 
N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP), tetrahydrofuran 
(THF) and methanol, were purchased from Fisher Scientific (Pittsburgh, PA) and 
used as purchased. 
The ring-opening polymerization of ε-caprolactone is highly water-sensitive, 
and therefore, all monomers and reagents for this purpose were carefully dried 
before use. 15 g MeO-PEG (Mn = 5000 Da; ~3 mmol) was dissolved in 150 mL 
toluene and dried via a Dean-Stark trap at 130˚C under N2 environment. The dried 
MeO-PEG was concentrated by distillation at 40 ˚C, precipitated in diethyl ether at -
20˚C, then further dried in vacuo. In a separate vessel, 150 mL ε-caprolactone (161.7 
g; 1.41 mol) was mixed with 2 g calcium hydride (47.5 mmol) overnight under N2 
gas. The product was distilled in vacuo at 70 ˚C, and stored under N2 until use. 
 
Synthesis of Biaminated PEG-Pn-PEG ‘Crosslinkers’ 
The peptide sequences KPPPPPK (P5), KPPPPPPPK (P7), and KPPPPPPPPPPK 
(P10) were synthesized via standard Fmoc-based solid phase methods on a Rink 
amide-MBHA resin (Figure 22). The peptides were then acetylated in excess acetic 
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anhydride for 4 h, prior to cleavage in a 95:5:3:2 mixture of trifluoroacetic acid : 
thioanisole : ethanedithiol : anisole for 2 h. The liberated peptide was precipitated in 
diethyl ether and lyophilized to form a dense, white powder. All peptides were at 
least 70% acetylated as determined by HPLC-MS, therefore, containing only two 
amine groups for downstream coupling, which are located on the lysine residues. As 
a result of incomplete acetylation of the peptides, the remaining < 30% of peptide 
also contained a third amine group responsible for the N-terminus of the peptide 
chain. 
 
 
FIGURE 22. Synthesis of Biaminated PEG-Pn-PEG Crosslinkers. 
 
 
 Fmoc-PEG12-COOH (EMD Biosciences) was then coupled to the peptides via 
standard carbodiimide chemistry.(Hermanson, 2008 (2nd ed.)) Removal of the 
Fmoc-protecting group was achieved via 20% piperidine in DMF, followed by 
dialysis of the completed crosslinkers in 1 kDa MWCO membranes for 48 h against 
nanopure water. Lyophilization of the retentate yielded a white, fluffy powder that 
was stored at -20°C until use.  
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FIGURE 23. Synthesis of x%PEG-y%PCL-z%cPCL Backbone Polymers. 
 
 
Synthesis of 4%PEG-86%PCL-10%cPCL ‘Backbone’ Polymers 
To synthesize x%PEG-y%PCL block copolymers (Figure 23), 0.4 g dried MeO-
PEG (0.08 mmol) was added to a round bottom flask. The flask was capped with 
septum, heated to 40°C, and degassed with repeated cycles of evacuation followed 
by equilibration with N2. Next, 9.4 g ε-caprolactone (82 mmol) and 17.9 mg of tin 2-
ethylhexanoate (44.2 μmol) in 500 µL toluene were injected sequentially into the 
reaction vessel. The polymerization was carried out at 140°C for 4 h. The resultant 
100 kDa 4%PEG-96%PCL was cooled to room temperature, dissolved in 200 mL 
methylene chloride, precipitated in diethyl ether, and dried in vacuo. 
The formation of x%PEG-y%PCL-z%cPCL was carried out via random 
carboxylation of the x%PEG-y%PCL diblock copolymers. 8.57 g of 4%PEG-96%PCL 
was evacuated in a round bottom flask for 1 h, and then dissolved in 300 mL 
anhydrous THF. The solution was cooled to -78°C, and 37.5 mL 2 M lithium 
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diisopropylamide (LDA; 75 mmol) was injected drop-wise by syringe. This reaction 
proceeded for 30 min at -78°C. In a separate Schlenk flask, CO2 was generated 
through the reaction of concentrated sulfuric acid with sodium carbonate, and dried 
through a column filled with molecular sieves and sodium hydride. The resulting 
dry CO2 was bubbled through the 4%PEG-96%PCL/LDA reaction for 30 min at -
78°C, during which the reaction exhibits a color change from orange to white. The 
solution was then brought to room temperature, and 150 mL of 1 M ammonium 
chloride was added drop-wise. The solution was then neutralized by drop-wise 
addition of hydrochloric acid. The crude product was extracted with 500 mL of 
methylene chloride, and the pooled organic fractions were concentrated via rotary 
evaporation. 4%PEG-86%PCL-10%CPCL was precipitated in diethyl ether and dried 
in vacuo. 1H NMR (400 MHz; CDCl3): δ 9.25 (s, <1 H, COOH), 4.06 (t, 2H, -OCH2), 3.4 
(m, 1H, - CH-COOH), 2.31 (t, 2H, -CH2), 1.66 (m, 4H, -CH2), 1.5 (m, 2H, -CH2), 1.37 (m, 
2H, -CH2). 
 
Scaffold Fabrication 
0.3 g of the 4%PEG-86%PCL-10%cPCL terpolymers were dissolved in 3 mL 
of ice cold CH2Cl2, and was followed by the addition of 67 mg of crosslinkers and 12 
mg of N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC). For 
control scaffolds, 2 kDa PEG-dihydrazide (Laysan Bio, Arab, AL) was used in place of 
the PEG-Pn-PEG crosslinkers. After vortexing this mixture vigorously, the solution 
was poured into a Teflon dish 5 cm in diameter, containing 10 g of pre-sieved NaCl 
crystals (212-425 μm). This mixture was manually mixed vigorously to spread the 
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salt crystals evenly throughout the pre-polymer, and then the pre-polymer was 
evenly spread throughout the bottom of the Teflon dish. The pre-polymer was 
allowed to crosslink over ice for 30 min. Next, the polymers were immersed in liquid 
N2 for 2 minutes and lyophilized overnight to remove all traces of organic solvents. 
The removal of excess byproducts, salts, and reagents was achieved by salt-leaching 
the scaffolds in nanopure water over 5 days. Water was changed daily. Finally, the 
completed scaffolds were dried in vacuo overnight at room temperature, and 
weighed prior to use in any experiments. Wet masses of the scaffolds were 
measured after allowing scaffolds 3 days to swell to equilibrium. Swollen scaffolds 
were blotted dry to remove excess buffer before weighing. Swelling ratio was 
calculated according to the formula [Swelling ratio] = (Wet mass)/(Dry mass). 
 
Oxidation Experiments and Chromatography 
To investigate oxidative degradation, peptide crosslinkers were incubated in 
1 mg/mL in phosphate-buffered saline (PBS, pH 7.4) at 37°C, and then H2O2 and 
CuSO4 were added to the samples to final concentrations of 5 mM H2O2 and 50 μM 
Cu(II). Peptide crosslinkers that were incubated in the absence of H2O2 and CuSO4 
served as a control. Reactions were incubated in the dark at 37°C until they were 
ready for analysis, at which point they were frozen at -20°C. 
 For scaffold degradation experiments, dry scaffolds were weighed before 
incubation then allowed 3 days to swell to equilibrium in PBS prior to the beginning 
of the experiment. From here, scaffolds were incubated in PBS with or without 1 
mM SIN-1 for 28 days. Buffers were changed daily owing to the relatively short half-
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life of SIN-1 in aqueous environments (< 10 h). At days 3, 7, 14, and 28 post 
incubation, scaffolds were dried in vacuo overnight prior to re-weighing and further 
characterization.  
 GPC was performed by injecting samples into three serial Tosoh Biosciences 
TSKGel Alpha columns (Tokyo, Japan), operated at 60°C. For various experiments, 
water or DMF with 0.1 M LiBr were used as mobile phases. Chromatograms were 
recorded via a Shimadzu SPD-10A UV detector and RID-10A refractive index 
detector (Shimadzu Scientific Instruments, Columbia, MD), and a Wyatt miniDAWN 
Treos multi-angle light scattering detector (MALS; Wyatt Technology, Santa Barbara, 
CA). Data acquisition and analysis was performed on Wyatt ASTRA software 
(version 5.3.4). 
 Analytical high performance liquid chromatography-mass spectrometry 
(HPLC-MS) was performed on an Agilent 1200 series system equipped with UV 
detection at 215 and 254 nm and a 6130 quadrupole mass spectrometer with 
electrospray ionization (Agilent Technologies, Santa Clara, CA). On-line evaporative 
light-scattering detection was also activated for some samples (Varian, Santa Clara, 
CA). C18 columns were purchased from Phenomenex (Kinetex 2.1 x 5.0 mm; 
Torrance, CA), and run with a gradient of 10-95% acetonitrile (over 2 min) in 0.1% 
trifluoroacetic acid in water. 
 
Scanning Electron Microscopy (SEM) 
SEM was performed on a Hitachi S-4200 system (Tokyo, Japan). An 
accelerating voltage of 2 kV was used for all images. To prepare scaffolds for 
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imaging, scaffolds were sputter-coated with gold (Cressington Sputter Coater 108, 
Watford, United Kingdom) at a plasma current of 30 mA for 120 seconds. 
 
Differential Scanning Calorimetry (DSC) 
All polymeric scaffolds were analyzed for thermal transitions and heat 
capacity via DSC (TA Instruments, Newcastle, DE). Samples were weighed (2-5 mg), 
and sealed within aluminum sample pans with tops. The measurement procedure 
included two temperature sweeps from -80°C to 100°C at a ramp rate of 10°C/min. 
The values from the second sweep were reported such that thermal history was 
erased. 
 
Cell Studies 
For cell studies, immortalized bone marrow-derived macrophages (BMDMs) 
were generated from NGL (NF-κB-GFP-Luciferase construct) transgenic mouse lines 
on C57Bl6/DBA background (NGL-BMDMs), and were provided by the laboratory of 
Dr. Fiona E. Yull (Vanderbilt-Ingram Cancer Center, Nashville, TN) (Everhart et al., 
2006). NGL-BMDMs were grown in high-glucose (4.5 g/L) DMEM containing 4 mM 
L-glutamine, and further supplemented with 10% (v/v) FBS and 1% (v/v) 
penicillin-streptomycin. All cells were cultured at 37°C in a 5% CO2 incubator. 
 For all experiments, NGL-BMDMs were detached from flasks by gently 
rinsing the confluent monolayers with serum-free medium (high-glucose DMEM 
with 4 mM L-glutamine, 1% penicillin-streptomycin, 1X non-essential amino acids, 
and 1X MEM vitamins), counted via a Coulter Counter (Beckman Coulter, Miami, FL), 
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and seeded into scaffolds or directly to 24-well plates at a density of 300,000 
cells/cm2. Cells were allowed 24 h to associate with scaffolds or well plates before 
further experimentation. The serum-free medium was used in the course of the 
experiment to minimize serum-induced changes in macrophage activation states. 
 For pro-inflammatory activation, NGL-BMDMs were treated with 50 ng/mL 
IFNγ and 10 μg/mL LPS in serum-free medium. In order to maintain a high level of 
macrophage activation, media containing these activators was replaced daily for the 
duration of the experiments. 
 
Micro-Computed Tomography (μCT) Imaging of Scaffolds 
To analyze the porosity and the distribution of pore size in the scaffolds, 
portions of each scaffold were imaged using a µCT50 (Scanco Medical, AG, 
Switzerland) and the manufacturer’s software.  Images of an approximately 6 mm 
wide by 10 mm long section of each sample were acquired with an isotropic voxel 
size of 1 µm at 45 kV, 200 µA, 1000 projections per rotation, and an integration time 
of 1 sec without beam filtering and using the default beam hardening correction. 
Three different scaffolds were imaged per experimental condition (n=3). The low X-
ray attenuation of the scaffolds was offset by the extremely low noise produced by 
the extended acquisition protocol which maintained signal-to-noise ratio sufficient 
for threshold based segmentation of scaffold from internal pores. A cylinder of 1355 
µm in diameter and 500 µm long was selected as the volume of interest in each 
sample.  After creating a z-stack of the individual slices, the volume of interest (VOI) 
was extracted and the threshold and noise filter applied to extract the 3D pore 
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structure from the grey-scale images.  The mean pore diameter and distribution of 
the pore diameters within each scaffold was calculated using standard, accepted ball 
filling method reported elsewhere (Hildebrand & Ruegsegger, 1997; Ruegsegger, 
Hildebrand, Laib, Muller, & Dequeker, 1999). By distance transformation, the 
calculation of the metric distance of every pore voxel to the nearest pore-matrix 
interface is understood. These distances can be imagined as the radius of a sphere 
with center in this voxel that fits inside the pore. Redundant spheres are removed 
such that big spheres incorporate small, encompassed spheres. The result is the 
mid-axes transformed structure with the centers of maximal spheres filling the pore 
completely. To calculate pore thickness, each voxel then gets the value of the radius 
of the maximal sphere it sits within. 
 
 
 
FIGURE 24. GPC chromatograms of the oxidation-responsive scaffold components. (A) 
PEG-Pn-PEG crosslinkers (10 mg/mL in DMF + 0.1M LiBr) prior to final Fmoc deprotection 
are detectable via a UV detector set at 310 nm. The presence of a small, earlier-eluting hump 
at ~27 min represents the tri-PEGylated peptides due to incomplete acetylation of the 
peptide sequences. The major peak at 29-30 min is the major, bi-PEGylated product. (B) The 
4%PEG-86%PCL-10%cPCL backbone (10 mg/mL in THF) is relatively monodisperse, as 
evidenced by the near-complete overlap of the MALS and differential refractive index (dRI) 
chromatograms. With the dn/dc of the terpolymer measured at 0.0663 mL/g in THF, the 
molecular weights were calculated at Mn = 99.4 kDa and Mw = 115 kDa (PDI = 1.16). 
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Results 
Synthesis and Characterization of PEG-Pn-PEG Crosslinkers and 4%PEG-
86%PCL-10%cPCL Backbone 
 
The two major components of the scaffolds were synthesized via well-
characterized methods as described, and characterized by GPC (Figure 24). The 
crosslinkers primarily consisted of bi-PEGylated proline oligomers, as evidenced by 
the predominant peak at 29.5 min, but also included smaller amounts of tri-
PEGylated proline oligomers, as indicated by the earlier-eluting peak between 26-27 
min. The presence of this minor peak is due to incomplete acetylation of the peptide 
prior to coupling of the PEG sequences. Nevertheless, all three crosslinker 
sequences exhibited similar sizes, as indicated by their overlapping chromatograms. 
 The terpolymer backbone was synthesized via the polymerization of ε-
caprolactone onto a PEG-based macroinitiator, followed by random carboxylation of 
the PCL block (Gimenez, Ponsart, Coudane, & Vert, 2001). This scheme led to a 
relatively monodisperse terpolymer of Mn = 99.4 kDa and Mw = 115 kDa (PDI = 
1.16), as measured via GPC-MALS. The terpolymer exhibited a dn/dc of 0.0663 
mL/g in THF and was poorly soluble in methanol, DMF, and N-methylpyrolidone—
characteristics that are consistent with the primarily PCL composition of the 
terpolymer (An & Cho, 2004). 
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H2O2-Mediated Degradation of Pn Peptides and PEG-Pn-PEG Crosslinkers 
 
FIGURE 25. Metal-catalyzed oxidation of proline oligomers. (A) P10 was incubated at 
37°C for 4 days in PBS only or PBS containing H2O2 and Cu(II), then analyzed via HPLC-MS. 
The latter treatment resulted in the disappearance of chromatograms and mass spectra 
characteristic of the intact peptide. To further confirm oxidative degradation of the peptide, 
PEG-Pn-PEG was incubated under the same conditions prior to analysis via GPC (B-E). In all 
cases, these molecules eluted at later times following only 2 d in the oxidative environment. 
(E) Peak molecular weights were calculated based on elution time, relative to monodisperse 
PEG standards. Within the first 2 d of treatment, degradation rate was proportional to the 
length of the proline oligomers. Further, all crosslinkers degraded to form a 550 Da product 
within 6 d, which is consistent with the molecular weight of the PEG reagent that was 
coupled to both ends of the peptides used in the study, to form the PEG-Pn-PEG crosslinkers 
for the scaffolds. 
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The susceptibility of the peptide components to oxidative cleavage was 
validated at multiple intermediate steps in the scaffold synthesis, starting from the 
completed peptides. In this way, the oxidation-responsiveness of the scaffolds can 
be attributed primarily to the peptide components and not any other polymeric 
components. 
 To begin, as-synthesized proline oligomers were incubated in PBS at 37°C, 
with or without the mediators of metal-catalyzed oxidation (MCO). The samples 
were then analyzed by HPLC-MS to detect the presence of peptides and degradation 
byproducts (Figure 25). In particular, after four day incubation in the MCO 
environment, the P10 oligomers demonstrated significant changes in their UV 
chromatogram within the elution time regions specific for the intact peptide, as well 
as the concomitant disappearance of MS peaks at 1244 and 623 m/z that are 
characteristic of the intact peptide. These phenomena were not observed for 
reactions that were incubated at room temperature for the same time period (data 
not shown), indicating that physiological temperature is required to induce the 
oxidative cleavage of peptides. 
 To confirm the oxidation-induced cleavage of the peptides, the PEG-Pn-PEG 
crosslinkers were incubated under the same conditions, and analyzed by GPC. In all 
cases, MCO-treated crosslinkers eluted later than untreated crosslinkers, indicating 
a decrease in the hydrodynamic size of these crosslinkers following oxidative 
treatment. Further, the average molecular weights of the crosslinkers were 
calculated relative to monodisperse PEG standards, and within the first two days of 
MCO treatment, the degradation rate of the crosslinkers was proportional to the 
104 
length of the proline oligomers contained within the crosslinkers. Moreover, after 
six days of MCO treatment, the molecular weights of the different crosslinkers 
converged on 550 Da, the molecular weight of the PEG component flanking each end 
of the peptides, indicating the complete degradation of the proline component of the 
crosslinkers. 
 
 
FIGURE 26. SEM of scaffolds of 4%PEG-86%PCL-10%cPCL by crosslinker type. Two 
different magnifications showcase macropores of > 100 μm diameter (top row) and 
micropores of < 10 μm in diameter (bottom row). Only the PEG-dihydrazide-crosslinked 
scaffolds failed to show any widespread microporous architecture. Macropores were 
templated into the polymer network through a salt-leaching procedure, while micropores 
were generated through the phase separation of the water generated during the 
crosslinking reaction from the hydrophobic solvent used to dissolve the pre-polymer. 
 
Fabrication and Characterization of Crosslinked 4%PEG-86%PCL-10%cPCL 
Terpolymer Scaffolds 
 
Polymeric scaffolds exhibiting macroporous and microporous architecture 
were fabricated using a procedure adapted from previous methods (Sung et al., 
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2008). The completed scaffolds were morphologically examined via SEM (Figure 
26). By dissolving the pre-polymer mixture in a hydrophobic solvent, the 
condensation of water due to the amine-carboxylic acid crosslinking reaction results 
in the phase separation of water from the bulk solvent, producing micropores 
(diameter < 10 μm) in the polymer network. Macropores of > 100 μm in diameter 
were templated into the polymer network by performing this crosslinking reaction 
in a bed of pre-sieved NaCl salt crystals. While all scaffold types appeared 
morphologically similar, PEG-dihydrazide-crosslinked scaffolds produced 
noticeably fewer micropores.  
 
 
FIGURE 27. Swelling ratios of 4%PEG-86%PCL-10%cPCL scaffolds by crosslinker 
type. Upper and lower ends of boxes represent the 25th and 75th percentiles, respectively. 
Solid lines represent the median swelling ratios. Whiskers indicate 90th and 10th 
percentiles, and dots indicate outliers. The ability of the scaffolds to retain water was 
somewhat related to the length of the proline oligomer used as a crosslinker. PEG-P10-PEG-
crosslinked scaffolds retained significantly less water than PEG-dihydrazide-crosslinked 
scaffolds (*p < 0.05, n = 24). Differences in swelling ratios versus the other two scaffold 
types were not statistically significant. 
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To examine if this was due in part to the hygroscopic nature of PEG-
dihydrazide, swelling ratios of the scaffolds were measured as a function of the 
crosslinker employed. Due to the primarily PCL composition of the polymers, the 
resulting scaffolds exhibited swelling ratios that were on the order of 10x lower 
than those typically exhibited by hydrogels (Figure 27). However, the swelling ratios 
can be controlled to some extent by varying the length of the oligo(proline) peptide 
used in the crosslinker. PEG-dihydrazide, PEG-P5-PEG, PEG-P7-PEG, and PEG-P10-
PEG-crosslinked scaffolds exhibited swelling ratios of 12.4 ± 1.9 (n = 24), 11.1 ± 1.9 
(n = 12), 10.4 ± 3.2 (n = 24), and 9.5 ± 2.1 (n = 24), respectively. Across these four 
groups, only PEG-dihydrazide versus PEG-P10-PEG exhibited statistically significant 
differences in hydration (p < 0.05).  
 We also attempted the fabrication of the scaffolds using other solvents to 
dissolve the pre-polymer, including N-methylpyrrolidone (NMP), THF, and toluene. 
When NMP is used, the resulting scaffolds completely disintegrate into small clumps 
during the salt-leaching process. This is consistent with the poor solubility of PCL in 
NMP, and suggests that widespread crosslinked polymer networks were not 
successfully formed under these conditions. Toluene and THF both solubilized the 
pre-polymer, and produced crosslinked, macroporous scaffolds following salt-
leaching. However, examination of these scaffolds via SEM failed to show any 
micropores in the resulting polymer network.  
 Overall, these results suggest the successful formulation of widespread 
crosslinked polymeric scaffolds of relatively uniform macroporous and microporous 
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architecture, via the methods described above. The scaffolds are also capable of 
absorbing about ten-fold their dry mass in water. 
 
 
FIGURE 28. Accelerated degradation of terpolymer scaffolds crosslinked with PEG-P7-
PEG crosslinkers. Scaffolds crosslinked with PEG-dihydrazide or PEG-P7-PEG were soaked 
in PBS or PBS + 1 mM SIN-1 for 28 days. (A) At each time point, scaffolds were dried and 
massed. The average remaining mass fraction of each scaffold is calculated by dividing dry 
mass following treatment, by dry mass at the beginning of the study. Scaffolds containing 
both crosslinker types experienced some degree of oxidative degradation, but PEG-P7-PEG-
crosslinked scaffolds lost more mass under oxidative conditions (#,* p < 0.05, n = 3). (B) 
Heat capacity of scaffolds for the melting point transition following 14 d treatment was 
measured via DSC. Error bars represent standard deviation of 3 independent experiments 
(# p < 0.01, n = 3; * p < 0.05; § p < 0.05). 
 
ROS-Mediated Oxidative Degradation of Crosslinked Scaffolds 
Because control PEG-dihydrazide-crosslinked scaffolds and PEG-P7-PEG-
crosslinked scaffolds demonstrated similar morphology (Figure 26) and 
insignificant difference in swelling ratios, these two scaffold types were selected for 
108 
further study. To verify that the proline crosslinkers can accelerate the degradation 
of the scaffolds under oxidative conditions, scaffolds were soaked for up to 28 d at 
37°C in buffer with or without 1 mM of the ROS generator SIN-1. SIN-1 is typically 
known to produce nitric oxide and superoxide simultaneously, which can further 
lead to the generation of peroxynitrite and hydroxyl radicals in situ (Hogg, Darley-
Usmar, Wilson, & Moncada, 1992). At each time point, scaffolds were dried and 
weighed. 
 Whereas the dry mass of scaffolds soaked in PBS only did not change 
significantly over the 28 d incubation period, both scaffold types underwent 
significant degradation within the oxidative environment (Figure 28). Under 
oxidative conditions, PEG-dihydrazide-crosslinked scaffolds retained 85 ± 5% of 
their mass following 28 d of treatment, while PEG-P7-PEG-crosslinked scaffolds 
retained 72 ± 18% of their mass (n = 3). Neither scaffold completely degraded in 
this time frame. This can be attributed to the composition of the scaffolds, which is 
~82% terpolymer by weight.  
 The oxidative degradation of both scaffold types was further characterized 
by DSC. These results showed that all scaffolds exhibited melting points at 53-56°C 
regardless of treatment duration and type or crosslinker. However, the oxidative 
degradation of the PEG-P7-PEG scaffolds resulted in significantly decreased heat 
capacities during this phase transition (67.8 ± 1.8 J/g, n = 3), relative to PBS only-
treated scaffolds (73.8 ± 1.2 J/g). This difference was not seen for the 
correspondingly treated PEG-dihydrazide-crosslinked scaffolds (75.0 ± 3.0 J/g in 
PBS versus 74.4 ± 1.6 J/g in SIN-1). Further, following 14 d of treatment with SIN-1 
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in PBS, all scaffolds exhibited significantly lower heat capacities, as compared to 
their day 0, untreated counterparts. This phenomenon is attributable to hydrolysis 
of the polymer networks, which can occur throughout the incubation period. 
 
 
FIGURE 29. LPS/IFNγ-activated BMDMs exhibited H2O2-dependent degradation of 
PEG-P7-PEG-crosslinked scaffolds. (A) Immortalized murine BMDMs cultured in tissue 
culture plates for 24 h in the presence of 50 ng/mL IFNγ and 10 μg/mL LPS produced 
higher levels of H2O2 per cell (H2O2 production normalized to cell number indirectly via 
protein assay), relative to untreated BMDMs (*p < 0.05, n = 3). (B) SEM images (40x and 
900x) of scaffolds incubated with untreated or activated BMDMs for 9 d. Only PEG-P7-PEG-
crosslinked scaffolds incubated with activated BMDMs exhibited the appearance of 
widespread pitting and < 10 μm pores in the polymer network. 
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FIGURE 30. μCT imaging of scaffolds incubated with NGL-BMDMs (Mφ). Isotropic voxel 
size = 1 μm. (A) 3D pore diameter heat maps of scaffolds following incubation with 
untreated or activated (LPS/IFNγ-treated) BMDMs for 9 d. (B-C) Pore diameter histograms 
for scaffolds by crosslinker and treatment (average of n = 3 independent experiments). (D) 
From these histograms, a range of pore diameters (0-10 μm) was gated as an ROI, and the 
cumulative percentage of voxels containing pores of diameters within this range was 
plotted versus crosslinker type and treatment method. Consistent with the intended drug 
delivery function of this scaffold, the PEG-P7-PEG-crosslinked scaffolds experienced an 
increase in the appearance of small pores ≤ 10 μm in diameter. These results are consistent 
with SEM observations demonstrating the appearance of micropores and pits in these 
polymer matrices, as well as the widespread disintegration of the macroporous scaffold 
structure as shown in (A). 
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Macrophage-Mediated Oxidative Degradation of Crosslinked Scaffolds 
To evaluate the oxidative degradation of the scaffolds in a cellular model of 
oxidative stress, immortalized murine BMDMs were cultured on the scaffolds for 9 d 
with or without pro-inflammatory activation using 50 ng/mL IFNγ and 10 μg/mL 
LPS. This model was used because macrophages primed with γ-interferon (IFNγ) 
and activated with LPS typically respond through the upregulation of the M1, pro-
inflammatory phenotype, which results in increased production of ROS and nitric 
oxide (Antonio Sica, Schioppa, Mantovani, & Allavena, 2006). When cultured in 
tissue culture plates, the immortalized BMDMs produced higher levels of H2O2 per 
cell, relative to untreated BMDMs (Figure 29A). 
 The increased peroxide production by the immortalized BMDMs due to 
IFNγ/LPS treatment likely facilitated the accelerated degradation of PEG-P7-PEG-
crosslinked scaffolds (Figure 29B). This was evidenced by the appearance of 
widespread pitting and < 10 μm pores in the polymer networks of peptide-
containing scaffolds incubated in the presence of activated BMDMs. For all scaffolds 
that were incubated with non-activated BMDMs, as well as PEG-dihydrazide-
crosslinked scaffolds treated with activated BMDMs, the scaffolds exhibited no 
observable changes in pore architecture during the same incubation period. 
To quantify these changes in the pore architecture of the scaffolds, scaffolds 
were imaged via μCT, and the porosity was assessed from the reconstructed images 
(Figure 30). 3D heat maps of the pore sizes at each voxel were constructed, and 
pores were visualized as the blue regions in the images (Figure 30A). Notably, 
macropores were evident in all non-degraded scaffolds. However, the high density 
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of blue voxels in the PEG-P7-PEG-crosslinked scaffolds seeded with activated 
BMDMs, indicating the increased occurrence of micropores in this scaffold (Figure 
30A). These observations are consistent with observations via SEM (Figure 29).  
 The distribution of pore diameters was plotted from these images. PEG-
dihydrazide-crosslinked scaffolds exhibited similar pore size distributions 
regardless of whether they were incubated with untreated or activated BMDMs 
(Figure 30B). However, in PEG-P7-PEG-crosslinked scaffolds, activated BMDMs 
elevated the presence of micropores (diameters < 10 μm; Figure 30C). Because SEM 
results showed an increase in the occurrence of pores with diameters < 10 μm 
within these particular scaffolds, the 0-10 μm pore diameter range was gated as a 
region of interest (ROI), and the number of voxels that contain pores within this 
range can be measured as a percentage of the total number of voxels in the 3D 
image. After incubation with untreated BMDMs for 9 d, 1.4 ± 0.7% and 2.2 ± 0.6% of 
pores within PEG-dihydrazide- and PEG-P7-PEG-crosslinked scaffolds, respectively, 
were generated within the ROI. PEG-dihydrazide-crosslinked scaffolds incubated 
with activated BMDMs for the same time period contained 1.1 ± 0.2% pores within 
the ROI. PEG-P7-PEG-crosslinked scaffolds under these same conditions 
demonstrated a noticeable increase in pores within the ROI (4.0 ± 2.4%) relative to 
the same scaffold type incubated with untreated BMDMs. 
 
Discussion 
 The goal of the present work is to demonstrate proof-of-concept of ROS-
mediated degradable scaffolds through the covalent association of ROS-responsive 
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crosslinkers with non-responsive backbone polymers. Such a scaffold provides a 
new model in the toolbox to design an ROS-responsive biomaterials platform that 
exerts effects over a much longer time scale than the poly(propylene sulfide)-based 
platform (Napoli, et al., 2004). 
Proline oligomers were selected to be the ROS-responsive component of the 
model scaffold, based on earlier work by Amici et al., which demonstrated that 
proline, histidine, lysine, and arginine residues within polypeptide chains are 
particularly susceptible to oxidative cleavage (Amici, et al., 1989). While oligomers 
of these other amino acids were not investigated as crosslinkers in the work 
presented here, they are expected to also be degradable under oxidative 
environments. Nevertheless, proline oligomers were selected in this study, because 
proline is the only amino acid that is capable of forming a tertiary amide bond, 
which is known to be more easily oxidized than secondary amide bonds (Schuessler 
& Schilling, 1984). It is therefore expected that linear peptide or polymer chains 
containing secondary amide linkages can also degrade under oxidative conditions, 
although the degradation rate may be slower than that of the proline oligomers 
shown here. The oxidative degradation of the polymer networks containing 
secondary amide bonds was evidenced by our data, where control PEG-dihydrazide-
crosslinked scaffolds also experienced degradation through 28 d in 1 mM SIN-1, 
although not to the same extent as the P7-crosslinked scaffolds (Figure 28).  
With the intended controlled release application of these scaffolds, methods 
to increase the surface area of contact between the scaffold and the fluid 
environment were of paramount importance. To achieve this goal, a salt-leaching 
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process was employed in order to introduce pores throughout the crosslinked 
polymer network. Further, the crosslinking reaction takes place in a hydrophobic 
solvent. Hence, the condensation of water due to the amine-carboxylic acid 
crosslinking reaction results in the phase separation of water from the bulk solvent, 
producing smaller diameter ‘micropores’ (diameter < 10 μm) in the polymer 
network (Figure 26). The presence of micropores further increases the surface area 
of contact between the scaffolds and their environments, but μCT of the scaffolds 
suggests that micropores account for less than 1% of all the pores in the scaffolds 
following synthesis. However, following oxidative degradation of the PEG-P7-PEG-
crosslinked scaffolds, an increase in the occurrence of these micropores was 
observed (Figure 30C). 
It is also notable that the observed response rates for the polymeric scaffolds 
in this study are much slower than those observed for other oxidation-responsive 
scaffolds. For example, poly(propylene sulfide)-based systems have been shown to 
degrade within the time scale of < 6 h in response to H2O2 (Napoli, et al., 2004). 
More recently, polythioether ketal nanoparticles were shown to degrade in 
response to ROS on the order of 15 h, but required an acidic environment to 
completely degrade (Mahmoud, Sankaranarayanan, Morachis, Kim, & Almutairi, 
2011). Therefore, the complete degradation of the polymeric system discussed in 
the current study is expected to occur in > 10x as much time as other, alternative 
systems.  
In order to completely isolate oxidation-responsive behavior to the 
crosslinkers, alternative coupling chemistries may be necessary to covalently bind 
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the crosslinkers to the backbone polymers. The Huisgen 1,3-dipolar cycloaddition 
reaction—better known as azide-alkyne ‘click’ chemistry—has been suggested to 
form linkages that remain relatively inert under oxidative conditions (Kolb & 
Sharpless, 2003). Alternatively, disulfide bridges are not susceptible to oxidative 
cleavage, as such conditions actually promote the formation of these ‘crosslinks’—
even under physiologically relevant constraints (Tu, Ho-Schleyer, Travers, & 
Weissman, 2000). This strategy has been successfully employed by others to form 
highly-crosslinked hydrogels (Shu, Liu, Luo, Roberts, & Prestwich, 2002). With the 
goals and scope of the present work in mind, these modifications are an appropriate 
subject for further development and refinement of our system.  
Nevertheless, the oxidation response of the proline oligomers was tracked 
throughout the synthetic process, from the free peptides to the crosslinkers to the 
scaffolds. It is clear that the proline oligomers are more susceptible to oxidative 
cleavage rather than their flanking PEG chains. This was supported by GPC 
measurements that suggested that the PEG-Pn-PEG crosslinkers retained intact PEG 
structure under MCO conditions (Figure 25). The harsh MCO conditions were 
chosen because in the presence of copper ions, H2O2 can be decomposed into highly 
reactive hydroxyl radicals (McCall & Frei, 2000). 
While the MCO system has been widely employed to mimic oxidative stress 
in vitro, evidence for its physiological relevance in vivo remain controversial in spite 
of the availability of plausible mechanisms (McCall & Frei, 2000; Murphy, Packer, 
Scarlett, & Martin, 1998; Earl R. Stadtman, 1990). This is partly because significantly 
greater concentrations of free metals and H2O2 are used in the in vitro model than 
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what is typically found in vivo. Alternatively, the contributions of peroxynitrite 
(ONOO-) to oxidative stress in vivo are known to be more significant, because of 
their high reactivity, and capability of diffusing across lipid bilayers (Murphy, et al., 
1998). Therefore, upon formation of the crosslinked scaffolds, oxidative 
environments were established via a SIN-1 treatment, since SIN-1 slowly 
decomposes under aqueous conditions to form O2- and NO· ions, which can very 
rapidly combine to form ONOO-. This treatment regime produces a more 
physiologically relevant model of the oxidative stress environment versus the MCO 
system used in preceding studies. Under these conditions, the presence of proline 
oligomers within the scaffolds promoted the ROS-responsiveness of the model 
scaffolds.  
Because the scaffolds contained approximately 18% PEG-Pn-PEG by weight, 
oxidized scaffolds were expected to retain up to ~82% of their mass (the backbone 
polymer component) following oxidative treatment. While control PEG-dihydrazide-
crosslinked scaffolds retained more than 82% of their mass during the study period, 
the peptide-containing scaffolds retained ~70%. These findings suggest that 
oxidative degradation is not limited to the crosslinker components of the scaffolds. 
Although we selected a 4%PEG-86%PCL-10%cPCL-based polymer to avert this 
possibility, the PCL/cPCL components are polyesters and therefore, can undergo 
both hydrolytic and oxidative degradation. These conclusions are consistent with 
the findings of other groups (Ali, et al., 1994).  
The scaffolds were next incubated with untreated or activated murine 
macrophages in order to establish the ability of these scaffolds to respond to 
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oxidative stimuli presented in a more physiologically-relevant model. SEM and μCT 
imaging were used to observe changes in the pore architecture of the scaffolds after 
the 9 d incubation period, and confirmed that PEG-P7-PEG-crosslinked scaffolds, 
only when incubated with activated macrophages, experienced structural changes 
and an increase in the occurrence of micropores. Therefore, within this in vitro 
model of inflammation-related oxidative stress, the activated macrophages 
degraded the proline oligomer-containing scaffolds more effectively than they did 
the control scaffolds that were crosslinked with PEG-dihydrazide. This is likely due 
to increased H2O2 production by activated macrophages relative to untreated 
macrophages. Because of the relatively short study period, complete degradation 
and disintegration of the scaffolds was not observed.  
This is, to our knowledge, the first demonstration of an ROS-mediated, 
degradable polymeric scaffold, and paves the way for applications in tissue 
engineering and controlled release where chronic oxidative stress is expected due to 
disease progression, or as a response to implanted materials. The results presented 
in this study also have widespread implications, since polymeric scaffolds 
containing peptide-based elements, such as protease-degradable peptide sequences 
and cell binding motifs, are very widely used (DeLong, Gobin, & West, 2005; Miller 
et al., 2010; West & Hubbell, 1998). In particular, protease-treated hydrogels 
containing degradable peptide sequences have been shown to degrade significantly 
over the course of a few days. Because oxidative degradation of peptide-containing 
scaffolds occurs over longer time frames, this phenomenon is unlikely to 
significantly affect their proteolytic degradation in vivo. However, our findings 
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suggest that in applications where an implanted, peptide-containing biomaterial is 
required to remain viable for months, local ROS production may influence the 
function and stability of the implant. 
In conclusion, we have synthesized polymeric biomaterials scaffolds 
chemically crosslinked with proline oligomers, which are degradable via local ROS 
production. These scaffolds may be potentially loaded with drugs and other species 
for the site-specific therapy of conditions where ROS levels are elevated due to 
pathogenesis, such as in implant rejection and atherosclerotic plaques. Due to the 
weeks-to-months timescale required to completely degrade these materials, the use 
of these materials to treat such conditions, where chronic oxidative stress is often 
observed, will reduce the necessity for multiple injections or implantation 
procedures to address the condition.  
 
Summary 
 Recent work in the laboratory of Craig Duvall has shown that polymeric 
scaffolds can be loaded with polymeric nanoparticles carrying siRNA, in order to 
achieve localized, intracellular delivery of drugs and other biologics at pathologic 
sites (C. E. Nelson, et al., 2012). In light of this work, a combination of the work in 
this chapter and the previous one offers a glimpse of how local, pathologic 
inflammatory processes can be leveraged to achieve localized delivery of siRNA into 
macrophages via the ManNPs, released via oxidation-degradable scaffolds. 
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CHAPTER V 
 
SYSTEMIC INJECTION OF MANNOSYLATED POLYMERIC MICELLES FOR 
TARGETED DRUG DELIVERY TO TUMOR-ASSOCIATED MACROPHAGES 
 
In Chapter III, I described the design, synthesis, and in vitro performance of 
ManNPs, which are composed of mannosylated triblock copolymers, including a 
cationic block for electrostatic condensation of nucleic acid-based therapeutics, as 
well as a pH-responsive block that is hydrophobic at physiologic pH ranges, enabling 
the potential for encapsulation of hydrophobic small-molecule drugs. The ManNPs 
are targeted to CD206, which is upregulated by TAMs, and were minimally 
internalized into human breast cancer cell lines in vitro (Figure 18). In this chapter, 
the ManNPs were administered retro-orbitally into two murine tumor-bearing 
models, including the polyoma middle T oncogene (PyMT) model of spontaneously-
arising breast cancer, and a tail-vein tumor cell injection model of metastatic breast 
cancer. The purpose of these experiments was to evaluate the cell-specificity of the 
ManNPs and the potential to achieve TAM-targeted drug delivery. While the 
ManNPs delivered fluorescently-labeled siRNA into TAMs more specifically than 
into tumor cells in both models, significant levels of TAMs remained untreated as 
evaluated by flow cytometry, suggesting that the first generation of ManNPs 
developed here may require further refinement and optimization in order to enable 
more widespread targeting of TAMs. Nevertheless, the cell-specificity of the carriers 
described in this work provides new avenues for TAM-centric immunotherapies. 
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Introduction 
 TAMs represent an intriguing target for cancer immunotherapy, because of 
their ability to perform a spectrum of functions, from pro-inflammatory, cytotoxic 
activities, to anti-inflammatory, growth-promoting functions. In various human 
cancers, TAMs have been observed in the tumor periphery and in some cases, in the 
necrotic, hypoxic core regions. In either case, TAMs have been known to be anti-
inflammatory, secreting an array of proteins that lead to immunosuppression, 
tumor growth, extracellular matrix proteolysis, and local angiogenesis (Fridman, 
Pages, Sautes-Fridman, & Galon, 2012; Antonio Sica, et al., 2006). Therefore, TAM-
targeted interventions, including depletion, modification, and reprogramming have 
been proposed as potential immunotherapeutic routes in cancer (DeNardo et al., 
2011; Hagemann, et al., 2008). 
 Because macrophages are among the most phagocytic cell types in the body, 
it is not difficult to deliver drugs into these cells. Work by others suggests that 
targeting motifs may not be necessary in order to target nanoparticles for 
macrophage uptake (Daldrup-Link et al., 2011; Van Rooijen & Sanders, 1994). In 
many cases, the minimization of macrophage uptake of drug delivery systems is a 
significant challenge (Li & Huang, 2009). However, macrophages are resident cells 
in many tissues and organs, including the bone marrow, liver, and spleen. Therefore, 
site-specific drug delivery into TAMs presents a significant challenge in order to 
minimize the risk of eliciting autoimmune manifestations in off-target organs and 
tissues. 
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 To achieve this, molecularly-targeted drug delivery systems have been 
developed that home into receptors and biomarkers upregulated in macrophages 
located at pathologic sites. These include the LyP-1 peptide directed against p32, 
toll-like receptor agonists, dextran-coated nanoparticles against SIGNR-1, 
monosaccharides against various macrophage lectins, and HDL-mimetic peptides 
and nanoparticles (Cormode, Briley-Saebo, et al., 2008; Cormode, Skajaa, et al., 2008; 
Fogal, Zhang, Krajewski, & Ruoslahti, 2008; Frias, Ma, Williams, Fayad, & Fisher, 
2006; Kortylewski, et al., 2009; Laakkonen, Porkka, Hoffman, & Ruoslahti, 2002; 
Morishige et al., 2010; Song et al., 2012; Taylor et al., 2004). With the exception of 
the monosaccharide-based approaches, most of these approaches exhibited some 
targeting of other tumor cells or immune cells, suggesting that such approaches hold 
the most promise for TAM-specific drug delivery systems. 
 Mannose receptor (CD206) is an endocytotic receptor present mainly on 
macrophages and dendritic cells, and upregulated on TAMs (East & Isacke, 2002; 
Joyce & Pollard, 2009; A. Sica, et al., 2008; Taylor, et al., 2005). Through the use of 
endosomolytic polymers such as those developed in Chapter III, intracellular 
delivery of biologics can be achieved, potentially enabling the interference with 
pathological mechanisms present in TAMs. These polymers self-assembled into 
micellar structures with a mannose-presenting corona, and have been shown to 
promote siRNA delivery into primary macrophages and immortalized human 
macrophages in vitro. In this work, the TAM-specificity of these particles is further 
evaluated in an in vivo environment, in order to showcase its potential applicability 
to TAM-centric immunotherapies and imaging approaches. 
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Materials and Methods 
Animals and Cell Lines 
Animal work was approved by the Vanderbilt University Institutional Animal 
Care and Use Committee. All mice were on an FVB background strain. The primary, 
spontaneously-arising tumor model involved FVB mice carrying the polyoma middle 
T oncoprotein (PyVT) gene. Originally developed by Bill Muller and colleagues, the 
PyVT mouse model is now commercially available through Jackson Laboratories, 
and naturally develop palpable mammary tumors as early as 5 weeks of age, with 
pulmonary metastases observed in 80-94% of adult mice 12-15 weeks of age (Guy, 
Cardiff, & Muller, 1992). At 13 weeks old, female mice were anesthesized via 
isoflurane inhalation, and injected retro-orbitally with 1 mg/kg FAM-labeled siRNA 
loaded into polymers at a 4:1 N:P ratio. The mice were then incubated for 24 h, 
sacrificed via CO2 inhalation and then cervical dislocation, and then organs (tumors, 
liver, lungs, spleen, kidneys, and small intestines) were collected for detection of 
FAM-siRNA via immunohistochemistry or flow cytometry. Hematoxylin and eosin 
staining of paraformaldehyde-fixed, paraffin-embedded tissues (lungs, liver) was 
performed by the Vanderbilt Translational Pathology Shared Resource using 
standard techniques.  
 
Flow Cytometry 
 Whole organs were isolated from mice post-mortem, and minced into a 
cleavage cocktail containing 3 mg/mL collagenase-A and 3 mg/mL DNAse I (Roche 
Applied Science, Indianapolis, IN). After 2 h incubation at 37°C, the cell suspensions 
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were run through 40-μm cell strainers and treated with ACK lysing buffer (Life 
Technologies) according to manufacturer’s instructions, to lyse red blood cells. After 
pelleting the remaining cells by centrifugation at 300 x g for 5 min, cells were fixed 
in 8% paraformaldehyde for 10 min, treated with anti-CD16/CD32 (BD Biosciences, 
San Jose, CA) to block Fcγ receptors, and then stained with rat anti-mouse CD45-
PECy7 (Clone 30-F11) and rat anti-mouse CD11b-APC (Clone M1/70; both 
antibodies from eBioscience, San Diego, CA). Multi-color flow cytometry, including 
analysis of single-stained controls for compensation calculation, was performed on a 
BD FACSCanto II system, operated by the BD FACSDiva software. Post-acquisition 
data analysis and reporting were performed on FlowJo (version 7.6.4). 
 
Confocal Microscopy of Frozen Sections 
 For frozen sections, murine organs were collected into TissueTek OCT 
compound (Fisher Scientific), frozen at -80°C, and then cut into 5μm-thick sections 
prior to fixation in 4% paraformaldehyde for 20 min. After rinsing sections 3x with 
PBS, tissues were permeabilized via treatment with 1% Triton X-100 for 30 min, 
then blocked for 1 h in 1% BSA in PBS. After rinsing 3x with PBS, tissues were 
stained with RPE-conjugated rat anti-mouse CD206 (AbD Serotec, Raleigh, NC) 
overnight at 4°C. After rinsing 3x with PBS, slides were stained with DAPI, mounted, 
and imaged as described above. FAM (siRNA) and PE (CD206 Ab) images were 
collected separately using the available 488 nm and 561 nm lasers, respectively, in 
order to prevent spectral overlap between the two dyes. Correlation plots were 
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constructed using the JaCoP (Just Another Correlation Plugin) macro, loaded into 
ImageJ (version 1.45s) (Bolte & CordeliÈRes, 2006). 
 
Results 
Because ManNPs enhanced siRNA delivery and knockdown relative to 
untargeted diblock nanoparticles in primary and immortalized macrophage cell 
lines in vitro, we next evaluated the performance of the nanoparticles in vivo in 
tumor-bearing mice. For these studies, we used FVB mice expressing the polyoma 
middle T oncoprotein (PyVT), which spontaneously develop primary tumors within 
5-7 weeks of age, with pulmonary metastases occurring as early as 12-15 weeks of 
age (Guy, et al., 1992). In this way, PyVT mice model the natural progression of 
human disease from localized tumors into metastatic disease, and the involvement 
of leukocytic subtypes in disease progression continues to make this model among 
the most reliable murine models of breast cancer in humans today (Lin et al., 2003). 
 Therefore, 13-week old, female PyVT mice were injected retro-orbitally with 
1 mg/kg FAM-siRNA, loaded into ManNPs or non-targeted diblock nanoparticles, 
and allowed to incubate for 24 h prior to sacrifice and collection of organs for 
detection of FAM-siRNA via flow cytometry and confocal microscopy (Figure 31). As 
a control, some mice received a blank PBS injection (mock). 
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FIGURE 31. ManNPs Enhance siRNA Delivery into TAMs in Primary Murine Breast 
Tumor Model. 24 h after retro-orbital administration of 1 mg/kg FAM-labeled siRNA, 
injections are well-tolerated by the mice as evidenced by the lack of significant necrotic 
tissue or abnormal staining patterns via H&E of harvested livers and lungs, where 
nanoparticles are either cleared or can cause acute toxicity (A; scale bars = 500 μm). (B) 
Flow cytometry analysis of CD45+ CD11b+ cells in the lungs (top) and spleen (below) reveal 
some homing of ManNPs into these cells in the lungs, as well as splenic localization of non-
targeted diblock nanoparticles. (C) Co-localization of FAM-siRNA with CD206+ cells in 
primary mammary tumors is only observed when ManNPs were used as the vehicle (Scale 
bars = 100 μm). 
 
 In all cases, injections were well-tolerated by the animals, as evidenced by 
insignificant differences in lung and liver morphology by hematoxylin & eosin 
staining (Figure 31A). Injected nanoparticles typically clear through the liver and 
the spleen, and consistent with this, some siRNA localization was observed in the 
spleen, when the untargeted diblock nanoparticles were used as the delivery vehicle 
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(Figure 31B) (Alexis, Pridgen, Molnar, & Farokhzad, 2008). The lungs are also 
typically home to a small subset of alveolar and interstitial macrophages, and some 
siRNA localization was also observed here (Laskin, Weinberger, & Laskin, 2001).  
 Most importantly, ManNPs enhanced siRNA colocalization with CD206 in 
frozen sections of the primary tumors (Figure 31C). This was not observed for 
sections collected from mice treated with free siRNA or siRNA complexed with 
untargeted diblock nanoparticles. These results suggest that mannosylation of the 
polymers via ‘click’ chemistry enables cell-specific siRNA delivery into TAMs in vivo. 
 
Discussion 
 The modulation of TAM behavior in vivo requires cell-specific drug delivery 
vehicles in order to reactivate pro-inflammatory functions in TAMs while leaving 
resident macrophages elsewhere untouched. This is particularly important because 
inadvertent activation of off-target macrophages may lead to autoimmune 
manifestations (Caspi, 2008). Because ManNPs were previously shown to enhance 
siRNA delivery into primary macrophages, while demonstrating modest delivery 
into tumor cells, we investigated their ability to achieve TAM-specific siRNA delivery 
in a spontaneous murine breast tumor model (Lin, et al., 2003). 
 As shown earlier, the ManNPs are block copolymers that exhibit a mannose-
presenting corona for CD206 targeting, a cationic layer for complexation of nucleic 
acids, and a pH-responsive endosomolytic layer to enable endosomal escape of the 
polymers and their cargo (Figures 12, 19). Overall, the ManNPs exhibit a positive 
surface charge (Table 5). Significant safety issues hamper the translation of cationic 
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gene and siRNA delivery vehicles into humans. Some major questions include (1) 
the rapid adsorption of serum proteins onto the cationic surface, thereby mitigating 
the targeting functions and ligands on the nanoparticle corona and leading to rapid 
clearance and toxicity in the RES, (2) the induction of platelet aggregation and 
coagulopathies, (3) formation of emboli in the smallest-diameter (<10 μm) 
capillaries in the lungs (Alexis, et al., 2008; Fako & Furgeson, 2009; Jones et al., 
2012). Because of these safety concerns, it is necessary to examine the effects of in 
vivo nanoparticle injection on the host animal’s lungs and clearing organs. A 
pathological examination of these organs showed that the nanoparticles were well-
tolerated and did not cause significant emboli formation or necrosis here. 
 Further, the nanoparticles were able to home into the primary tumors of the 
mice, and mannosylated carriers even targeted TAMs in these tissues, as evidenced 
by CD206+ (macrophage mannose receptor) staining, which is almost exclusive to 
these cells Figure 31C). While this study did not quantify effects of siRNA delivery 
on target gene expression in the TAMs versus in other cells in the tumor, previous 
evidence in vitro suggests that the delivered siRNA remains functional (Figure 21A). 
Future extensions of this work are ongoing and to quantify siRNA-mediated gene 
knockdown in TAMs within the same PyVT mouse model described here, as well as 
in metastatic tumor models. 
 Other strategies also exist to target macrophages in vivo, including peptides, 
antibodies, synthetic lipid nanoparticles, and non-targeted PEGylated nanoparticles 
(Bastu s et al., 2009; Larsen, et al., 2009; Shann S. Yu et al., 2011). In many cases, 
macrophages are among the most phagocytic cell types present in the body, and 
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therefore, molecular targeting motifs may not be necessary to produce significant 
macrophage targeting in vivo (Daldrup-Link, et al., 2011). To deliver genes or siRNA 
into macrophages, the vehicle must overcome the highly degradative lysosomal and 
phagosomal compartments present within these cells, in order to access the target 
intracellular compartments where these agents can function (Stacey, et al., 1993). 
 Because ManNPs are able to selectively target TAMs without affecting other 
tumor cells, they provide a platform for the interrogation of TAMs with the goals of 
characterizing downstream effects on the tumor and on the rest of the immune 
system. To achieve these ends, key targets of interest for siRNA knockdown within 
TAMs include the NF-κB and STAT families of pathways, which regulate their 
expression of whole libraries of cytokines, growth factors, enzymes, and angiogenic 
factors (Connelly et al., 2011; Murray, 2007; Porta, et al., 2009). These families of 
pathways include more than 40 interesting genes to target, and the potential effects 
of siRNA-mediated knockdown have been studied through the use of genetically-
engineered knockout models. Some, such as STAT3, have additionally been studied 
in the context of therapeutic siRNA-mediated knockdown, resulting in the induction 
of anti-tumor immune responses in murine tumor models (Kortylewski, et al., 2009). 
Therefore, this area remains a burgeoning area for investigation of new 
immunotherapeutic strategies for cancer. 
 
Summary 
 In this chapter, the ManNPs developed earlier (Chapter III) were systemically 
injected in vivo into a well-investigated spontaneous murine model of breast cancer, 
129 
in order to evaluate the ability of these glycoconjugates to home into TAMs. The 
preliminary data shown here suggests that these nanoparticles are well-tolerated by 
the mice at the doses administered, and enhance siRNA delivery into CD206+ cells 
present in the tumor. The ManNPs present a viable platform for the interrogation of 
TAMs without affecting other cell types present in the tumor environment. 
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CHAPTER VI 
 
ASSESSMENT OF THE EFFICACY OF CANCER IMMUNOTHERAPIES IN HUMAN 
BREAST CANCER PATIENTS 
 
Despite the successful treatment of some patients with recent cancer 
immunotherapies, many non-responders have been reported. It is increasingly clear 
that this is partly due to the ability of tumors to exhibit multiple mechanisms for the 
suppression of anti-tumor immunity, suggesting that combination 
immunotherapeutic approaches may be necessary to overcome these barriers. 
Because T-cells are the primary effector cells that clear tumor masses, many 
immunotherapies are designed with the goal of augmenting anti-tumor T-cell 
responses. While phenotypic biomarkers of T-cell subtypes and activation states 
have been well-documented, T-cell-based biomarkers of immunotherapeutic 
efficacy have not been identified. Therefore, the purpose of this study was to design 
flow cytometric and miRNA-profiling assays for the longitudinal assessment of T-
cell responses in patients enrolled in cancer immunotherapy clinical trials, with the 
ultimate goal of uncovering biomarkers of the efficacy of anti-cancer 
immunotherapies. The ongoing work presented here may promote the development 
of new, streamlined methods for the temporal tracking of patients enrolled in future 
immunotherapeutic clinical trials, and the identification of novel biomarkers and 
targets for drug development. 
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Introduction 
Cancer immunotherapies seek to jump-start anti-tumor immune responses 
and have the potential to induce long-term immunity to phenotypically similar 
tumor cells due to the ability of the immune system to ‘remember’ past antigens. 
However, the activation of anti-tumor immunity requires the involved immune cells 
to overcome several hurdles. First, dendritic cells with access to the tumor must be 
capable of sampling tumor antigens and becoming activated, leading to their 
migration into the lymph nodes. There, they must be able to interact with immature 
T-cells, selecting and expanding clones that are specific for tumor antigens. Finally, 
the activated T-cells must be able to migrate back into the tumor, where they must 
then overcome the immunosuppressive environment promoted by the tumor and its 
supporting stroma, which commonly includes TAMs, myeloid-derived suppressor 
cells (MDSCs), and Treg cells, all of which contribute towards the de-activation of the 
incoming T-cells (Mellman, Coukos, & Dranoff, 2011). 
A number of current FDA-approved immunotherapeutic approaches are 
capable of achieving one of these three requirements. A recent example is the anti-
CTLA4 antibody (ipilimumab), which essentially releases the ‘brakes’ on T-cell 
activation, re-activating pre-existing anti-tumor T-cells that may have become 
suppressed by the tumor (Mellman, et al., 2011). While these therapies have 
improved long-term survival through the induction of anti-tumor immunity in some 
patients, many non-responders exist, suggesting the need for an integrative, multi-
pronged immunotherapeutic approach that uses several agents in combination, in 
order to tackle the three hurdles listed above. The recognition that such 
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combination approaches may improve the efficacy of immunotherapies was among 
the reasons behind the recent creation of the Cancer Immunotherapy Trials 
Network (CITN) by the National Cancer Institute, and its first clinical trials include a 
few such approaches ("Immunotherapy Network Launches First Trial," 2012). 
While various immunotherapies differ in terms of target cell type or 
biomarker, approach, and mechanism of action, the ultimate goal is typically to 
activate anti-tumor CD3+/CD8+ T-cells. These cells, also called cytotoxic T 
lymphocytes (CTLs), are capable of potent anti-tumor cell effector functions, and 
thus, their presence at tumor sites has been commonly correlated with promising 
clinical outcomes and longer disease-free survival for patients of various cancers 
(Fridman, et al., 2012). In consequence, the characterization of the T-cell response 
in clinical trials patients treated with experimental immunotherapies is of 
significant interest to the community. 
While much is known about phenotypic markers of various T-cell subtypes 
and activation, biomarkers of immunotherapy efficacy remain elusive. The 
identification of such biomarkers may streamline the longitudinal assessment of 
patient responses during the clinical trials, and also provide new avenues for drug 
development aimed at the promotion or suppression of those biomarkers. For this 
purpose, we designed a multiparameter flow cytometry panel aimed at 
characterization of T-cell phenotypic subtypes and activation states (Table 6). 
Further, we also assessed the miRNA expression profile within the T-cells, as 
miRNAs have been shown to regulate entire gene pathways and networks due to 
their polygamous nature (Pritchard, Cheng, & Tewari, 2012). 
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TABLE 6. Multicolor Phenotyping Panel for Assessment of T-Cell Responses in 
Immunotherapy Clinical Trials Patients. 
Marker Fluorophore Description Reference 
CD3 FITC Associated with T-cell receptor 
(Kindt, et al., 
2007) 
CD4 AF700 Marker of TH cells 
(Kindt, et al., 
2007) 
CD8 APC-Cy7 Marker of TC cells 
(Kindt, et al., 
2007) 
CD25 APC IL-2 receptor α-chain 
(B. H. Nelson, 
2004; Papiernik, 
de Moraes, 
Pontoux, Vasseur, 
& Pénit, 1998) 
CD28 PE-CF594 
T-cell co-stimulatory factor, related to 
CTLA-4 
(Boise et al., 1995; 
Sharpe & 
Freeman, 2002) 
CD45 AmCyan 
Marker of all immune cell subtypes, also 
known as leukocyte common antigen 
(Kindt, et al., 
2007) 
CD45RA PE-Cy51 Commonly used to identify naïve T-cells 
(Kindt, et al., 
2007) 
CD56 PE-Cy7 
Neural cell-adhesion molecule (NCAM), 
also commonly used to identify NK cells 
(Lanier, Testi, 
Bindl, & Phillips, 
1989) 
CD127 BV4212 
IL-7 receptor α-chain; mediates 
expansion and survival of memory and 
naïve T-cells 
(Hartigan-
O'Connor, Poon, 
Sinclair, & 
McCune, 2007) 
CD197 PerCP-Cy5.5 
CCR7; Receptor for chemoattractants 
CCL19/21, mediates functional 
organization of the immune system and 
lymph nodes 
(Worbs & Förster, 
2007) 
CD278 PE 
Inducible T-cell costimulatory molecule 
(ICOS) 
(Hutloff et al., 
1999) 
CD279 BV7112 
Programmed cell death-1; engagement 
by PD-L1 reduces T-cell activation, 
proliferation, and cytokine secretion 
(Freeman et al., 
2000) 
HLA-DR BV6052 MHC-II isotype 
(Choi, Majumder, 
& Boss, 2011) 
1This particular fluorophore appears to give a significant level of spectral overlap into other 
channels, and has since been replaced with a dye that exhibits a narrower emission 
spectrum. 
2BV dyes are shorthand for “Brilliant Violet.” 
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Materials and Methods 
Patients and Human Subjects 
For assay development, healthy human volunteers were consented and 
whole blood samples were collected into heparin-coated tubes via venipuncture on 
the median cubital vein. For microarray experiments, blood samples were obtained 
from consented patients enrolled in a clinical trial approved by the United States 
Food and Drug Administration and the University of Washington Human Subjects 
Division. Full description of the enrollment criteria and the characteristics of the 
patients were documented elsewhere (Disis et al., 2009). 
  
Antibodies and Flow Cytometry 
 All antibodies were purchased from BD Biosciences (Franklin Lakes, NJ) 
unless otherwise noted, and titrated on heparinized whole blood isolated from 
consenting healthy human volunteers. The antibodies included CD3-FITC (clone 
SK7), CD4-AlexaFluor 700 (clone RPA-T4; BioLegend, San Diego, CA), CD8-APC-Cy7 
(clone SK1), CD25-APC (clone M-A251), CD28-PE-CF594 (clone CD28.2), CD45-
AmCyan (clone 2D1), CD45RA-PE-Cy5 (clone HI100), CD56-PE-Cy7 (clone 
NCAM16.2), CD127-Brilliant Violet 421 (clone HIL-7R-M21), CD197-PerCP-Cy5.5 
(clone 150503), CD278-PE (clone DX29), CD279-Brilliant Violet 711 (clone 
EH12.2H7; BioLegend), and HLA-DR-Brilliant Violet 605 (clone L243; BioLegend). 
 Antibodies were first diluted into FACS Buffer (1% BSA in PBS), to a total 
volume of 100 μL of the 13-antibody master mix per sample to be tested. After 
aliquoting 100 μL of the master mix into individual FACS tubes, 100 μL of whole 
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blood was added directly to the antibodies by reverse-pipeting, and mixed by 
vortexing briefly. The samples were incubated at room temperature in the dark for 
15 min, after which 900 μL of 1X FACS lysis buffer (BD Biosciences; contains 
buffered < 1.5% formaldehyde and < 5% diethylene glycol) was added to each tube 
in order to fix the PBMCs while simultaneously lysing excess erythrocytes. After 
incubating samples for another 15 min at room temperature, they were stored at 
4°C prior to same-day analysis, or -80°C for analysis within 1 week. 
 Data was acquired on a five-laser (355, 408, 488, 532, and 633 nm lasers), 
eighteen-channel BD LSR-II flow cytometer at the Fred Hutchinson Cancer Research 
Center Flow Cytometry Core (Seattle, WA). Spectral compensation using single-
stained control samples, data analysis and graph generation was performed on 
FlowJo software. 
 
T-Cell miRNA Profiling 
PBMC aliquots (10,000,000 cells/patient/timepoint) from 10 patients, taken 
at 0 and 12 weeks post-treatment, were thawed and resuspended into ice-cold 
MACS buffer (PBS + 2% FBS + 2 mM EDTA). They were then treated with CD3-
antibody-coated magnetic beads and eluted through magnetic selection columns 
according to the manufacturer’s instructions (Miltenyi Biotec, Cologne, Germany). 
The purity of the isolated CD3+ cells was determined to be 70-80% via flow 
cytometry, using antibodies against CD3 and CD4. 
1,000,000 CD3+ cells were then lysed and total RNA was isolated using a 
commercial kit according to manufacturer’s instructions (Clontech NucleoSpin 
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miRNA kit; Clontech Laboratories, Mountain View, CA). RNA purity, concentration, 
and quality were assessed via Agilent BioAnalyzer (Santa Clara, CA) and NanoDrop 
(ThermoFisher Scientific, Waltham, MA), prior to hybridization onto Affymetrix 
human miRNA microarrays (Santa Clara, CA). 
 
Results 
13-Marker T-Cell Phenotyping Panel 
Multiparameter flow cytometry panels suffer from issues of spectral overlap 
due to fluorophores of similar excitation and emission spectrum, leading to the 
necessity to ‘compensate’ for this effect through mathematical algorithms (Perfetto, 
Chattopadhyay, & Roederer, 2004). Crucial steps to create these matrices include 
the acquisition of single-stained controls (ie, samples that were stained with single 
antibodies from the proposed panel; Figure 32), and fluorescence-minus-one 
controls (ie, samples that were stained with all of the antibodies in the panel minus 
one of the antibodies; Figure 33). The ultimate result of this protocol is a 
compensation matrix such as that shown below (Table 7), which describes the 
interactions between individual dyes with unintended channels. In some cases, 
values above 100% may result, which signifies that cells stained with a certain dye 
show up more brightly on an unintended channel, compared with cells stained with 
a different dye intended for the same channel. 
 In particular, the original CD45RA antibody used in this panel (PE-Cy5 
fluorophore) showed significant levels of spectral overlap into multiple channels, 
and has since been replaced with a different dye to mitigate these effects. 
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Nevertheless, the original panel was still functional enough for use in basic 
phenotyping of whole blood (Figure 34). 
 
FIGURE 32. Uncompensated Acquisition of Representative Whole Blood Sample 
Stained with Single Antibodies from the 13-Marker Panel. Whole blood samples from a 
consenting human volunteer were treated with individual antibodies from the proposed 
panel (Table 6) or left untreated (NT) and analyzed by flow cytometry to quantify cell 
fluorescence in the 13 channels corresponding to each fluorophore present in the panel. In 
all plots, SSC-A (side scatter) has been plotted on the y-axis, and fluorescence intensity in 
the x-axis. Each row corresponds to a different sample, and columns correspond to each 
channel used in acquisition. Cells were gated for singlets and then lymphocytes based on 
size scatter plots. Gray highlighted boxes indicate the intended channel for which each 
sample is expected to show any positive signal. Some antibodies (e.g., CD25, CD278, CD279) 
stain the whole population and appear to cause a population shift. 
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FIGURE 33. Post-Compensation Fluorescence-Minus-One (FMO) Stains of 
Representative Whole Blood Sample. Whole blood samples were stained with 12 of 13 of 
the antibodies in the proposed panel (Table 6) and analyzed by flow cytometry. Each row 
corresponds to a different sample missing the antibody indicated on the left, with columns 
indicating the channel represented. Each plot is a side scatter (y-axis) vs. fluorescence (x-
axis) distribution. Gray highlights indicate plots where no positive staining should be 
observed, due to the particular antibody being missing from the sample. Two samples 
stained with the full panel and an untreated sample (NT) have been shown for comparison. 
All samples were gated on CD45+ singlets and on size scatter plots, except CD45 plots and 
the CD45 FMO, which was gated based on singlets and size scattering alone. 
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TABLE 7. Compensation Matrix Resulting From the 13-Color Panel, with Significant 
Channels of Spectral Overlap Highlighted In Yellow. 
 
 
 
FIGURE 34. Phenotyping T-Cells in Whole Blood via the 13-Antibody Panel. A 
representative whole blood sample from a consenting human volunteer was stained with 
the 13-antibody panel described in Table 6. Gating strategy has been delineated with black 
arrows. Some major ramifications of >100% spectral overlap (as shown in Table 7) include 
the appearance of large populations with <0 fluorescence signal as marked with red 
arrowheads. 
CD278-PE CD3-FITC CD127-BV421CD4-AF700 CD56-PECy7CCR7-PerCPCy5.5D8-APCCy7CD28-ECD CD25-APC CD45-AmCyanHLADR-BV605CD45RA-PECy5CD279-BV711
CD278-PE 45.70 7.32 87.44 5.62 152.50 8.65 173.30 78.96 161.20 59.60 17.24 14.37
CD3-FITC -11.04 -1.32 -19.76 -1.40 -25.42 -3.00 -33.38 -17.77 -5.60 -2.82 -4.00 -1.90
CD127-BV421 6.11 12.24 4.46 0.51 6.49 0.95 10.61 9.47 128.70 30.47 0.31 5.22
CD4-AF700 -3.00 -1.70 -0.47 -0.67 -5.65 3.74 -6.99 -7.20 -0.07 -0.10 -1.57 0.09
CD56-PECy7 40.18 0.27 0.54 -7.83 -8.99 29.65 15.62 -14.05 9.18 8.49 -1.15 1.45
CCR7-PerCPCy5.5 -2.30 -0.08 0.10 74.41 1.38 4.50 -6.14 5.04 0.49 1.11 0.07 30.06
CD8-APCCy7 -3.23 -0.99 -0.38 10.13 1.89 -6.70 -8.23 37.27 -3.66 1.20 -0.83 -0.14
CD28-ECD 4.94 -0.08 -0.08 0.06 0.17 20.88 -0.16 1.36 -0.86 5.41 3.69 0.37
CD25-APC -0.13 0.24 0.00 23.32 0.00 0.00 1.12 -0.27 1.09 0.78 0.64 0.42
CD45-AmCyan -0.62 9.12 0.10 -1.04 -0.07 -1.36 -0.15 -1.72 -0.91 3.02 -0.20 0.00
HLADR-BV605 1.76 0.00 1.63 0.54 0.09 1.65 0.00 24.26 1.02 1.41 1.39 8.86
CD45RA-PECy5 20.44 -0.15 -0.16 250.10 8.51 669.30 10.07 10.13 443.50 -2.43 0.34 10.81
CD279-BV711 1.01 3.38 4.87 126.80 -0.06 24.57 9.45 0.92 3.74 25.63 8.31 -0.16
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Optimization of miRNA Extraction Methods for Microarray Analysis of T-Cells 
in Immunotherapy Clinical Trials Patients 
 
 Patients for study were selected based on their response or non-response to 
concurrent treatment with trastuzumab and a HER2/neu peptide vaccine (Figure 
35). In this clinical trial, it was observed that all patients had existing immunity to 
HER2/neu and other breast cancer antigens, which were boosted in some patients 
following vaccination (Disis, et al., 2009). 
 
 
FIGURE 35. Long-Term Outcomes of Patients Enrolled in Clinical Trials for a 
HER2/neu Peptide Vaccine. Patients were tracked long-term for progression of breast 
cancer (y-axis) or death (x-axis) following concurrent treatment with trastuzumab and a 
HER2/neu peptide vaccine as previously described (Disis, et al., 2009). Selected responders 
(green) and non-responders (red) were selected for further study based on the availability 
of PBMCs for analysis. 
 
First, we optimized the T-cell purification process via magnet-assisted cell 
sorting (MACS). PBMCs isolated by Ficoll-gradient separation were treated with 
magnetic beads for positive selection of CD3+ cells or CD4+/CD8+ cells, and were 
analyzed by flow cytometry for CD3 cell purity, as well as the expression of the 
activation markers CD25, CD278, CD279, and HLA-DR (Figure 36). While CD4+/CD8+ 
selection resulted in higher purity of T-cells versus CD3+ selection (85% vs. 74%,  
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FIGURE 36. Analysis of T-Cell Purity and Activation Before and After MACS 
Purification from Thawed PBMCs. PBMCs (top panel) or purified T-cells via CD3+ 
selection (middle panel) or CD4+/CD8+ selection (bottom panel) were stained with 
antibodies for CD3, CD4, CD25, CD278 (ICOS), CD279 (PD-1), and HLA-DR in order to 
analyze for T-cell purity and activation before and after MACS purification. Gating strategies 
have been shown with black arrows. Size scatter plots of all of the cells in the samples prior 
to any gating have also been shown (left).  
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relative to 13% pre-MACS), it also resulted in a significant level of activation of the 
T-cells. HLA-DR appeared to be the most sensitive marker to T-cell activation, as it 
was the only marker of the four investigated that showed significant differences in 
expression before and after MACS. Initially, 3.5% of CD3+ cells expressed the marker, 
but this increased to 6.6% post-CD3+ selection, or 11.3% post-CD4+/CD8+ selection. 
Because it is of paramount importance to preserve the original T-cell miRNA/gene 
expression profiles at isolation from the patients, the poor cell purity and significant 
cell activation observed here was not undesirable and motivated our switch to the 
use of FACS for the purification of CD3+ cell populations for microarray analysis. 
 Next, we quantified the amount of RNA yielded per cell in light of the 
requirements for microarray analysis (200-250 ng RNA in 8μL; 25-32 ng/μL). This 
was done by collecting RNA from known numbers of purified T-cells, and analyzing 
the resulting RNA mixtures by BioAnalyzer and NanoDrop (Table 8). In all cases, the 
BioAnalyzer gave “run indexes” of >9, which indicate sufficient RNA purity for 
microarray analysis. 
 
TABLE 8. Purity and Concentration of Total RNA Collected from Purified T-Cells. 
Cell 
Source 
T-Cell 
Purity 
Total Cells 
Lysed 
Final 
[RNA] 
Final 
Volume 
RNA Yield 
(ng) 
Comments 
P 107250 - 500,000 7 ng/μL 100 μL 700 Too dilute 
Healthy 78% 500,000 23.4 ng/μL 35 μL 819 OK for array 
Healthy 78% 500,000 20.8 ng/μL 35 μL 728 OK for array 
Healthy 78% 1,000,000 32.8 ng/μL 35 μL 1148 OK for array 
Healthy 78% 1,000,000 44.4 ng/μL 35 μL 1554 OK for array 
 
 While the commercial kit used for miRNA isolation recommended the use of 
30-100 μL water for elution and collection of total RNA in the final step of the 
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included protocol, it is clear that lower amounts of water are necessary to achieve 
the necessary RNA yields and contents for downstream analysis. In one case, 100 μL 
of water was used for RNA collection, and this resulted in very low RNA 
concentrations (7 ng/μL; Table 8). In all cases, the total quantity of RNA collected (in 
μg) was sufficient for analysis. Therefore, in order to meet microarray requirements, 
all further studies were conducted by lysing 1,000,000 T-cells and collecting the 
purified RNA in 35 μL of water. 
 At the time of writing, miRNA microarrays are in progress, and may take 
weeks for the completion of data acquisition and analysis. 
 
Discussion 
 Continuing the early success of novel cancer immunotherapies such as the 
anti-CTLA4 and anti-PD-1 antibodies, more and more immunotherapies are 
entering clinical trials. To assess the efficacy of these agents, many have continued 
to use metrics that previously enabled the evaluation of other anti-cancer agents, 
such as anti-proliferative agents and anti-angiogenic agents. These metrics may 
include the quantification of short-term and immediate endpoints such as tumor 
growth, spreading and progression. However, immunotherapies exert their anti-
tumor functions under very different mechanisms, and therefore,  in some cases, 
effective immunotherapies were developed that enhanced immunity to tumor 
antigens in patients, but were shelved due to the inability of the agent to reduce 
tumor growth according to RECIST criteria (Mellman, et al., 2011; Pardoll & Drake, 
2012). Frequently, effective immunotherapies may successfully elicit antigen-
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specific T-cells, but these T-cells will still have to overcome the immunosuppressive 
tumor microenvironment in order to clear tumor cells (Mellman, et al., 2011). 
Therefore, new methods and metrics are necessary in order to independently assess 
the efficacy of immunotherapeutic agents, instead of subjecting them to the same 
criteria used to evaluate anti-proliferative or anti-angiogenic agents. 
 While significant strides have been made, there continues to be limited 
information on consensus biomarkers that correlate with the efficacy of 
immunotherapy. For example, the induction of optimal anti-tumor immunity 
through the CTLA-4 antibody seems to correlate with CD278 (ICOS) expression on 
T-cells (Fu, He, & Sharma, 2011). At the same time, CD279 (PD-1) expression on the 
same cells inversely correlates with efficacy and has been suggested as an indicator 
of poor prognosis (Disis, 2010). Therefore, the assays developed here represent 
efforts to assess vaccine efficacy and response to immunotherapy, informed through 
current understanding of tumor immunology or clinical trials involving other FDA-
approved immunotherapeutic agents (Maecker, McCoy, & Nussenblatt, 2012; 
Mitchell et al., 2008; Perfetto, et al., 2004; Pritchard, et al., 2012; Ruffell et al., 2012).  
 The current 13-marker flow cytometry panel enables the gating of leukocytic 
subtypes (CD45) for the classification of multiple T-cell subtypes (CD3, CD4, CD8, 
CD25, CD45RA, CD56, CD127, CD197) and the quantification of activation states 
(CD28, CD278, CD279, HLA-DR) of these cells in clinical trials patients. The 
phenotyping markers were selected based on current understanding of different T-
cell subtypes identified by the Human Immunology Project Consortium (Maecker, et 
al., 2012). The activation markers were chosen because of their central roles as part 
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of various T-cell activation cascades (CD28, CD278, CD279) (Boise, et al., 1995; 
Freeman, et al., 2000; Fu, et al., 2011; Hutloff, et al., 1999; Sharpe & Freeman, 2002) 
or in antigen cross-presentation and T-cell priming (HLA-DR) (Choi, et al., 2011). 
Therefore, the panel (Table 6) represents biomarkers currently known to play roles 
in anti-tumor responses elicited by other immunotherapeutic agents.  
While many other markers exist that would also be interesting to include in 
this panel, conventional flow cytometry suffers from the need to compensate for 
spectral overlap of various fluorophores (Perfetto, et al., 2004). The recent advent of 
mass cytometry (CyTOF) bypasses the need to ‘compensate’ because cellular 
biomarkers are quantified using antibodies tagged with lanthanide metals not 
typically found in living systems above trace background levels. Labeled cells are 
then injected into a mass spectrometer, which quantifies the amount of metals 
present (Bendall et al., 2011). To date, others have used CyTOF to quantify 30 
biomarkers at single-cell resolutions, although theoretically, much higher 
parallelization is possible (Bendall, et al., 2011). 
At the same time, there is also a pressing need to discover other markers that 
correlate with vaccine response. In the HER2/neu clinical trial noted earlier, all 
patients were treated concurrently with trastuzumab and a HER2/neu peptide 
vaccine, which boosted anti-tumor immunity and promoted long-term survival in a 
small subset of patients (Figure 35) (Disis, et al., 2009). Because some patients did 
not respond to treatment, and PBMCs were collected from the patients over a long-
term follow-up period, this study provided a sample set that allows us to probe for 
biomarkers that were upregulated in the responders over the course of treatment, 
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and also biomarkers that were differentially regulated between the responders and 
non-responders. As this study is ongoing, it has potential to improve our ability to 
more accurately assess patient responses to treatment with cancer 
immunotherapies. It will also potentially lead to the identification of biomarkers 
that enable prediction of response or non-response in the patients, allowing for 
further treatments to be discontinued if they are unlikely to benefit the patients. 
 
Summary 
 T-cells form the most potent effector arms of the immune system, and it is 
believed that effective cancer immunotherapies will require the elicitation of strong, 
anti-tumor T-cells. In this chapter, T-cell-centric assays were developed that enable 
(1) phenotyping and analysis of T-cell activation via flow cytometry and (2) the 
discovery of regulatory biomarkers (miRNA or mRNA) that are selectively 
upregulated in cancer patients that responded well to concurrent trastuzumab and 
HER2/neu vaccine treatment. These assays represent current understanding of the 
assessment of the responses of cancer patients to immunotherapy, while seeking to 
push the boundaries of understanding by providing novel, robust biomarkers for 
these purposes. 
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CHAPTER VII 
 
SYNOPSIS AND CONCLUSIONS 
 
 In my dissertation work, we worked towards the development of novel 
nanomaterials for the delivery of immunotherapeutics in cancer patients. The 
ultimate goal was to overcome the immunosuppressive tumor environment and re-
activate immune responses in breast cancer patients, which has promise in 
promoting long-term immunity from phenotypically similar cancer cells, by 
leveraging the immune system’s ability to ‘remember’ past challengers. In particular, 
I focused on the macrophage, which can become hijacked in the context of a tumor 
into promoting tumor growth and invasiveness. While we have not yet identified the 
best drug candidates to enable reprogramming of the tumor-associated 
macrophages, my work has enables us to take strides in other ways. 
 First, I identified design parameters that governed nanoparticle-macrophage 
interactions, with a focus on nanoparticle size and charge. I found that PEGylated 
nanoparticles are internalized by macrophages in a size-dependent fashion for 
diameters between 30-100 nm. Charge-uptake relationships were investigated by 
varying the surface properties of nanoparticles. However, within the ranges 
investigated, nanoparticle size, not charge, is a stronger determinant of non-specific 
uptake by macrophages. The results presented here inform the design of 
nanoparticles to target or evade macrophages in future in vivo applications. 
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 With this evidence, I designed the mannosylated nanoparticles to exhibit a 
30-40 nm diameter in order to discourage non-specific recognition by macrophages. 
The nanoparticles were mannosylated in order to encourage mannose receptor-
mediated uptake mechanisms, which are primarily present on macrophages and 
antigen-presenting cells, but upregulated on tumor-associated macrophages. I 
showed that this mannose layer led to improved siRNA delivery into primary 
macrophages. The delivered siRNA also retains its activity and successfully 
facilitates knockdown of a model gene in these cells, which are known to be 
notoriously difficult-to-transfect stably. I also showed that these cells appear to 
target tumor-associated macrophages in a spontaneously-arising primary mammary 
murine tumor model. 
 For applications where long-term stable transfections may be desirable, I 
also designed polymeric scaffolds crosslinked with proline oligomers, which can be 
actively degraded by environmental ROS to release biologics and other encapsulated 
active agents. Other work in our group shows that nanoparticle-mediated siRNA 
delivery can be accomplished by encapsulating siRNA-loaded nanoparticles in 
degradable scaffolds (C. E. Nelson, et al., 2012). 
 To summarize, in this work, I identified nanoparticle size ranges ideal for the 
reduction of non-specific uptake of injected nanomaterials into resident 
macrophages in the body (< 50 nm diameter; Chapter II), synthesized mannosylated 
nanoparticles that enable siRNA-mediated knockdown of target gene expression in 
primary macrophages (Chapter III), created polymeric scaffolds that respond to 
environmental ROS, which may be loaded with such nanoparticles to enable long-
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term modulation of macrophage function (Chapter IV), evaluated TAM-specific 
targeting of the nanoparticles in an in vivo tumor model (Chapter V), and designed 
of T-cell-based assays to enable the characterization of the efficacy of 
immunotherapies in clinical trial patients (Chapter VI). Taken together, this work 
provides a framework to enable us to interrogate TAM function and activity in pre-
clinical models, with the goals of identifying drugs that can reprogram TAMs into 
exerting anti-tumor functions. Downstream, if the agents developed here were to 
become the centerpiece of a clinical trial, we have designed assays that may enable 
us to quantify the wider effects of TAM-centric immunotherapy on T-cells and in 
mediating T-cell-mediated immunity in the patients. 
 Moving from here, significant challenges exist for future work by my 
successors and other future lab members, including (1) the identification of 
immunotherapeutic agents—small molecules or peptides or nucleic acids, that can 
reprogram TAMs into combating tumors, (2) optimization of nanoparticle 
properties for efficient in vivo targeting of TAMs within primary and metastatic 
tumor sites, (3) the creation of new in vitro assays to evaluate and characterize the 
serum stability of nanoparticles and their interactions with blood cells in circulation, 
and (4) the optimization of the assays shown in Chapter VI to facilitate their 
adoption into other immunotherapeutic clinical trials and studies. 
 Today, cancer immunotherapy remains a burgeoning and promising area for 
further study across both academic and industrial labs, following the recent FDA 
approvals of the agents Provenge (Sipuleucel-T; Dendreon) and Yervoy (ipilimumab; 
Bristol-Myers Squibb) (Mellman, et al., 2011). The development of this field will 
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continue to require novel approaches to optimally and robustly promote anti-tumor 
immunity, as well as reliable and accurate assays and methods to characterize that 
immune response. 
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153 
5. H. Li, S.S. Yu, M. Miteva, C.E. Nelson, T.D. Giorgio, & C.L. Duvall. (2012) “Matrix 
Metalloproteinase Responsive, Proximity-Activated Targeting Polymeric 
Nanoparticles for siRNA Delivery to Tumor Metastases.” Molecular Therapy 20: 
S266. 
 See publication #2 above. 
 
6. S.S. Yu, C.M. Lau, S.N. Thomas, W.G. Jerome, D.J. Maron, J.H. Dickerson, J.A. 
Hubbell, & T.D. Giorgio. (2012) “Size- and Charge-Dependent Non-Specific 
Uptake of PEGylated Nanoparticles by Macrophages.” Int J Nanomedicine 7: 
799-813. 
 Designed, planned, and carried out all experiments. 
 Managed and analyzed all data. 
 Wrote the manuscript. 
 
7. S.S. Yu, R.L. Koblin, A.L. Zachman, D.S. Perrien, L.H. Hofmeister, T.D. Giorgio, & 
H.J. Sung. (2011) “Physiologically Relevant Oxidative Degradation of 
Oligo(proline)-Cross-linked Polymeric Scaffolds.” Biomacromolecules 12(12): 
4357-4366. 
 Designed, planned, and carried out all experiments. 
 Managed and analyzed all data. 
 Wrote the manuscript. 
 
154 
8. M.K. Gupta, J.M. Walthal, R. Venkataraman, S.W. Crowder, D.K. Jung, S.S. Yu, T.K. 
Feaster, T.D. Giorgio, C.C. Hong, F.J. Baudenbacher, A.K. Hatzopoulos, & H.J. 
Sung. (2011) "Combinatorial Electrospun Matrices Promote Physiologically-
Relevant Cardiomyogenic Stem Cell Differentiation." PLoS ONE 6(12): e28935. 
 Optimized the electrospinning protocol that enabled all of the studies 
documented in this paper. 
 Consultant for biological data interpretation. 
 Edited the manuscript. 
 
9. S.S. Yu, R.A. Ortega, B.W. Reagan, J.A. McPherson, H.J. Sung, & T.D. Giorgio. 
(2011) “Emerging applications of nanotechnology for the diagnosis and 
management of vulnerable atherosclerotic plaques.” Wiley Interdiscip Rev 
Nanomed Nanobiotechnol 3(6): 620-646. 
 Assembled the team of authors and coordinated writing assignments 
for various sections. 
 Wrote 60% of the manuscript. 
 Edited and compiled all of the pieces of writing into the cohesive 
manuscript that was ultimately submitted. 
 
10. C.S. Bell, S.S. Yu, & T.D. Giorgio. (2011) “The MultiStrata Nanoparticle: A 
FeOx/Au Core/Shell Enveloped in a Silica-Gold Shell.” Small 7(9): 1158-1162.  
 Consultant for the design and synthesis of the nanoparticles; co-
developed synthetic scheme with CSB. 
155 
11. S.S. Yu, R.L. Scherer, R.A. Ortega, C.S. Bell, C.P. O’Neil, J.A. Hubbell, & T.D. 
Giorgio. (2011) “PPS-b-PEG block copolymers for the encapsulation of 
ultrasmall superparamagnetic iron oxides (USPIOs).” J. Nanobiotechnology 9:7. 
 Designed, planned, and carried out all experiments. 
 Managed and analyzed all data. 
 Wrote the manuscript. 
 
12. S.N. Thomas, C.P. O’Neil, A.J. van der Vlies, S.S. Yu, T.D. Giorgio, M.A. Swartz, & 
J.A. Hubbell. (2011) “Engineering complement activation on polypropylene 
sulfide vaccine nanoparticles.” Biomaterials 32(8): 2194-3303. 
 Synthesized all iron oxide nanoparticles used in this work. 
 Wrote relevant Materials & Methods sections. 
 Edited the manuscript.  
156 
BIBLIOGRAPHY 
 
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008). Factors affecting the 
clearance and biodistribution of polymeric nanoparticles. Molecular 
Pharmaceutics, 5(4), 505-515. 
Ali, S. A. M., Doherty, P. J., & Williams, D. F. (1994). The mechanisms of oxidative 
degradation of biomedical polymers by free radicals. Journal of Applied 
Polymer Science, 51(8), 1389-1398. 
Amici, A., Levine, R. L., Tsai, L., & Stadtman, E. R. (1989). Conversion of amino acid 
residues in proteins and amino acid homopolymers to carbonyl derivatives 
by metal-catalyzed oxidation reactions. J Biol Chem, 264(6), 3341-3346. 
An, S. G., & Cho, C. G. (2004). Synthesis and Characterization of Amphiphilic 
Poly(caprolactone) Star Block Copolymers. Macromolecular Rapid 
Communications, 25(5), 618-622. 
Azuma, H., & Tilney, N. L. (1994). Chronic graft rejection. Current Opinion in 
Immunology, 6(5), 770-776. 
Bastu s, N. G., Sa nchez-Tillo , E., Pujals, S., Farrera, C., Lo pez, C., Giralt, E., et al. (2009). 
Homogeneous Conjugation of Peptides onto Gold Nanoparticles Enhances 
Macrophage Response. Acs Nano, 3(6), 1335-1344. 
Bendall, S. C., Simonds, E. F., Qiu, P., Amir el, A. D., Krutzik, P. O., Finck, R., et al. 
(2011). Single-cell mass cytometry of differential immune and drug 
responses across a human hematopoietic continuum. Science, 332(6030), 
687-696. 
Benoit, D. S. W., Srinivasan, S., Shubin, A. D., & Stayton, P. S. (2011). Synthesis of 
Folate-Functionalized RAFT Polymers for Targeted siRNA Delivery. 
Biomacromolecules, 12(7), 2708-2714. 
Berlett, B. S., & Stadtman, E. R. (1997). Protein oxidation in aging, disease, and 
oxidative stress. J Biol Chem, 272(33), 20313-20316. 
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., et al. (1995). 
CD28 costimulation can promote T cell survival by enhancing the expression 
of Bcl-XL. Immunity, 3(1), 87-98. 
Bolte, S., & CordeliÈRes, F. P. (2006). A guided tour into subcellular colocalization 
analysis in light microscopy. Journal of Microscopy, 224(3), 213-232. 
Bonizzi, G., & Karin, M. (2004). The two NF-kappaB activation pathways and their 
role in innate and adaptive immunity. Trends Immunol, 25(6), 280-288. 
Bouwens, L., Baekeland, M., de Zanger, R., & Wisse, E. (1986). Quantitation, tissue 
distribution and proliferation kinetics of kupffer cells in normal rat liver. 
Hepatology, 6(4), 718-722. 
Boyer, C., Bulmus, V., Davis, T. P., Ladmiral, V., Liu, J., & Perrier, S. (2009). 
Bioapplications of RAFT polymerization. Chem Rev, 109(11), 5402-5436. 
Brancato, S. K., & Albina, J. E. (2011). Wound macrophages as key regulators of 
repair: origin, phenotype, and function. The American journal of pathology, 
178(1), 19-25. 
Briley-Saebo, K. C., Cho, Y. S., Shaw, P. X., Ryu, S. K., Mani, V., Dickson, S., et al. (2011). 
Targeted Iron Oxide Particles for In Vivo Magnetic Resonance Detection of 
157 
Atherosclerotic Lesions With Antibodies Directed to Oxidation-Specific 
Epitopes. J Am Coll Cardiol, 57(3), 337-347. 
Brown, M. S., & Goldstein, J. L. (1983). Lipoprotein metabolism in the macrophage: 
implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem, 
52, 223-261. 
Cammas, S., Suzuki, K., Sone, C., Sakurai, Y., Kataoka, K., & Okano, T. (1997). Thermo-
responsive polymer nanoparticles with a core-shell micelle structure as site-
specific drug carriers. Journal of Controlled Release, 48(2-3), 157-164. 
Cao, Y., Bonizzi, G., Seagroves, T. N., Greten, F. R., Johnson, R., Schmidt, E. V., et al. 
(2001). IKKalpha provides an essential link between RANK signaling and 
cyclin D1 expression during mammary gland development. Cell, 107(6), 763-
775. 
Cao, Y., & Karin, M. (2003a). NF-kappaB in mammary gland development and breast 
cancer. J Mammary Gland Biol Neoplasia, 8(2), 215-223. 
Cao, Y., & Karin, M. (2003b). NF-kappaB in mammary gland development and breast 
cancer. Journal of mammary gland biology and neoplasia, 8(2), 215-223. 
Caspi, R. R. (2008). Immunotherapy of autoimmunity and cancer: the penalty for 
success. Nat Rev Immunol, 8(12), 970-976. 
Chan, W. C., & White, P. D. (2000). Fmoc solid phase peptide synthesis : a practical 
approach. Oxford ; New York: Oxford University Press. 
Chnari, E., Nikitczuk, J. S., Wang, J., Uhrich, K. E., & Moghe, P. V. (2006). Engineered 
Polymeric Nanoparticles for Receptor-Targeted Blockage of Oxidized Low 
Density Lipoprotein Uptake and Atherogenesis in Macrophages. 
Biomacromolecules, 7(6), 1796-1805. 
Choi, N. M., Majumder, P., & Boss, J. M. (2011). Regulation of major 
histocompatibility complex class II genes. Current Opinion in Immunology, 
23(1), 81-87. 
Christian, G. D. (1994). Analytical chemistry (5th ed.). New York: Wiley & Sons. 
Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K., & Baldwin, A. S., Jr. (2000). 
Selective activation of NF-kappa B subunits in human breast cancer: potential 
roles for NF-kappa B2/p52 and for Bcl-3. Oncogene, 19(9), 1123-1131. 
Connelly, L., Barham, W., Onishko, H. M., Chen, L., Sherrill, T. P., Zabuawala, T., et al. 
(2011). NF-kappaB activation within macrophages leads to an anti-tumor 
phenotype in a mammary tumor lung metastasis model. Breast cancer 
research : BCR, 13(4), R83. 
Connelly, L., Jacobs, A. T., Palacios-Callender, M., Moncada, S., & Hobbs, A. J. (2003). 
Macrophage endothelial nitric-oxide synthase autoregulates cellular 
activation and pro-inflammatory protein expression. J Biol Chem, 278(29), 
26480-26487. 
Convertine, A. J., Benoit, D. S., Duvall, C. L., Hoffman, A. S., & Stayton, P. S. (2009). 
Development of a novel endosomolytic diblock copolymer for siRNA delivery. 
J Control Release, 133(3), 221-229. 
Cormode, D. P., Briley-Saebo, K. C., Mulder, W. J., Aguinaldo, J. G., Barazza, A., Ma, Y., 
et al. (2008). An ApoA-I mimetic peptide high-density-lipoprotein-based MRI 
contrast agent for atherosclerotic plaque composition detection. Small, 4(9), 
1437-1444. 
158 
Cormode, D. P., Skajaa, T., van Schooneveld, M. M., Koole, R., Jarzyna, P., Lobatto, M. 
E., et al. (2008). Nanocrystal core high-density lipoproteins: a multimodality 
contrast agent platform. Nano Lett, 8(11), 3715-3723. 
Crowder, S. W., Gupta, M. K., Hofmeister, L. H., Zachman, A. L., & Sung, H.-J. (2011). 
Modular polymer design to regulate phenotype and oxidative response of 
human coronary artery cells for potential stent coating applications. Acta 
Biomaterialia, in press(0). 
Crownover, E., Duvall, C. L., Convertine, A., Hoffman, A. S., & Stayton, P. S. (2011). 
RAFT-synthesized graft copolymers that enhance pH-dependent membrane 
destabilization and protein circulation times. Journal of controlled release : 
official journal of the Controlled Release Society, 155(2), 167-174. 
Daldrup-Link, H. E., Golovko, D., Ruffel, B., DeNardo, D., Castaneda, R., Ansari, C., et al. 
(2011). MR Imaging of Tumor Associated Macrophages with Clinically-
Applicable Iron Oxide Nanoparticles. Clinical Cancer Research. 
de Nooijer, R., Verkleij, C. J., von der Thusen, J. H., Jukema, J. W., van der Wall, E. E., 
van Berkel, T. J., et al. (2006). Lesional overexpression of matrix 
metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions 
but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol, 
26(2), 340-346. 
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the 
immune system during cancer development. Nat Rev Cancer, 6(1), 24-37. 
Deguchi, J. O., Aikawa, M., Tung, C. H., Aikawa, E., Kim, D. E., Ntziachristos, V., et al. 
(2006). Inflammation in atherosclerosis: visualizing matrix 
metalloproteinase action in macrophages in vivo. Circulation, 114(1), 55-62. 
Dejardin, E., Bonizzi, G., Bellahcene, A., Castronovo, V., Merville, M. P., & Bours, V. 
(1995). Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-
related proteins in the cytoplasm of human breast cancer cells. Oncogene, 
11(9), 1835-1841. 
DeLong, S. A., Gobin, A. S., & West, J. L. (2005). Covalent immobilization of RGDS on 
hydrogel surfaces to direct cell alignment and migration. J Control Release, 
109(1-3), 139-148. 
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., et al. 
(2011). Leukocyte Complexity Predicts Breast Cancer Survival and 
Functionally Regulates Response to Chemotherapy. Cancer Discovery, 1(1), 
54-67. 
Devaraj, S., & Jialal, I. (2011). C-Reactive Protein Polarizes Human Macrophages to 
an M1 Phenotype and Inhibits Transformation to the M2 Phenotype. 
Arterioscler Thromb Vasc Biol, ATVBAHA.111.225508. 
Dirkx, A. E., Oude Egbrink, M. G., Wagstaff, J., & Griffioen, A. W. (2006). 
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J 
Leukoc Biol, 80(6), 1183-1196. 
Disis, M. L. (2010). Immune Regulation of Cancer. Journal of Clinical Oncology, 
28(29), 4531-4538. 
Disis, M. L., Wallace, D. R., Gooley, T. A., Dang, Y., Slota, M., Lu, H., et al. (2009). 
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients 
159 
With Metastatic Breast Cancer. Journal of Clinical Oncology, 27(28), 4685-
4692. 
Doshi, N., & Mitragotri, S. (2010). Macrophages recognize size and shape of their 
targets. PLoS One, 5(4), e10051. 
Duvall, C. L., Convertine, A. J., Benoit, D. S., Hoffman, A. S., & Stayton, P. S. (2010). 
Intracellular Delivery of a Proapoptotic Peptide via Conjugation to a RAFT 
Synthesized Endosomolytic Polymer. Mol Pharm, 7(2), 468-476. 
East, L., & Isacke, C. M. (2002). The mannose receptor family. Biochimica et 
Biophysica Acta (BBA) - General Subjects, 1572(2–3), 364-386. 
Ece Gamsiz, D., Shah, L. K., Devalapally, H., Amiji, M. M., & Carrier, R. L. (2008). A 
model predicting delivery of saquinavir in nanoparticles to human 
monocyte/macrophage (Mo/Mac) cells. Biotechnol Bioeng, 101(5), 1072-
1082. 
Eliopoulos, A. G., Caamano, J. H., Flavell, J., Reynolds, G. M., Murray, P. G., Poyet, J. L., 
et al. (2003). Epstein-Barr virus-encoded latent infection membrane protein 
1 regulates the processing of p100 NF-kappaB2 to p52 via an 
IKKgamma/NEMO-independent signalling pathway. Oncogene, 22(48), 7557-
7569. 
Espuelas, S., Thumann, C., Heurtault, B. a., Schuber, F., & Frisch, B. (2008). Influence 
of Ligand Valency on the Targeting of Immature Human Dendritic Cells by 
Mannosylated Liposomes. Bioconjugate Chemistry, 19(12), 2385-2393. 
Evans, B. C., Nelson, C. E., Yu, S. S., Kim, A. J., Li, H., Nelson, H. M., et al. (2012). Ex Vivo 
Red Blood Cell Hemolysis Assay for the Evaluation of pH-responsive 
Endosomolytic Agents for Cytosolic Delivery of Biomacromolecular Drugs. J 
Vis Exp, in press. 
Everhart, M. B., Han, W., Sherrill, T. P., Arutiunov, M., Polosukhin, V. V., Burke, J. R., et 
al. (2006). Duration and intensity of NF-kappaB activity determine the 
severity of endotoxin-induced acute lung injury. J Immunol, 176(8), 4995-
5005. 
Fako, V. E., & Furgeson, D. Y. (2009). Zebrafish as a correlative and predictive model 
for assessing biomaterial nanotoxicity. Advanced Drug Delivery Reviews, 
61(6), 478-486. 
Fattori, R., & Piva, T. (2003). Drug-eluting stents in vascular intervention. Lancet, 
361(9353), 247-249. 
Felix, R., Cecchini, M. G., Hofstetter, W., Elford, P. R., Stutzer, A., & Fleisch, H. (1990). 
Rapid publication: Impairment of macrophage colony-stimulating factor 
production and lack of resident bone marrow macrophages in the 
osteopetrotic op/op Mouse. Journal of Bone and Mineral Research, 5(7), 781-
789. 
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998). 
Potent and specific genetic interference by double-stranded RNA in 
Caenorhabditis elegans. Nature, 391(6669), 806-811. 
Fogal, V., Zhang, L., Krajewski, S., & Ruoslahti, E. (2008). Mitochondrial/cell-surface 
protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. 
Cancer research, 68(17), 7210-7218. 
160 
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. 
(2000). Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 
Family Member Leads to Negative Regulation of Lymphocyte Activation. The 
Journal of Experimental Medicine, 192(7), 1027-1034. 
Frias, J. C., Ma, Y., Williams, K. J., Fayad, Z. A., & Fisher, E. A. (2006). Properties of a 
versatile nanoparticle platform contrast agent to image and characterize 
atherosclerotic plaques by magnetic resonance imaging. Nano Lett, 6(10), 
2220-2224. 
Fridman, W. H., Pages, F., Sautes-Fridman, C., & Galon, J. (2012). The immune 
contexture in human tumours: impact on clinical outcome. Nature Reviews 
Cancer, 12(4), 298-306. 
Fu, T., He, Q., & Sharma, P. (2011). The ICOS/ICOSL Pathway Is Required for Optimal 
Antitumor Responses Mediated by Anti–CTLA-4 Therapy. Cancer Research, 
71(16), 5445-5454. 
Galis, Z. S., Sukhova, G. K., Lark, M. W., & Libby, P. (1994). Increased expression of 
matrix metalloproteinases and matrix degrading activity in vulnerable 
regions of human atherosclerotic plaques. J Clin Invest, 94(6), 2493-2503. 
Gimenez, S., Ponsart, S., Coudane, J., & Vert, M. (2001). Synthesis, properties and in 
vitro degradation of carboxyl-bearing PCL. Journal of Bioactive and 
Compatible Polymers, 16(1), 32-46. 
Gleissner, C. A., Shaked, I., Little, K. M., & Ley, K. (2010). CXC Chemokine Ligand 4 
Induces a Unique Transcriptome in Monocyte-Derived Macrophages. The 
Journal of Immunology, 184(9), 4810-4818. 
Gordon, S. (2003). Alternative activation of macrophages. Nature reviews. 
Immunology, 3(1), 23-35. 
Gough, P. J., Gomez, I. G., Wille, P. T., & Raines, E. W. (2006). Macrophage expression 
of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J 
Clin Invest, 116(1), 59-69. 
Griffin, E. E., Ullery, J. C., Cox, B. E., & Jerome, W. G. (2005). Aggregated LDL and lipid 
dispersions induce lysosomal cholesteryl ester accumulation in macrophage 
foam cells. Journal of lipid research, 46(10), 2052-2060. 
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005). 
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic 
cells towards tumor rejection. Cancer Res, 65(8), 3437-3446. 
Gupta, P., Vermani, K., & Garg, S. (2002). Hydrogels: from controlled release to pH-
responsive drug delivery. Drug Discovery Today, 7(10), 569-579. 
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992). Induction of mammary tumors by 
expression of polyomavirus middle T oncogene: a transgenic mouse model 
for metastatic disease. Mol Cell Biol, 12(3), 954-961. 
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., et 
al. (2008). "Re-educating" tumor-associated macrophages by targeting NF-
kappaB. J Exp Med, 205(6), 1261-1268. 
Halliwell, B., Clement, M. V., & Long, L. H. (2000). Hydrogen peroxide in the human 
body. FEBS letters, 486(1), 10-13. 
Han, F., Li, S., Yin, R., Liu, H., & Xu, L. (2008). Effect of surfactants on the formation 
and characterization of a new type of colloidal drug delivery system: 
161 
Nanostructured lipid carriers. Colloids and Surfaces A: Physicochemical and 
Engineering Aspects, 315(1-3), 210-216. 
Hartigan-O'Connor, D. J., Poon, C., Sinclair, E., & McCune, J. M. (2007). Human CD4+ 
regulatory T cells express lower levels of the IL-7 receptor alpha chain 
(CD127), allowing consistent identification and sorting of live cells. Journal of 
Immunological Methods, 319(1–2), 41-52. 
Henry, S. M., Convertine, A. J., Benoit, D. S., Hoffman, A. S., & Stayton, P. S. (2009). 
End-functionalized polymers and junction-functionalized diblock copolymers 
via RAFT chain extension with maleimido monomers. Bioconjug Chem, 20(6), 
1122-1128. 
Herman, M. P., Sukhova, G. K., Libby, P., Gerdes, N., Tang, N., Horton, D. B., et al. 
(2001). Expression of neutrophil collagenase (matrix metalloproteinase-8) in 
human atheroma: a novel collagenolytic pathway suggested by 
transcriptional profiling. Circulation, 104(16), 1899-1904. 
Hermanson, G. T. (2008 (2nd ed.)). Bioconjugate Techniques. San Diego: Academic 
Press. 
Hildebrand, T., & Ruegsegger, P. (1997). A new method for the model-independent 
assessment of thickness in three-dimensional images. Journal of Microscopy-
Oxford, 185, 67-75. 
Hirose, K., Iwabuchi, K., Shimada, K., Kiyanagi, T., Iwahara, C., Nakayama, H., et al. 
(2011). Different responses to oxidized low-density lipoproteins in human 
polarized macrophages. Lipids in health and disease, 10, 1. 
Hogg, N., Darley-Usmar, V. M., Wilson, M. T., & Moncada, S. (1992). Production of 
hydroxyl radicals from the simultaneous generation of superoxide and nitric 
oxide. Biochem. J., 281(2), 419-424. 
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, 
I., et al. (1999). ICOS is an inducible T-cell co-stimulator structurally and 
functionally related to CD28. Nature, 397, 263-266. 
Immunotherapy Network Launches First Trial. (2012). Cancer Discovery. 
Insull, W., Jr. (2009). The pathology of atherosclerosis: plaque development and 
plaque responses to medical treatment. Am J Med, 122(1 Suppl), S3-S14. 
Jerome, W. G., Cox, B. E., Griffin, E. E., & Ullery, J. C. (2008). Lysosomal cholesterol 
accumulation inhibits subsequent hydrolysis of lipoprotein cholesteryl ester. 
Microscopy and microanalysis : the official journal of Microscopy Society of 
America, Microbeam Analysis Society, Microscopical Society of Canada, 14(2), 
138-149. 
Johnson, C., Sung, H. J., Lessner, S. M., Fini, M. E., & Galis, Z. S. (2004). Matrix 
metalloproteinase-9 is required for adequate angiogenic revascularization of 
ischemic tissues: potential role in capillary branching. Circ Res, 94(2), 262-
268. 
Jones, C. F., Campbell, R. A., Franks, Z., Gibson, C. C., Thiagarajan, G., Vieira-de-Abreu, 
A., et al. (2012). Cationic PAMAM Dendrimers Disrupt Key Platelet Functions. 
Molecular Pharmaceutics, 9(6), 1599-1611. 
Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nat 
Rev Cancer, 9(4), 239-252. 
162 
Kindt, T. J., Goldsby, R. A., Osborne, B. A., & Kuby, J. (2007). Kuby immunology (6th 
ed.). New York: W.H. Freeman. 
Kirkland-York, S., Zhang, Y., Smith, A. E., York, A. W., Huang, F., & McCormick, C. L. 
(2010). Tailored design of Au nanoparticle-siRNA carriers utilizing reversible 
addition-fragmentation chain transfer polymers. Biomacromolecules, 11(4), 
1052-1059. 
Kolb, H. C., & Sharpless, K. B. (2003). The growing impact of click chemistry on drug 
discovery. Drug Discovery Today, 8(24), 1128-1137. 
Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., et al. 
(2009). In vivo delivery of siRNA to immune cells by conjugation to a TLR9 
agonist enhances antitumor immune responses. Nat Biotechnol, 27(10), 925-
932. 
Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric 
nanoparticles based drug delivery systems. Colloids and Surfaces B: 
Biointerfaces, 75(1), 1-18. 
Laakkonen, P., Porkka, K., Hoffman, J. A., & Ruoslahti, E. (2002). A tumor-homing 
peptide with a targeting specificity related to lymphatic vessels. Nature 
medicine, 8(7), 751-755. 
Lanier, L. L., Testi, R., Bindl, J., & Phillips, J. H. (1989). Identity of Leu-19 (CD56) 
leukocyte differentiation antigen and neural cell adhesion molecule. The 
Journal of Experimental Medicine, 169(6), 2233-2238. 
Larsen, E. K., Nielsen, T., Wittenborn, T., Birkedal, H., Vorup-Jensen, T., Jakobsen, M. 
H., et al. (2009). Size-Dependent Accumulation of PEGylated Silane-Coated 
Magnetic Iron Oxide Nanoparticles in Murine Tumors. ACS Nano. 
Laskin, D. L., Weinberger, B., & Laskin, J. D. (2001). Functional heterogeneity in liver 
and lung macrophages. Journal of Leukocyte Biology, 70(2), 163-170. 
Li, S. D., & Huang, L. (2009). Nanoparticles evading the reticuloendothelial system: 
role of the supported bilayer. Biochim Biophys Acta, 1788(10), 2259-2266. 
Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420(6917), 868-874. 
Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., et al. (2003). 
Progression to malignancy in the polyoma middle T oncoprotein mouse 
breast cancer model provides a reliable model for human diseases. Am J 
Pathol, 163(5), 2113-2126. 
Linehan, S. A., Martinez-Pomares, L., & Gordon, S. (2000). Mannose receptor and 
scavenger receptor: two macrophage pattern recognition receptors with 
diverse functions in tissue homeostasis and host defense. Advances in 
experimental medicine and biology, 479, 1-14. 
Lipinski, M. J., Amirbekian, V., Frias, J. C., Aguinaldo, J. G., Mani, V., Briley-Saebo, K. C., 
et al. (2006). MRI to detect atherosclerosis with gadolinium-containing 
immunomicelles targeting the macrophage scavenger receptor. Magn Reson 
Med, 56(3), 601-610. 
Liu, Y., Stewart, K. N., Bishop, E., Marek, C. J., Kluth, D. C., Rees, A. J., et al. (2008). 
Unique expression of suppressor of cytokine signaling 3 is essential for 
classical macrophage activation in rodents in vitro and in vivo. J Immunol, 
180(9), 6270-6278. 
163 
Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., et al. 
(2010). Heart disease and stroke statistics--2010 update: a report from the 
American Heart Association. Circulation, 121(7), e46-e215. 
Luo, Y., Zhou, H., Krueger, J., Kaplan, C., Lee, S.-H., Dolman, C., et al. (2006). Targeting 
tumor-associated macrophages as a novel strategy against breast cancer. The 
Journal of Clinical Investigation, 116(8), 2132-2141. 
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006). Toxicity of cationic lipids and 
cationic polymers in gene delivery. Journal of Controlled Release, 114(1), 100-
109. 
Maecker, H. T., McCoy, J. P., & Nussenblatt, R. (2012). Standardizing 
immunophenotyping for the Human Immunology Project. Nat Rev Immunol, 
12(3), 191-200. 
Mahmoud, E. A., Sankaranarayanan, J., Morachis, J. M., Kim, G., & Almutairi, A. (2011). 
Inflammation responsive logic gate nanoparticles for the delivery of proteins. 
Bioconjugate chemistry, 22(7), 1416-1421. 
Mantovani, A., Garlanda, C., & Locati, M. (2009). Macrophage Diversity and 
Polarization in Atherosclerosis: A Question of Balance. Arterioscler Thromb 
Vasc Biol, 29(10), 1419-1423. 
Mantovani, A., Sica, A., & Locati, M. (2005). Macrophage Polarization Comes of Age. 
Immunity, 23(4), 344-346. 
Mantovani, A., Sozzani, S., Locati, M., Allavena, P., & Sica, A. (2002). Macrophage 
polarization: tumor-associated macrophages as a paradigm for polarized M2 
mononuclear phagocytes. Trends Immunol, 23(11), 549-555. 
Martin, P. (1997). Wound Healing--Aiming for Perfect Skin Regeneration. Science, 
276(5309), 75-81. 
Martinez, F. O., Gordon, S., Locati, M., & Mantovani, A. (2006). Transcriptional 
Profiling of the Human Monocyte-to-Macrophage Differentiation and 
Polarization: New Molecules and Patterns of Gene Expression. The Journal of 
Immunology, 177(10), 7303-7311. 
Massia, S. P., Holecko, M. M., & Ehteshami, G. R. (2004). In vitro assessment of 
bioactive coatings for neural implant applications. Journal of Biomedical 
Materials Research Part A, 68A(1), 177-186. 
McCall, M. R., & Frei, B. (2000). Mechanisms of LDL Oxidation. In J. F. Keaney, Jr. 
(Ed.), Oxidative Stress and Vascular Disease (1st ed., pp. 75-98). Norwell, MA, 
USA: Kluwer Academic Publishers. 
Mellman, I., Coukos, G., & Dranoff, G. (2011). Cancer immunotherapy comes of age. 
Nature, 480(7378), 480-489. 
Miller, J. S., Shen, C. J., Legant, W. R., Baranski, J. D., Blakely, B. L., & Chen, C. S. (2010). 
Bioactive hydrogels made from step-growth derived PEG-peptide macromers. 
Biomaterials, 31(13), 3736-3743. 
Miselis, N. R., Wu, Z. J., Van Rooijen, N., & Kane, A. B. (2008). Targeting tumor-
associated macrophages in an orthotopic murine model of diffuse malignant 
mesothelioma. Mol Cancer Ther, 7(4), 788-799. 
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-
Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based 
164 
markers for cancer detection. Proceedings of the National Academy of Sciences, 
105(30), 10513-10518. 
Moilanen, E., Moilanen, T., Knowles, R., Charles, I., Kadoya, Y., al-Saffar, N., et al. 
(1997). Nitric oxide synthase is expressed in human macrophages during 
foreign body inflammation. The American journal of pathology, 150(3), 881-
887. 
Morishige, K., Kacher, D. F., Libby, P., Josephson, L., Ganz, P., Weissleder, R., et al. 
(2010). High-resolution magnetic resonance imaging enhanced with 
superparamagnetic nanoparticles measures macrophage burden in 
atherosclerosis. Circulation, 122(17), 1707-1715. 
Mosser, D. M., & Edwards, J. P. (2008). Exploring the full spectrum of macrophage 
activation. Nat Rev Immunol, 8(12), 958-969. 
Muller, K., Skepper, J. N., Posfai, M., Trivedi, R., Howarth, S., Corot, C., et al. (2007). 
Effect of ultrasmall superparamagnetic iron oxide nanoparticles 
(Ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials, 
28(9), 1629-1642. 
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008). The role of myeloid 
cells in the promotion of tumour angiogenesis. Nat Rev Cancer, 8(8), 618-631. 
Murphy, M. P., Packer, M. A., Scarlett, J. L., & Martin, S. W. (1998). Peroxynitrite: A 
Biologically Significant Oxidant. General Pharmacology: The Vascular System, 
31(2), 179-186. 
Murray, P. J. (2007). The JAK-STAT Signaling Pathway: Input and Output Integration. 
The Journal of Immunology, 178(5), 2623-2629. 
Naghavi, M., & Falk, E. (2010). From Vulnerable Plaque to Vulnerable Patient 
Asymptomatic Atherosclerosis (pp. 13-38): Humana Press. 
Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., Jr., & Sledge, G. W., Jr. 
(1997). Constitutive activation of NF-kappaB during progression of breast 
cancer to hormone-independent growth. Mol Cell Biol, 17(7), 3629-3639. 
Napoli, A., Valentini, M., Tirelli, N., Muller, M., & Hubbell, J. A. (2004). Oxidation-
responsive polymeric vesicles. Nat Mater, 3(3), 183-189. 
Nelson, B. H. (2004). IL-2, Regulatory T Cells, and Tolerance. The Journal of 
Immunology, 172(7), 3983-3988. 
Nelson, C. E., Gupta, M. K., Adolph, E. J., Shannon, J. M., Guelcher, S. A., & Duvall, C. L. 
(2012). Sustained local delivery of siRNA from an injectable scaffold. 
Biomaterials, 33(4), 1154-1161. 
Palanca-Wessels, M. C., Convertine, A. J., Cutler-Strom, R., Booth, G. C., Lee, F., Berguig, 
G. Y., et al. (2011). Anti-CD22 antibody targeting of pH-responsive micelles 
enhances small interfering RNA delivery and gene silencing in lymphoma 
cells. Molecular therapy : the journal of the American Society of Gene Therapy, 
19(8), 1529-1537. 
Papiernik, M., de Moraes, M. L., Pontoux, C., Vasseur, F., & Pénit, C. (1998). 
Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal 
deletion and IL-2 dependency. International Immunology, 10(4), 371-378. 
Pardoll, D., & Drake, C. (2012). Immunotherapy earns its spot in the ranks of cancer 
therapy. The Journal of Experimental Medicine, 209(2), 201-209. 
165 
Perez, J. M., O'Loughin, T., Simeone, F. J., Weissleder, R., & Josephson, L. (2002). DNA-
based magnetic nanoparticle assembly acts as a magnetic relaxation 
nanoswitch allowing screening of DNA-cleaving agents. Journal of the 
American Chemical Society, 124(12), 2856-2857. 
Perfetto, S. P., Chattopadhyay, P. K., & Roederer, M. (2004). Seventeen-colour flow 
cytometry: unravelling the immune system. Nat Rev Immunol, 4(8), 648-655. 
Perkins, N. D. (2003). Oncogenes, tumor suppressors and p52 NF-kappaB. Oncogene, 
22(48), 7553-7556. 
Phillips, N. C., & Heydari, C. (1996). Modulation of Cationic Liposomal DNA Zeta 
Potential and Liposome-protein Interaction by Amphiphilic Poly (ethylene 
glycol)*. Pharmacy and Pharmacology Communications, 2(2), 73-76. 
Plotz, P. H., & Rifai, A. (1982). Stable, Soluble, Model Immune-Complexes Made with 
a Versatile Multivalent Affinity-Labeling Antigen. Biochemistry, 21(2), 301-
308. 
Pluddemann, A., Neyen, C., & Gordon, S. (2007). Macrophage scavenger receptors 
and host-derived ligands. Methods, 43(3), 207-217. 
Pollard, J. W. (2008). Macrophages define the invasive microenvironment in breast 
cancer. J Leukoc Biol, 84(3), 623-630. 
Porta, C., Rimoldi, M., Raes, G., Brys, L., Ghezzi, P., Di Liberto, D., et al. (2009). 
Tolerance and M2 (alternative) macrophage polarization are related 
processes orchestrated by p50 nuclear factor kappaB. Proceedings of the 
National Academy of Sciences of the United States of America, 106(35), 14978-
14983. 
Pritchard, C. C., Cheng, H. H., & Tewari, M. (2012). MicroRNA profiling: approaches 
and considerations. Nature reviews. Genetics, 13(5), 358-369. 
Ratner, B. D. (1996). Biomaterials science : an introduction to materials in medicine. 
San Diego: Academic Press. 
Raynal, I., Prigent, P., Peyramaure, S., Najid, A., Rebuzzi, C., & Corot, C. (2004). 
Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: 
mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest 
Radiol, 39(1), 56-63. 
Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A., & Swartz, M. A. (2006). In vivo 
targeting of dendritic cells in lymph nodes with poly(propylene sulfide) 
nanoparticles. Journal of Controlled Release, 112(1), 26-34. 
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., et 
al. (2007). Exploiting lymphatic transport and complement activation in 
nanoparticle vaccines. Nat Biotechnol, 25(10), 1159-1164. 
Rehor, A., Hubbell, J. A., & Tirelli, N. (2005). Oxidation-sensitive polymeric 
nanoparticles. Langmuir, 21(1), 411-417. 
Rettig, G. R., & Behlke, M. A. (2012). Progress toward in vivo use of siRNAs-II. 
Molecular therapy : the journal of the American Society of Gene Therapy, 20(3), 
483-512. 
Ribatti, D., Levi-Schaffer, F., & Kovanen, P. T. (2008). Inflammatory angiogenesis in 
atherogenesis--a double-edged sword. Ann Med, 40(8), 606-621. 
Romieu-Mourez, R., Landesman-Bollag, E., Seldin, D. C., Traish, A. M., Mercurio, F., & 
Sonenshein, G. E. (2001). Roles of IKK kinases and protein kinase CK2 in 
166 
activation of nuclear factor-kappaB in breast cancer. Cancer Research, 61(9), 
3810-3818. 
Ruegsegger, P., Hildebrand, T., Laib, A., Muller, R., & Dequeker, J. (1999). Direct 
three-dimensional morphometric analysis of human cancellous bone: 
Microstructural data from spine, femur, iliac crest, and calcaneus. Journal of 
Bone and Mineral Research, 14(7), 1167-1174. 
Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2012). 
Leukocyte composition of human breast cancer. Proceedings of the National 
Academy of Sciences, 109(8), 2796-2801. 
Saam, T., Hatsukami, T. S., Takaya, N., Chu, B., Underhill, H., Kerwin, W. S., et al. 
(2007). The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR 
imaging for characterization and assessment. Radiology, 244(1), 64-77. 
Saitoh, T., Nakayama, M., Nakano, H., Yagita, H., Yamamoto, N., & Yamaoka, S. (2003). 
TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB 
activation. J Biol Chem, 278(38), 36005-36012. 
Schellenberger, E., Rudloff, F., Warmuth, C., Taupitz, M., Hamm, B., & Schnorr, J. 
(2008). Protease-specific nanosensors for magnetic resonance imaging. 
Bioconjug Chem, 19(12), 2440-2445. 
Scherer, R. L., McIntyre, J. O., & Matrisian, L. M. (2008). Imaging matrix 
metalloproteinases in cancer. Cancer Metastasis Rev, 27(4), 679-690. 
Schmedlen, R. H., Elbjeirami, W. M., Gobin, A. S., & West, J. L. (2003). Tissue 
engineered small-diameter vascular grafts. Clin Plast Surg, 30(4), 507-517. 
Schuessler, H., & Schilling, K. (1984). Oxygen Effect in the Radiolysis of Proteins. 
International Journal of Radiation Biology, 45(3), 267-281. 
Scott, P. (1993). IL-12: initiation cytokine for cell-mediated immunity. Science, 
260(5107), 496-497. 
Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Krahn, G., Bonizzi, G., et al. (2001). 
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B 
signaling pathway. Science, 293(5534), 1495-1499. 
Sewell, S. L., & Giorgio, T. D. (2009). Synthesis and enzymatic cleavage of dual-ligand 
quantum dots. Materials Science & Engineering C-Materials for Biological 
Applications, 29(4), 1428-1432. 
Sharpe, A. H., & Freeman, G. J. (2002). The B7-CD28 superfamily. Nat Rev Immunol, 
2(2), 116-126. 
Shu, X. Z., Liu, Y., Luo, Y., Roberts, M. C., & Prestwich, G. D. (2002). Disulfide Cross-
Linked Hyaluronan Hydrogels. Biomacromolecules, 3(6), 1304-1311. 
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., et al. (2008). 
Macrophage polarization in tumour progression. Semin Cancer Biol, 18(5), 
349-355. 
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006). Tumour-associated 
macrophages are a distinct M2 polarised population promoting tumour 
progression: Potential targets of anti-cancer therapy. European journal of 
cancer (Oxford, England : 1990), 42(6), 717-727. 
Sluijter, J. P., Pulskens, W. P., Schoneveld, A. H., Velema, E., Strijder, C. F., Moll, F., et al. 
(2006). Matrix metalloproteinase 2 is associated with stable and matrix 
metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a 
167 
study in human endarterectomy specimen pointing to a role for different 
extracellular matrix metalloproteinase inducer glycosylation forms. Stroke, 
37(1), 235-239. 
Smith, R., Sewell, S. L., & Giorgio, T. D. (2008). Proximity-activated nanoparticles: in 
vitro performance of specific structural modification by enzymatic cleavage. 
Int J Nanomedicine, 3(1), 95-103. 
Solan, N. J., Miyoshi, H., Carmona, E. M., Bren, G. D., & Paya, C. V. (2002). RelB cellular 
regulation and transcriptional activity are regulated by p100. J Biol Chem, 
277(2), 1405-1418. 
Song, E.-H., Manganiello, M. J., Chow, Y.-H., Ghosn, B., Convertine, A. J., Stayton, P. S., 
et al. (2012). In vivo targeting of alveolar macrophages via RAFT-based 
glycopolymers. Biomaterials, 33(28), 6889-6897. 
Sovak, M. A., Bellas, R. E., Kim, D. W., Zanieski, G. J., Rogers, A. E., Traish, A. M., et al. 
(1997). Aberrant nuclear factor-kappaB/Rel expression and the 
pathogenesis of breast cancer. J Clin Invest, 100(12), 2952-2960. 
Stacey, K. J., Ross, I. L., & Hume, D. A. (1993). Electroporation and DNA-dependent 
cell death in murine macrophages. Immunol Cell Biol, 71(2), 75-85. 
Stadtman, E. R. (1990). Metal ion-catalyzed oxidation of proteins: Biochemical 
mechanism and biological consequences. Free Radical Biology and Medicine, 
9(4), 315-325. 
Stadtman, E. R., & Berlett, B. S. (1997). Reactive oxygen-mediated protein oxidation 
in aging and disease. Chem Res Toxicol, 10(5), 485-494. 
Stadtman, E. R., & Levine, R. L. (2003). Free radical-mediated oxidation of free amino 
acids and amino acid residues in proteins. Amino Acids, 25(3), 207-218. 
Stahl, P. D., & Ezekowitz, R. A. B. (1998). The mannose receptor is a pattern 
recognition receptor involved in host defense. Current Opinion in Immunology, 
10(1), 50-55. 
Stout, R. D., Jiang, C., Matta, B., Tietzel, I., Watkins, S. K., & Suttles, J. (2005). 
Macrophages sequentially change their functional phenotype in response to 
changes in microenvironmental influences. J Immunol, 175(1), 342-349. 
Sumerlin, B. S., Tsarevsky, N. V., Louche, G., Lee, R. Y., & Matyjaszewski, K. (2005). 
Highly Efficient “Click” Functionalization of Poly(3-azidopropyl methacrylate) 
Prepared by ATRP. Macromolecules, 38(18), 7540-7545. 
Sung, H. J., Luk, A., Murthy, N. S., Liu, E., Jois, M., Joy, A., et al. (2010). Poly(ethylene 
glycol) as a sensitive regulator of cell survival fate on polymeric biomaterials: 
the interplay of cell adhesion and pro-oxidant signaling mechanisms. Soft 
Matter, 6(20), 5196-5205. 
Sung, H. J., Sakala Labazzo, K. M., Bolikal, D., Weiner, M. J., Zimnisky, R., & Kohn, J. 
(2008). Angiogenic competency of biodegradable hydrogels fabricated from 
polyethylene glycol-crosslinked tyrosine-derived polycarbonates. Eur Cell 
Mater, 15, 77-87. 
Sung, H. J., Su, J., Berglund, J. D., Russ, B. V., Meredith, J. C., & Galis, Z. S. (2005). The 
use of temperature-composition combinatorial libraries to study the effects 
of biodegradable polymer blend surfaces on vascular cells. Biomaterials, 
26(22), 4557-4567. 
168 
Tabas, I. (2010). Macrophage death and defective inflammation resolution in 
atherosclerosis. Nat Rev Immunol, 10(1), 36-46. 
Tanaka, T., Decuzzi, P., Cristofanilli, M., Sakamoto, J. H., Tasciotti, E., Robertson, F. M., 
et al. (2009). Nanotechnology for breast cancer therapy. Biomed Microdevices, 
11(1), 49-63. 
Taylor, P. R., Brown, G. D., Herre, J., Williams, D. L., Willment, J. A., & Gordon, S. 
(2004). The Role of SIGNR1 and the β-Glucan Receptor (Dectin-1) in the 
Nonopsonic Recognition of Yeast by Specific Macrophages. The Journal of 
Immunology, 172(2), 1157-1162. 
Taylor, P. R., Gordon, S., & Martinez-Pomares, L. (2005). The mannose receptor: 
linking homeostasis and immunity through sugar recognition. Trends in 
Immunology, 26(2), 104-110. 
Thomas, S. N., van der Vlies, A. J., O'Neil, C. P., Reddy, S. T., Yu, S. S., Giorgio, T. D., et al. 
(2011). Engineering complement activation on polypropylene sulfide vaccine 
nanoparticles. Biomaterials, 32(8), 2194-2203. 
Tsimikas, S., Willerson, J. T., & Ridker, P. M. (2006). C-reactive protein and other 
emerging blood biomarkers to optimize risk stratification of vulnerable 
patients. J Am Coll Cardiol, 47(8 Suppl), C19-31. 
Tu, B. P., Ho-Schleyer, S. C., Travers, K. J., & Weissman, J. S. (2000). Biochemical Basis 
of Oxidative Protein Folding in the Endoplasmic Reticulum. Science, 
290(5496), 1571-1574. 
Vallabhapurapu, S., & Karin, M. (2009). Regulation and function of NF-kappaB 
transcription factors in the immune system. Annu Rev Immunol, 27, 693-733. 
van der Vlies, A. J., O'Neil, C. P., Hasegawa, U., Hammond, N., & Hubbell, J. A. (2010). 
Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating 
thiol-containing small molecules, peptides, and proteins. Bioconjugate 
chemistry, 21(4), 653-662. 
Van Rooijen, N., & Sanders, A. (1994). Liposome mediated depletion of macrophages: 
mechanism of action, preparation of liposomes and applications. Journal of 
immunological methods, 174(1-2), 83-93. 
Vasievich, E. A., & Huang, L. (2011). The Suppressive Tumor Microenvironment: A 
Challenge in Cancer Immunotherapy. Molecular Pharmaceutics, 8(3), 635-641. 
Velluto, D., Demurtas, D., & Hubbell, J. A. (2008). PEG-b-PPS diblock copolymer 
aggregates for hydrophobic drug solubilization and release: cyclosporin A as 
an example. Mol Pharm, 5(4), 632-642. 
Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., & Miyamoto, S. (1995). 
Rel/NF-kappa B/I kappa B family: intimate tales of association and 
dissociation. Genes Dev, 9(22), 2723-2735. 
Watkins, S. K., Egilmez, N. K., Suttles, J., & Stout, R. D. (2007). IL-12 rapidly alters the 
functional profile of tumor-associated and tumor-infiltrating macrophages in 
vitro and in vivo. J Immunol, 178(3), 1357-1362. 
Weischenfeldt, J., & Porse, B. (2008). Bone Marrow-Derived Macrophages (BMM): 
Isolation and Applications. Cold Spring Harb Protoc, 2008(12), pdb.prot5080-. 
West, J. L., & Hubbell, J. A. (1998). Polymeric Biomaterials with Degradation Sites for 
Proteases Involved in Cell Migration. Macromolecules, 32(1), 241-244. 
169 
Williams, L. M., Sarma, U., Willets, K., Smallie, T., Brennan, F., & Foxwell, B. M. J. 
(2007). Expression of Constitutively Active STAT3 Can Replicate the 
Cytokine-suppressive Activity of Interleukin-10 in Human Primary 
Macrophages. Journal of Biological Chemistry, 282(10), 6965-6975. 
Woo, K., Hong, J., Choi, S., Lee, H. W., Ahn, J. P., Kim, C. S., et al. (2004). Easy synthesis 
and magnetic properties of iron oxide nanoparticles. Chemistry of Materials, 
16(14), 2814-2818. 
Worbs, T., & Förster, R. (2007). A key role for CCR7 in establishing central and 
peripheral tolerance. Trends in Immunology, 28(6), 274-280. 
Xiao, G., Rabson, A. B., Young, W., Qing, G., & Qu, Z. (2006). Alternative pathways of 
NF-kappaB activation: a double-edged sword in health and disease. Cytokine 
Growth Factor Rev, 17(4), 281-293. 
Yu, S. S., Koblin, R. L., Zachman, A. L., Perrien, D. S., Hofmeister, L. H., Giorgio, T. D., et 
al. (2011). Physiologically relevant oxidative degradation of oligo(proline) 
cross-linked polymeric scaffolds. Biomacromolecules, 12(12), 4357-4366. 
Yu, S. S., Lau, C. M., Thomas, S. N., Jerome, W. G., Maron, D. J., Dickerson, J. H., et al. 
(2012). Size-and charge-dependent non-specific uptake of PEGylated 
nanoparticles by macrophages. International Journal of Nanomedicine, 7, 799-
813. 
Yu, S. S., Ortega, R. A., Reagan, B. W., McPherson, J. A., Sung, H.-J., & Giorgio, T. D. 
(2011). Emerging applications of nanotechnology for the diagnosis and 
management of vulnerable atherosclerotic plaques. Wiley Interdisciplinary 
Reviews: Nanomedicine and Nanobiotechnology, 3(6), 620-646. 
Yu, S. S., Scherer, R. L., Ortega, R. A., Bell, C. S., O'Neil, C. P., Hubbell, J. A., et al. (2011). 
Enzymatic- and temperature-sensitive controlled release of ultrasmall 
superparamagnetic iron oxides (USPIOs). Journal of Nanobiotechnology, 9, 7. 
Zhang, J. L., Srivastava, R. S., & Misra, R. D. K. (2007). Core-shell magnetite 
nanoparticles surface encapsulated with smart stimuli-responsive polymer: 
Synthesis, characterization, and LCST of viable drug-targeting delivery 
system. Langmuir, 23(11), 6342-6351. 
 
 
